Nitrogen-containing heterocyclic derivative regulators, their preparation and use

Nitrogen-containing heterocyclic derivatives are developed to irreversibly inhibit KRAS G12C, overcoming binding challenges and providing targeted cancer treatment.

JP7584451B2Active Publication Date: 2024-11-15SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Patent Information

Application Number
JP2021571028
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-25
Filing Date
2020-05-29
Publication Date
2024-11-15
Estimated Expiration
2040-05-29

AI Technical Summary

Technical Problem

Current treatments for KRAS G12C mutations in cancers lack specific targeted drugs due to the challenges of binding to the RAS protein's smooth structure and high affinity for GTP, necessitating the development of KRAS G12C inhibitors with higher selectivity and activity.

Method used

Development of nitrogen-containing heterocyclic derivative compounds represented by general formula (1) and its stereoisomers or pharmaceutically acceptable salts, designed to irreversibly lock KRAS G12C in an inactive state by covalent binding.

Benefits of technology

The compounds effectively target KRAS G12C mutations, potentially treating various cancers with higher selectivity and safety, addressing the clinical need for KRAS-specific inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584451000001
    Figure 0007584451000001
  • Figure 0007584451000002
    Figure 0007584451000002
  • Figure 0007584451000003
    Figure 0007584451000003
Patent Text Reader

Abstract

The present invention relates to nitrogen-containing heterocyclic derivative regulators, their preparation methods and uses. In particular, the present invention relates to compounds represented by general formula (1), their preparation methods, pharmaceutical compositions containing the compounds, and their use as KRASg12C mutation inhibitors in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer, and colon cancer, wherein each substituent in general formula (I) has the same definition as in the specification. [Formula 1] TIFF2022534765000316.tif44170
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from Chinese patent application no. CN2019104571616, filed May 29, 2019, Chinese patent application no. CN2019109185824, filed September 26, 2019, Chinese patent application no. CN2019110189099, filed October 24, 2019, Chinese patent application no. CN2019110901717, filed November 8, 2019, Chinese patent application no. CN2019113821593, filed December 27, 2019, and Chinese patent application no. CN202010451270X, filed May 25, 2020. The entire contents of the above applications are incorporated herein by reference. [Technical Field]

[0002] The present invention is in the field of drug synthesis, and specifically relates to nitrogen-containing heterocyclic derivative inhibitors, their preparation methods and uses. [Background technology]

[0003] Rat sarcoma (RAS) is encoded by the proto-oncogenes HRAS, NRAS, and KRAS, and is divided into four proteins, HRAS, NRAS, KRAS4A, and KRAS4B, which are guanosine triphosphate (GTP)-binding proteins. RAS is located on the inner surface of the cell membrane and is connected upstream to receptor tyrosine kinases (RTKs). After activation, RAS regulates downstream signaling pathways such as PI3K and RAF, thereby regulating cell growth, survival, migration, and differentiation.

[0004] RAS has two major states in the body: an inactive state bound to GDP (guanosine diphosphate) and an active state bound to GTP. Its activity is regulated by two proteins: guanine nucleotide exchange factors (GNFs) and guanine nucleotide exchange factors (GTPs). Guanine nucleotide exchange factors (GEFs) promote the release of GDP from the RAS protein, allowing GTP to bind and activate RAS; GTPase-activating proteins (GAPs) activate the GTPase of the RAS protein, hydrolyzing the GTP bound to the RAS protein to GDP, thereby inactivating RAS. Under normal circumstances, RAS protein is in an inactive state, but after mutation, its conformation changes, causing RAS to become continuously activated, and downstream signaling pathways are also continuously activated, leading to the development of various cancers.

[0005] As the first identified oncogene, RAS is the oncogene with the highest mutation rate, accounting for an average of 25% of human cancers. The most common oncogenic mutation in the RAS family is KRAS (85%), while NRAS (12%) and HRAS (3%) are relatively rare. KRAS mutations primarily occur in a range of cancers, including pancreatic cancer (95%), colorectal cancer (52%), and lung cancer (31%). The most common mutation mode of KRAS is point mutation, which occurs mainly at G12, G13 in the p-loop (aa 10-17), and Q61 in the Switch II region (aa 59-76), with G12 mutations being the most common (83%). KRAS G12C is one of the most common mutations in non-small cell lung cancer (NSCLC) and colorectal cancer.

[0006] Despite significant clinical need, no drugs directly targeting KRAS are currently available on the market. Currently, clinical treatment for patients with KRAS mutations generally involves chemotherapy. The difficulty in developing KRAS inhibitors is primarily due to two factors. First, the smooth structure of the RAS protein makes it difficult for small molecules to bind to the protein surface. Second, the high picomolar (pM) affinity of RAS GTPase for GTP, coupled with high endogenous GTP levels, makes it difficult for small molecules to block both binding mechanisms. Recent studies have shown that after glycine (Gly) at position 12 of KRAS is mutated to cysteine ​​(Cys), a conformational change occurs, forming a new pocket for covalent binding of small molecules and irreversibly locking KRASG12C in a GDP-bound, inactive state. Therefore, KRAS G12C inhibitors are expected to be the first drugs that directly target KRAS.

[0007] Currently, several KRAS G12C inhibitors are in clinical research, such as AMG 510 developed by Amgen, ARS-3248 developed by Wellspring Biosciences, and MTRX849 developed by Mirati, etc. Currently, all of these are in Phase I clinical research, but no KRASG12C inhibitors have been developed and marketed.

[0008] Currently, there is no specific targeted drug for KRAS G12C, and there is a great clinical demand. KRAS G12C inhibitors with higher selectivity, better activity, and better safety have the potential to treat various cancers and have broad market prospects. Summary of the Invention

[0009] An object of the present invention is to provide a compound represented by general formula (1), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (1) is as follows:

[0010] [ka]

[0011] During the ceremony, M is CR aa selected from R1 or NR1; X1 and X2 each independently represent O, S, N, NR2, CR2, or CR aa Selected from R2; X3 is selected from N, NR3, or CR3; R1 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or -(CH2) n C(O)CH=CHR aa wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl may optionally be further substituted; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl may optionally be further substituted; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl may optionally be further substituted; R a represents hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, oxo, Thioxo , deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl may optionally be further substituted; R b represents hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, oxo, Thioxo , deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl may optionally be further substituted; Alternatively, any two adjacent or non-adjacent R b are bonded to form a cycloalkyl, heterocyclic group, aryl or heteroaryl, and the cycloalkyl, heterocyclic group, aryl and The heteroaryl may be optionally further substituted; R c represents hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, oxo, Thioxo , deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, -CH=CH(CH2) n R bb , -CH=CH(CH2) n NR bb Rcc , -O(CH2) n R bb , -OC(R bb R cc ) n (CH2) m R dd , -CH=CH(CH2) n NR bb (CH2) m C(O)R cc , -CH=CH(CH2) n NR bb (CH2) m C(O)NR cc R dd , -NR bb (CH2) n R cc , -(CH2) n1 -, -(CH2) n R bb , -(CH2) n OR bb , -(CH2) n SR bb , -(CH2) n C(O)R bb , -(CH2) n C(O)OR bb , -(CH2) n1 S(O) m R bb , -(CH2) n NR bb R cc , -(CH2) n C(O)NR bb R cc , -(CH2) n NR bb C(O)R cc or -(CH2) n NR bb S(O) m R cc wherein said alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl and heterocyclic groups may optionally be further substituted; R aais selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said amino, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl may optionally be further substituted; R bb and R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkyl substituted with cyano, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein said amino, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkyl substituted with cyano, cycloalkyl, heterocyclic, aryl, and heteroaryl may optionally be further substituted; Or, R bb and R cc together with the adjacent atom(s) form a cycloalkyl, heterocyclic, aryl, or heteroaryl, which cycloalkyl, heterocyclic, aryl, and heteroaryl may optionally be further substituted; R dd is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkyl substituted with cyano, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein said amino, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkyl substituted with cyano, cycloalkyl, heterocyclic, aryl and heteroaryl may optionally be further substituted; Or, Rcc and R dd together with the adjacent atom(s) form a cycloalkyl, heterocyclic, aryl, or heteroaryl, which cycloalkyl, heterocyclic, aryl, and heteroaryl may optionally be further substituted; x is an integer from 0 to 6; y is an integer from 0 to 6; z is an integer from 0 to 6; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; n1 is 0, 1, 2 or 3; where X3 is NR3, R c is oxo or Thioxo and R c is X3 X1 is CH2 and X2 is NR2; When X3 is N, X1 is CH2 and X2 is NR2; alternatively, X1 is N and X2 is CR2.

[0012] In a preferred embodiment of the present invention, when X3 is NR3, R c is oxo or Thioxo and R c is attached to a carbon atom in the same ring adjacent to X3, X1 is selected from N, NR2 or CH2, and X2 is selected from CR2 or NR2; Alternatively, when X3 is N, X1 is selected from N, CH2 or NR2, and X2 is selected from CR2 or NR2; Preferably, when X3 is NR3, R c is oxo or Thioxo wherein X1 is CH2 and X2 is NR2; when X3 is N, X1 is CH2 and X2 is NR2, or X1 is N and X2 is CR2; Additionally, when X1 and X2 are similarly CR2 or NR2, R2 is not necessarily the same group and may be independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic group, aryl, or heteroaryl, and the alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclic group, aryl, and heteroaryl may optionally be further substituted.

[0013] In a preferred embodiment of the present invention, R1 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl or -(CH2) n C(O)CH=CHR aa is selected from Preferably, 3- to 12-membered heterocyclic groups and -(CH2) n C(O)CH=CHR aa and; More preferably, a 3- to 10-membered heterocyclic group and —C(O)CH═CR aa the 3- to 10-membered heterocyclic group is a 5- or 6-membered heterocyclic group containing 1 or 2 nitrogen atoms, oxygen atoms, or sulfur atoms, and is optionally substituted with one or more substituents selected from deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, and methylenyl; R aa is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy or C 1-6 hydroxyalkyl; preferably hydrogen or C 1-3 It is alkyl.

[0014] In a preferred embodiment of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl or -(CH2) n C(O)CH=CHR aa wherein C is selected from 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, methylene groups, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hi Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more substituents selected from aryl and 5- to 12-membered heteroaryl, and more preferably

[0015] [ka]

[0016] [ka]

[0017] [ka]

[0018] [ka]

[0019] and most preferably

[0020] [ka]

[0021] [ka]

[0022] [ka]

[0023] and; R aa are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Deuterated alkyl, C1 -6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy or C 1-6 hydroxyalkyl; preferably hydrogen or C 1-3 It is alkyl.

[0024] In a further preferred embodiment of the present invention, R1 is a 3- to 12-membered heterocyclic group or -(CH2) n C(O)CH=CHR aa wherein the 3- to 12-membered heterocyclic group is substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, and methylene groups.

[0025] In a further preferred embodiment of the present invention, R1 is a 3- to 10-membered heterocyclic group or —C(O)CH═CHR aa wherein the 3- to 12-membered heterocyclic group is optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, and methylene groups.

[0026] In a preferred embodiment of the present invention, R2 is C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, hydroxyl, halogen, amino, and C 1-6 substituted by one or more substituents of alkyl; Preferably, phenyl, pyridyl, naphthyl, biphenyl, benzoheteroaryl, pyridophenyl, or pyrazolophenyl, wherein the phenyl, pyridyl, naphthyl, biphenyl, benzoheteroaryl, pyridophenyl, and pyrazolophenyl are optionally selected from hydrogen, hydroxyl, halogen, amino, and C 1-6It is substituted by one or more substituents of alkyl.

[0027] In a preferred embodiment of the present invention, R2 is C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl or 5- to 12-membered heteroaryl may optionally be selected from hydrogen, hydroxyl, halogen, amino, cyano, Mercapto , C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylthio-alkylene, C 1-6 Haloalkylthio, C 3-12 Cycloalkyl, C 1-6 Alkylamino, Carbamoyl, C 1-6 Alkylamide, C 1-6 Alkyl sulfonamides, C 3-12 Cycloalkylamino, C 3-12 Cycloalkylsulfonamides, C 1-6 Alkylcarbamoyl, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl and C 1-6 It is substituted by one or more substituents of alkyl.

[0028] In a further preferred embodiment of the invention, R2 is selected from phenyl, pyridyl, naphthyl, indolyl, biphenyl, benzoheteroaryl, pyridophenyl or pyrazolophenyl, wherein said phenyl, pyridyl, naphthyl, indolyl, biphenyl, benzoheteroaryl, pyridophenyl and pyrazolophenyl are optionally selected from hydrogen, hydroxyl, halogen, amino, cyano, Mercapto , C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylthio-alkylene, C 1-6 Haloalkylthio, C3-12 Cycloalkyl, C 1-6 Alkylamino, Carbamoyl, C 1-6 Alkylamide, C 1-6 Alkyl sulfonamides, C 3-12 Cycloalkylamino, C 3-12 Cycloalkylsulfonamides, C 1-6 Alkylcarbamoyl, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl and C 1-6 The alkyl group is substituted by one or more substituents selected from the group consisting of C 1-6 Alkylamino is (CH3)2N-, (CH3CH2)2NH-,

[0029] [ka]

[0030] carbamoyl may be NHC(O)-; C 1-6 The alkylamide may be CHC(O)NH—, 1-6 The alkyl sulfonamide may be CHSONH-, 1-6 Alkylcarbamoyl may be CH3CH2NHC(O)-, (CH3)2NC(O)-, CH3NHC(O)-, C 1-6 Alkylsulfinyl may be CH3SO-, C 1-6 Alkylsulfonyl may be CH3SO2- and the like.

[0031] In a preferred embodiment of the present invention, R3 is C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, hydroxyl, halogen, amino, and C 1-6 substituted by one or more substituents of alkyl; Preferred are phenyl and pyridyl, wherein the phenyl and pyridyl are optionally selected from hydrogen, hydroxyl, halogen, amino and C 1-6 It is substituted by one or more substituents of alkyl.

[0032] In a preferred embodiment of the present invention, R3 is C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, Mercapto , C 1-6 Alkylthio, C 1-6 Alkylthio-alkylene, C 1-6 Haloalkylthio, C 1-6 Alkylaminocarbonyl and C 1-6 It is substituted by one or more substituents of alkyl.

[0033] In one preferred embodiment of the invention, R3 is selected from phenyl, naphthyl, indolyl or pyridyl, wherein said phenyl, naphthyl, indolyl and pyridyl are optionally selected from hydrogen, hydroxyl, halogen, amino, Mercapto , C 1-6 Alkylthio, C 1-6 Alkylthio-alkylene, C 1-6 Haloalkylthio, C 1-6 Alkylaminocarbonyl and C 1-6 It is substituted by one or more substituents of alkyl.

[0034] In a preferred embodiment of the present invention, R a are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl or cyano substituted C 1-6 alkyl.

[0035] In a further preferred embodiment of the present invention, R a is hydrogen, C 1-3 Alkyl or cyano substituted C 1-3 alkyl. In a preferred embodiment of the present invention, R a is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, hydroxy, Mercapto , nitro, oxo, methylene group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0036] In a preferred embodiment of the present invention, R b are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl or cyano substituted C 1-6 alkyl.

[0037] In a further preferred embodiment of the present invention, R b is hydrogen, halogen or C 1-3 alkyl; Or, two adjacent R b C together with the adjacent carbon atom 3-8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6-14 Forms an aryl or 5-14 membered heteroaryl.

[0038] In a further preferred embodiment of the present invention, two adjacent R b C together with the adjacent carbon atom 3-6 Forms a cycloalkyl. In a further preferred embodiment of the present invention, two adjacent R b together with the adjacent carbon atom form a cyclopropyl.

[0039] In a further preferred embodiment of the present invention, R c are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -CH=CH(CH2) n R bb , -CH=CH(CH2) n NR bb R cc , -O(CH2) n R bb , -OC(R bb R cc ) n (CH2) m R dd , -CH=CH(CH2) n NR bb (CH2) m C(O)R cc , -CH=CH(CH2) n NR bb (CH2) m C(O)NR cc R dd or -NR bb (CH2) n Rcc C is selected from 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; Preferably, hydrogen, oxo, Thioxo , C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, -CH=CH(CH2) n R bb , -CH=CH(CH2) n NR bb R cc , -O(CH2) n R bb or -OC(R bb R cc ) n (CH2) m R dd and C 3-12 The cycloalkyl and 3- to 12-membered heterocyclic groups are optionally hydrogen, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; R bb and R cc are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl, 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; Or, R bb and R cc C with adjacent atoms 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R ddis hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl, 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, cyano, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; Or, R cc and R dd C with adjacent atoms 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0040] In a further preferred embodiment of the present invention, R c are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -CH=CH(CH2) n R bb , -CH=CH(CH2) n NR bb R cc , -O(CH2) n R bb , -CH=CH(CH2) n NR bb (CH2) m C(O)R cc , -CH=CH(CH2) n NR bb (CH2) m C(O)NR cc R dd , -OC(R bb R cc ) n (CH2) m R dd or -NR bb (C H2) n R cc wherein C is selected from1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, C 1-6 It is substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups.

[0041] In a further preferred embodiment of the present invention, R c is hydrogen, C 1-3 Alkyl, C 1-3 Alkoxy, oxo, Thioxo , C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, -CH=CH(CH2) n R bb , -CH=CH(CH2) n NR bb R cc , -O(CH2) n R bb or -O(CR bb R cc ) n (CH2) m R dd wherein C is selected from 1-3 Alkyl, C 1-3 Alkoxy, C 3-12 The cycloalkyl and 3- to 12-membered heterocyclic groups are optionally hydrogen, C 1-6 It is substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups.

[0042] In a further preferred embodiment of the present invention, R bb and R cc are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; Or, R bb and R cc C with adjacent atoms 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0043] In a further preferred embodiment of the present invention, R dd are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, hydroxyl, halogen, amino, cyano, C 1-6 substituted by one or more substituents selected from alkyl and 3- to 12-membered heterocyclic groups; Or, R cc and R dd C with adjacent atoms 3-12 Cycloalkyl, 3-12 C-membered heterocyclic group 6-12 aryl or 5- to 12-membered heteroaryl,3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0044] In a further preferred embodiment of the present invention, there is provided a compound of formula (II) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0045] [ka]

[0046] During the ceremony: L is a bond, -CH=CH(CH2) n -, -CH=CH(CH2) n NR bb -, -O(CH2) n -, -CH=CH(CH2) n NR bb (CH2) m C(O)-, -CH=CH(CH2) n NR bb (CH2) m C(O)NR cc -, -OC(R bb R cc ) n (CH2) m -, -NR bb (CH2) nR cc , -(CH2) n1 -, -(CH2) n R bb -, -(CH2) n OR bb , -(CH2) n S-, -(CH2) n C(O)-, -(CH2) n C(O)O-, -(CH2) n1 S(O) m -, -(CH2) n NR bb -, -(CH2) n C(O)NR bb -, -(CH2) n NR bb C(O)- or -(CH2) n NR bb S(O) m -Selected from; R4 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0047] In a further preferred embodiment of the present invention, a compound of formula (III) having the specific structure: ) compounds, their stereoisomers, or pharmaceutically acceptable salts thereof.

[0048] [ka]

[0049] In a further preferred embodiment of the present invention, there is provided a compound of formula (IV) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0050] [ka]

[0051] In a further preferred embodiment of the present invention, there is provided a compound of formula (V) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0052] [ka]

[0053] During the ceremony: Ring A is C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl; preferably C 6-12 aryl and 5-12 membered heteroaryl; R d is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated A Lukil, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; p is an integer of 0 to 6.

[0054] In a further preferred embodiment of the present invention, there is provided a compound of formula (VI) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0055] [ka]

[0056] During the ceremony: Ring B is C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl; preferably C 3-12 cycloalkyl or a 3- to 12-membered heterocyclic group; R e are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; q is an integer of 0 to 6.

[0057] In a further preferred embodiment of the present invention, there is provided a compound of formula (VII) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0058] [ka]

[0059] In a further preferred embodiment of the present invention, there is provided a compound of formula (VIII) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0060] [ka]

[0061] During the ceremony: R5 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl; preferably hydrogen, halogen or C 1-3 alkyl; R6 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is selected from aryl or 5- to 12-membered heteroaryl; preferably, it is hydrogen.

[0062] In a further preferred embodiment of the present invention, there is provided a compound of formula (IX) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0063] [ka]

[0064] During the ceremony: Ring A is C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl; preferably C 6-12 aryl or 5-12 membered heteroaryl; R d are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, hydrogen, halogen, hydroxy, amino or C 1-3 is alkyl; p is an integer of 0 to 6.

[0065] In a further preferred embodiment of the present invention, there is provided a compound of formula (X) having the specific structure below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0066] [ka]

[0067] In a further preferred embodiment of the present invention, there is provided a compound of formula (XA) having the specific structure below, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0068] [ka]

[0069] During the ceremony: R7 is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, C 1-3 Alkyl or C 1-3 haloalkoxy; R8 and R9 are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 It is substituted by one or more of the following substituents: aryl and 5-12 membered heteroaryl.

[0070] In a preferred embodiment of the present invention, there is provided a compound represented by general formula (XI), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0071] [ka]

[0072] During the ceremony: M1 is CR 12 R 13 or NR 12 preferably selected from the following groups:

[0073] [ka]

[0074] and; Preferably, the following groups:

[0075] [ka]

[0076] is. Ring C is C 6-14 aryl or 5-14 membered heteroaryl; Preferably, it is phenyl or pyridyl. More preferably, the following groups:

[0077] [ka]

[0078] and; More preferably, the following groups:

[0079] [ka]

[0080] and; Ring D is C 6-14 aryl or 5-14 membered heteroaryl; Preferably it is phenyl or pyridyl, more preferably the following groups:

[0081] [ka]

[0082] and; More preferably, the following groups:

[0083] [ka]

[0084] Selected from; R 10 and R 11 are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R 12 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl or -(CH2) n2 C(O)CR ee =CR ff R gg wherein C is selected from 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, methylene groups, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, it is a 3- to 12-membered heterocyclic group or -(CH2) n2 C(O)CR ee =CR ff R gg wherein the 3- to 12-membered heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, and methylene groups; R 13are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R f is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl or -(CH2) n C(O)CH=CHR aa wherein C is selected from 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally selected from hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, oxo, methylene group, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C6-12 One or more substituents of aryl and 5- to 12-membered heteroaryl is replaced by; R g are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -O(CH2) n2 R ee , -OC(R ee R ff ) n2 (CH2) m1 R gg , -NR ee (CH2) n2 R ff , -(CH2) n2 SR ee , -(CH2) n2 R ee , -(CH2) n2 OR ee , -(CH2) n2 SR ee , -(CH2) n2 C(O)R ee , -(CH2) n2 C(O)OR ee , -(CH2) n2 S(O) m1 R ee , -(CH2) n2 NR bb R ee , -(CH2) n2 C(O)NR ee R ff , -(CH2) n2 NR ee C(O)R ff or -(CH2)n2 NR ee S(O) m1 R ff wherein the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R h are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12Aryl, 5-12 membered heteroaryl, -O(CH2) n2 R ee , -OC(R ee R ff ) n2 (CH2) m1 R gg , -NR ee (CH2) n2 R ff , -(CH2) n2 SR ee , -(CH2) n2 R ee , -(CH2) n2 OR ee , -(CH2) n2 SR ee , -(CH2) n2 C(O)R ee , -(CH2) n2 C(O)OR ee , -(CH2) n2 S(O) m1 R ee , -(CH2) n2 NR bb R ee , -(CH2) n2 C(O)NR ee R ff , -(CH2) n2 NR ee C(O)R ff or -(CH2) n2 NR ee S(O) m1 R ff wherein the amino, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R aa are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1- 6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; R ee , R ff and R gg are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; r is an integer from 0 to 5; s is an integer from 0 to 5; t is an integer from 0 to 5; n2 is an integer from 0 to 5; and m1 is 0, 1 or 2.

[0085] In a preferred embodiment of the present invention,

[0086] [ka]

[0087] teeth

[0088] [ka]

[0089] Selected from; R 14 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 heavy water Alkyl chloride, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, hydrogen, halogen, amino, C 1-3 alkyl or 3- to 8-membered heterocyclic group, 1-3 The alkyl and 3- to 8-membered heterocyclic groups may optionally further include hydrogen, halogen, C 1-3 Alkoxy and C 3-8 substituted by one or more substituents of cycloalkyl; More preferably, hydrogen, chlorine, fluorine, bromine, amino, methyl, methoxy, cyclopropyl, azetidinyl, morpholinyl, wherein the amino, methyl, methoxy, cyclopropyl, azetidinyl and morpholinyl are optionally substituted by one or more substituents selected from hydrogen, fluorine, chlorine, bromine and cyclopropyl; R 15are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; Preferably, hydrogen or C 1-3 is alkyl; More preferably, it is methyl.

[0090] In a preferred embodiment of the present invention, the present invention provides a compound represented by general formula (XI-A), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0091] [ka]

[0092] In the formula, R f are each independently hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Ha alkoxy or C 1-3 hydroxyalkyl, preferably C 1-3 is alkyl; R 10and R 11 are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 alkyl, preferably halogen; R g are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 alkyl, preferably hydroxy, amino or halogen; R h are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Alkylthio, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 alkyl, preferably C 1-3 Alkyl or C 1-3alkylthio, more preferably methylthio or isopropyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer of 1 to 3, and is preferably 2.

[0093] In a preferred embodiment of the present invention, the present invention provides a compound represented by general formula (XI-A), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0094] [ka]

[0095] In the formula, R f are each independently hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl, preferably C 1-3 is alkyl; R 10 and R 11 are independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl or cyano substituted C1 -3 alkyl, preferably halogen; R g are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 alkyl, preferably hydroxy, amino or halogen; R h are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Alkylthio, C 1-3 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 alkyl, preferably C 1-3 Alkyl or C 1-3 alkylthio, more preferably methylthio or isopropyl; r is an integer from 1 to 3; s is an integer from 1 to 4; t is an integer of 1 to 3, and is preferably 2.

[0096] In one preferred embodiment of the present invention, there is provided a compound represented by formula (XI-B) having the following structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0097] [ka]

[0098] During the ceremony: R 10 are each independently hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferably fluorine or chlorine; R 15 is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferably it is methyl; R 20 is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferably hydrogen or methyl; R 21 and R 22 are each independently hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferred are hydrogen, hydroxy, amino, fluorine, methyl, trifluoromethyl, methylthio, methylamino, aminoacyl or dimethylamino; R 23 and R 24 are each independently hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferably hydrogen, chlorine, fluorine or methyl; R 25is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkyl sulfonyl, C 1-3 Haloalkoxy or C 1-3 hydroxyalkyl; Preferably it is hydrogen, fluorine or methyl; q is an integer of 0 to 2.

[0099] In a further preferred embodiment of the present invention, in the compound represented by formula (XI-B), its stereoisomer, or a pharmaceutically acceptable salt thereof, R f is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, halomethoxy, haloethoxy, halopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably hydrogen or methyl; R 10is selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably fluorine or chlorine; R 15 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably methyl; R 21 and R 22 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably hydroxy, amino, fluorine, chlorine or methyl; R 23 and R 24 are each independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, Mercapto , cyano, nitro, C 1-3selected from alkyl, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably hydrogen, fluorine, chlorine or methyl; R 25 is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, Mercapto , cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably hydrogen, fluorine or methyl.

[0100] In a further preferred embodiment of the present invention, in the compound represented by formula (XI-B), its stereoisomer, or a pharmaceutically acceptable salt thereof, R f is hydrogen, deuterium, halogen, amino, hydroxyl, Mercapto , cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, halomethoxy, haloethoxy, halopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, preferably hydrogen or methyl; R 10is selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, preferably fluorine or chlorine; R 15 is selected from methyl, ethyl, propyl or isopropyl, preferably methyl; R 21 and R 22 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, preferably hydroxy, amino, fluorine, chlorine or methyl; R 23 and R 24 are each independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, Mercapto , cyano, nitro, C 1-3 selected from alkyl, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, preferably hydrogen, fluorine, chlorine or methyl; R 25 is hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, Mercapto , cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, heavy water The alkyl group is selected from ethyl halide, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxyisopropyl, and is preferably hydrogen, fluorine or methyl.

[0101] In a preferred embodiment of the present invention, there is provided a compound represented by formula (XI-C) or (XI-D), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, having the following structure:

[0102] [ka]

[0103] In a further preferred embodiment of the present invention, the structural formula of the compound of formula (XI-C) or (XI-D) is as follows:

[0104] [ka]

[0105] In a further preferred embodiment of the present invention, in the compound represented by formula (XI-C) or (XI-D), its stereoisomer, or a pharmaceutically acceptable salt thereof, R 21 and R 22 are each independently selected from amino or fluorine; R 23 and R 24 are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, or isopropyl; Or, R 21 and R 22 are each independently selected from hydroxy or fluorine; R 23 and R 24 are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, or isopropyl.

[0106] Preferably, R 21 is amino and R 22 is fluorine, or R 21 is hydroxy and R 22 is fluorine. In one preferred embodiment of the present invention, ring A is C 6-10 aryl or 5- to 12-membered heteroaryl, wherein the 5- to 12-membered heteroaryl is selected from heteroaryl containing 1 to 3 nitrogen atoms, preferably selected from 5- to 7-membered nitrogen-containing heteroaryl, benzo 5- to 7-membered nitrogen-containing heteroaryl or 5- to 7-membered nitrogen-containing heteroarylphenyl, more preferably selected from the following groups:

[0107] [ka]

[0108] and Optionally, hydroxy, halogen, amino, Mercapto , C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylthio-alkyl, C 1-6 Haloalkylthio, C 1-6 Alkylcarbamoyl, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl and C 1-6 It is substituted by one or more substituents of alkyl.

[0109] In a preferred embodiment of the present invention, ring B is selected from 5- to 12-membered heterocyclic groups containing 1 to 3 nitrogen atoms and is selected from the following groups:

[0110] [ka]

[0111] Includes: In a further preferred embodiment of the present invention, there is provided a compound of formula (XII) having the following specific structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0112] [ka]

[0113] R 16 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; More preferably, hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxy, cyano, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, epoxypropyl, epoxybutyl, epoxypentyl, epoxyhexyl, epoxyheptyl, aziridinyl, azetidinyl, azepinyl, azacyclohexyl, azepanyl, thienyl, pyrrolyl, pyridyl, pyranyl, piperazinyl, phenyl or naphthyl; R 17 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated A Lukil, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, C 3-8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl, 3-8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10The aryl and 5- to 10-membered heteroaryl may optionally further comprise hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 substituted by one or more substituents selected from aryl and 5-10 membered heteroaryl; More preferably, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, optionally further containing hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 substituted by one or more substituents selected from aryl and 5-10 membered heteroaryl; More preferably, it is cyclohexyl, tetrahydropyranyl, phenyl, pyrimidinyl, naphthyl, pyridyl or benzimidazolyl, wherein said cyclohexyl, tetrahydropyranyl, phenyl, pyrimidinyl, naphthyl, pyridyl and benzimidazolyl are optionally further substituted by one or more substituents of hydrogen, fluorine, chlorine, amino, hydroxy or methyl; R 18 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; Preferably, hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-5 Alkenyl, C 2-5 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; More preferred are hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxy, cyano, methyl, ethyl, propyl, vinyl, propenyl, allyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, bromomethyl, bromoethyl, bromopropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxy, ethoxy, propoxy, fluoromethoxy, fluoroethoxy, fluoropropoxy, chloromethoxy, chloroethoxy, chloropropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, epoxypropyl, epoxybutyl, epoxypentyl, epoxyhexyl, epoxyheptyl, aziridinyl, azetidinyl, azepinyl, azacyclohexyl, azepanyl, thienyl, pyrrolyl, pyridyl, pyranyl, piperazinyl, phenyl or naphthyl; R 19 are hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 aryl or 5- to 12-membered heteroaryl, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 The aryl and 5- to 12-membered heteroaryl are optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, oxo, Thioxo , C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic group, C 6-12 substituted by one or more substituents selected from aryl and 5-12 membered heteroaryl; Preferably, C 3-8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10 aryl or 5- to 10-membered heteroaryl, 3-8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6-10 The aryl and 5- to 10-membered heteroaryl may optionally further comprise hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 substituted by one or more substituents selected from aryl and 5-10 membered heteroaryl; More preferably, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, optionally further containing hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, oxo, Thioxo , C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 substituted by one or more substituents selected from aryl and 5-10 membered heteroaryl; More preferred are cyclohexyl, tetrahydropyranyl, phenyl, pyrimidinyl, naphthyl, pyridyl or benzimidazolyl, wherein said cyclohexyl, tetrahydropyranyl, phenyl, pyrimidinyl, naphthyl, pyridyl and benzimidazolyl are optionally further substituted by one or more substituents of hydrogen, fluorine, chlorine, amino, hydroxy or methyl.

[0114] The most preferred embodiments of the present invention include the following specific compounds:

[0115] [ka] TIFF0007584451000038.tif248169TIFF0007584451000039.tif221169TIFF00075844510 00040.tif231169TIFF0007584451000041.tif224169TIFF0007584451000042.tif224169 TIFF0007584451000043.tif232169TIFF0007584451000044.tif209169TIFF00075844510 00045.tif235169TIFF0007584451000046.tif215169TIFF0007584451000047.tif189169

[0116] Preferably, when selected from the compound structures below, they can be further separated into axially asymmetric compounds of enantiomeric configuration.

[0117] [ka]

[0118] Furthermore, the axially asymmetric compound structure of the compound is as follows:

[0119] [ka]

[0120] One embodiment of the present invention is The compound structure is

[0121] [ka]

[0122] where compounds 60-1 and 60-2 have the following parameters: Compound 60-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 60-2. Preferably, the retention time of compound 60-1 is tR = 1.92 min, and the retention time of compound 60-2 was t R = 2.43 min, The detection conditions are as follows:

[0123] [Table 1]

[0124] Alternatively, the compound structure is

[0125] [ka]

[0126] Two axially chiral isomers 75-1 and 75-2 are included when: Compound 75-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 75-2. Preferably, the retention time of compound 75-1 is t R = 1.97 min, and the retention time of compound 75-2 was t R = 3.75 min, The detection conditions are as follows:

[0127] [Table 2]

[0128] Alternatively, the compound structure is

[0129] [ka]

[0130] Two axially chiral isomers 114-1 and 114-2 are included, where compounds 114-1 and 114-2 have the following parameters: Compound 114-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 114-2. Preferably, the retention time of compound 114-1 is t R = 1.99 min, and the retention time of compound 114-2 was t R = 2.87 min, The detection conditions are as follows:

[0131] [Table 3]

[0132] Alternatively, the compound structure is

[0133] [ka]

[0134] When the compound is The compounds 150-1 and 150-2 have the following parameters: Compound 150-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 150-2. Preferably, the retention time of compound 150-1 is t R = 1.87 min, and the retention time of compound 150-2 was t R = 2.80 min, The detection conditions are as follows:

[0135] [Table 4]

[0136] Alternatively, the compound structure is

[0137] [ka]

[0138] Two axially chiral isomers 165-1 and 165-2 are included, where compounds 165-1 and 165-2 have the following parameters: Compound 165-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 165-2. Preferably, the retention time of compound 165-1 is t R = 1.74 min, and the retention time of compound 165-2 was t R = 2.49 min, The detection conditions are as follows:

[0139] [Table 5]

[0140] Alternatively, the compound structure is

[0141] [ka]

[0142] Two axially chiral isomers 166-1 and 166-2 are included, where compounds 166-1 and 166-2 have the following parameters: Compound 166-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than that of compound 166-2. Preferably, the retention time of compound 166-1 is t R = 2.46 min, and the retention time of compound 166-2 was t R = 3.08 min, The detection conditions are as follows:

[0143] [Table 6]

[0144] One embodiment of the present invention is The compound structure is

[0145] [ka] In this case, two axially asymmetric isomers 60-1 and 60-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 60-1 is the axially asymmetric compound that is washed out first, and its retention time is earlier than compound 60-2, and preferably, the retention time of compound 60-1 is t R = 1.92 min, and the retention time of compound 60-2 was t R = 2.43 min, and the SFC chiral preparation conditions are as follows:

[0146] [Table 7]

[0147] Alternatively, the compound structure is

[0148] [ka]

[0149] In this case, two axially chiral isomers 75-1 and 75-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 75-1 is the axially chiral compound that is washed out first, and its retention time is earlier than compound 75-2, and preferably, the retention time of compound 75-1 is t R = 1.97 min, and the retention time of compound 75-2 was t R = 3.75 min, and the SFC chiral preparation conditions are as follows:

[0150] [Table 8]

[0151] Alternatively, the compound structure is

[0152] [ka]

[0153] In this case, two axially chiral isomers 114-1 and 114-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 114-1 is the axially chiral compound that is washed out first, and its retention time is earlier than compound 114-2, and preferably, the retention time of compound 114-1 is t R = 1.99 min, and the retention time of compound 114-2 was t R = 2.87 min, and the SFC chiral preparation conditions are as follows:

[0154] [Table 9]

[0155] Alternatively, the compound structure is

[0156] [ka]

[0157] In this case, two axially chiral isomers 150-1 and 150-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 150-1 is the axially chiral compound that is washed out first, and its retention time is earlier than compound 150-2, and preferably, the retention time of compound 150-1 is t R = 1.87 min, and the retention time of compound 150-2 was t R = 2.80 min, and the SFC chiral preparation conditions are as follows:

[0158] [Table 10]

[0159] Alternatively, the compound structure is

[0160] [ka]

[0161] In this case, two axially chiral isomers 165-1 and 165-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 165-1 is the axially chiral compound that is washed out first, and its retention time is earlier than compound 165-2, and preferably, the retention time of compound 165-1 is t R = 1.74 min, and the retention time of compound 165-2 was t R = 2.49 min, and the SFC chiral preparation conditions are as follows:

[0162] [Table 11]

[0163] Alternatively, the compound structure is

[0164] [ka]

[0165] In this case, two axially chiral isomers 166-1 and 166-2 are obtained by separation under the following SFC chiral preparation conditions, where compound 166-1 is the axially chiral compound that is washed out first, and its retention time is earlier than compound 166-2, and preferably, the retention time of compound 166-1 is t R = 2.46 min, and the retention time of compound 166-2 was t R = 3.08 min, and the SFC chiral preparation conditions are as follows:

[0166] [Table 12]

[0167] Those skilled in the art can understand that the axially asymmetric isomers of the present invention can also be separated by other common separation methods or different separation conditions, and at the same time, different separation methods or different separation conditions may cause the retention time of the compound to change.Those skilled in the art can understand that the axially asymmetric isomers of the corresponding compounds of the present invention obtained by common separation methods, the corresponding racemates, and the axially asymmetric isomers obtained by separation under different conditions are all protected by the present invention.

[0168] In another embodiment, the axially chiral isomers of the present invention have the following inhibitory activity: (1) Compound 60 was separated into two axially chiral isomers, 60-1 and 60-2, by chiral separation. The IC value of compound 60-1 for the inhibitory activity against NCI-H358 cell proliferation was 50 or the IC value of the Mia PaCa-2 cell proliferation inhibitory activity of compound 60-1 is ≦100 nM, preferably ≦50 nM, more preferably ≦30 nM, and even more preferably 28 nM. 50 a value of ≦100 nM, preferably ≦80 nM, more preferably ≦60 nM, even more preferably 55 nM; Alternatively, (2) compound 75 was subjected to chiral separation to obtain two axially asymmetric isomers, 75-1 and 75-2, where the IC value of the inhibitory activity of compound 75-1 on NCI-H358 cell proliferation was 50 or the IC value of the Mia PaCa-2 cell proliferation inhibitory activity of compound 75-1 is ≦100 nM, preferably ≦50 nM, more preferably ≦30 nM, and even more preferably 25 nM. 50 the value is ≦100 nM, preferably ≦80 nM, more preferably ≦60 nM, even more preferably ≦60 nM, most preferably 36 nM; Alternatively, (3) compound 114 was subjected to chiral separation to obtain two axially asymmetric isomers, 114-1 and 114-2, where the IC value of the inhibitory activity of compound 114-1 on NCI-H358 cell proliferation was 50 or the IC value of the Mia PaCa-2 cell proliferation inhibitory activity of compound 114-1 is ≦100 nM, preferably ≦50 nM, more preferably ≦40 nM, and even more preferably 35 nM. 50a value of ≦100 nM, preferably ≦80 nM, even more preferably ≦60 nM, more preferably ≦50 nM, even more preferably ≦30 nM, and most preferably 29 nM; Alternatively, (4) Compound 150 can be separated into two axially chiral isomers, 150-1 and 150-2, by chiral separation, and the IC value of the inhibitory activity of compound 150-1 on NCI-H358 cell proliferation is 50 The value is ≦100 nM, preferably ≦50 nM, more preferably ≦20 nM, even more preferably ≦10 nM, and most preferably 6.6 nM; or the Mi of compound 150-1 a IC of PaCa-2 cell proliferation inhibitory activity 50 the value is ≦100 nM, preferably ≦50 nM, more preferably ≦20 nM, even more preferably ≦10 nM, and most preferably 3.5 nM; Alternatively, (5) compound 165 can be separated into two axially chiral isomers, 165-1 and 165-2, by chiral separation, and the IC value of the inhibitory activity of compound 165-1 on NCI-H358 cell proliferation was calculated. 50 or the IC value of the Mia PaCa-2 cell proliferation inhibitory activity of compound 165-1 is ≦100 nM, preferably ≦50 nM, more preferably ≦30 nM, even more preferably ≦10 nM, and even more preferably 6.6 nM; or 50 The value is ≦80 nM, preferably ≦50 nM, more preferably ≦20 nM, even more preferably ≦10 nM, even more preferably ≦5 nM, and most preferably 3.3 nM; Alternatively, (6) compound 166 can be separated into two axially chiral isomers, 166-1 and 166-2, by chiral separation. The IC value of compound 166-1 for the inhibitory activity against NCI-H358 cell proliferation was calculated. 50 or the IC value of the Mia PaCa-2 cell proliferation inhibitory activity of compound 166-1 is ≦50 nM, preferably ≦30 nM, more preferably ≦20 nM, and even more preferably 17 nM. 50 The value is ≦50 nM, preferably ≦30 nM, more preferably ≦20 nM, even more preferably ≦15 nM, and most preferably 11 nM.

[0169] In a preferred embodiment of the present invention, the method for detecting the inhibitory activity of NCI-H358 cell proliferation and Mia PaCa-2 cell proliferation is as follows: cell culture is performed, and compound solutions of different concentrations are added to the cultured cells. After culturing for a certain period of time, the cell proliferation status is measured.

[0170] Furthermore, the cell culture method involves adjusting the cells to an appropriate cell concentration in complete medium and then plating the cell suspension in a well plate. Preferably, the culture conditions are 37°C, 5% CO2, and overnight incubation in an incubator. Preferably, the cell suspension is plated in a 96-well plate, 48-well plate, 24-well plate, 12-well plate, or 6-well plate, more preferably in a 96-well plate. Preferably, the appropriate cell concentration is 1500 to 4000 cells / well, and 90 μL of the cell suspension is added to each well.

[0171] Alternatively, the compound solution may be prepared in DMSO and further diluted with culture medium. Preferably, the concentration gradient of the compound solution starts at 100 μM and is diluted 4-fold, more preferably starts at 30 μM and is diluted 4-fold, and most preferably starts at 10 μM and is diluted 4-fold.

[0172] Furthermore, the volume of the compound solution or solvent added to each well is 1-10 μL, preferably 10 μL. After the compound solution is added, the culture is continued in a 5% CO 2 incubator at 37° C. Preferably, the culture time is 24 to 72 hours, more preferably 72 hours.

[0173] Furthermore, methods for measuring the state of cell proliferation include MTT, CCK8, and CellTiter-Glo, with the preferred method being CellTiter-Glo. Furthermore, the status of cell proliferation can be monitored by a microplate reader, preferably a BioTek Read using a Synergy H1 microplate reader.

[0174] In another embodiment, the IC of the axially chiral isomer 114-1 of the compound of the present invention for pERK inhibition in Mia PaCa-2 cells is 50 The value is ≦100 nM, preferably ≦50 nM, more preferably ≦40 nM, and most preferably 38 nM.

[0175] Alternatively, the IC of the axially chiral isomer 150-1 of the compound for pERK inhibition in Mia PaCa-2 cells 50 The value is ≦50 nM, preferably ≦30 nM, more preferably is ≦10 nM, more preferably ≦5 nM, and most preferably 5 nM.

[0176] Alternatively, the IC of the axially chiral isomer 165-1 of the compound for pERK inhibition in Mia PaCa-2 cells 50 The value is ≦50 nM, preferably ≦30 nM, more preferably ≦20 nM, even more preferably ≦10 nM, even more preferably ≦5 nM, and most preferably 4.2 nM.

[0177] Alternatively, the IC of the axially chiral isomer 166-1 of the compound for pERK inhibition in Mia PaCa-2 cells 50 The value is ≦50 nM, preferably ≦30 nM, more preferably ≦20 nM, and most preferably 20 nM.

[0178] In a preferred embodiment of the present invention, the method for detecting the inhibitory activity of phosphorylated ERK level is as follows: Cell culture is performed, and compound solutions of different concentrations are added to cultured cells. After culturing for a certain period of time, the cells are lysed and centrifuged, and the affinity of the compound for the enzyme is measured.

[0179] Furthermore, the cell culture method involves adjusting the cells to an appropriate cell concentration in a complete medium, preferably a cell concentration of 1×10 6The cell suspension is adjusted to 10000 cells / mL and plated on a well plate for culture. Preferably, the culture conditions are 37°C, 5% CO2 incubator, and the cells are cultured overnight. Preferably, the cell suspension is plated on a 96-well plate, 48-well plate, 24-well plate, 12-well plate, or 6-well plate, more preferably on a 96-well plate. Preferably, the appropriate cell concentration is 50,000 cells / well.

[0180] Alternatively, the compound solution may be prepared in DMSO and further diluted with culture medium. Preferably, the concentration gradient of the compound solution starts at 100 μM and is diluted 4-fold, more preferably starts at 30 μM and is diluted 4-fold, and most preferably starts at 10 μM and is diluted 4-fold.

[0181] Furthermore, the volume of the compound solution or solvent added to each well is 1 to 50 μL, preferably 20 to 25 μL, and more preferably 25 μL. Furthermore, after the compound solution is added, the conditions for continuing the culture are an incubator at 37° C. and 5% CO 2. The culture time is preferably 1 to 6 hours, more preferably 2 hours.

[0182] Furthermore, cell lysis is performed by adding a lysis solution, preferably by adding 50 to 100 μL of the lysis solution, more preferably by adding 50 μL, or preferably by performing the lysis at room temperature under shaking conditions, more preferably for 30 minutes.

[0183] Furthermore, the centrifugation conditions are as follows: centrifugation at 1000 rpm for 1 minute in a centrifuge. Furthermore, a method for determining the affinity between a compound and an enzyme involves transferring the supernatant to a well plate, adding a detection mixture, and measuring the reaction using a microplate reader. Preferably, the volume of the supernatant is 10 to 30 μL, preferably 15 μL. Preferably, the detection mixture contains Eu-labeled anti-ERK1 / 2 (T202-Y204) antibody and ULight-labeled anti-ERK1 / 2 antibody; more preferably, the detection mixture contains Eu-labeled anti-ERK1 / 2 (T202-Y204) antibody with a final detection concentration of 0.5 nM. and ULight labeled anti-ERK1 / 2 antibody with a final detection concentration of 5 nM; more preferably, the volume of the detection mixture is 5 to 10 μL, more preferably 5 μL.

[0184] After lysis and centrifugation, the supernatant and the detection mixture are reacted for a certain period of time, preferably The reaction is carried out at room temperature overnight. Furthermore, the status of cell proliferation can be monitored by a microplate reader, preferably a BioTek Read using a Synergy H1 microplate reader.

[0185] Those skilled in the art will understand that the inhibitory activity of the axially asymmetric isomers of the present invention can also be measured by other common activity detection methods. Different detection methods or adjustment of detection conditions may cause the inhibitory activity of the compound to vary or to undergo greater changes, and all axially asymmetric isomers detected by different activity detection methods are protected by the present invention.

[0186] The present invention further relates to a method for producing a compound represented by general formula (IX-A) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, which comprises the following steps:

[0187] [ka]

[0188] Deprotecting the compound of general formula (IX-A5) to obtain a compound of general formula (IX-A3) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The general formula (IX-A3) and the general formula (IX-A4) undergo a condensation reaction to obtain a compound represented by the general formula (IX-A2) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The compound of general formula (IX-A2) and the compound of general formula (IX-A1) are subjected to a coupling reaction to obtain a compound represented by general formula (IX-A) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; where: Pg is an amino-protecting group, preferably allyloxycarbonyl, trifluoroacetyl, tert-butylsulfinyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, fluorenylmethoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyl, p-toluenesulfonyl, p-methoxybenzyl, formate, acetyl, benzyloxycarbonyl, phthaloyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl, more preferably tert-butoxycarbonyl; X1 is selected from halogen; preferably fluorine, chlorine, bromine or iodine; more preferably chlorine; R 26 is selected from halogen, boric acid or boric acid ester; preferably fluorine, chlorine, bromine, iodine, -B(OH)2 or

[0189] [ka]

[0190] and; When X1 is halogen, R 26 is selected from boric acid or boric acid esters; When X1 is selected from boric acid or boric acid esters, R 26 is a halogen; R 27is selected from halogen, hydroxy, or alkylcarbonyloxy; preferably chlorine or hydroxy.

[0191] The present invention further relates to a method for producing a compound represented by general formula (IX-A) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, which comprises the following steps:

[0192] [ka]

[0193] Deprotecting the compound of general formula (IX-A7) to obtain a compound of general formula (IX-A6) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The general formula (IX-A6) and the general formula (IX-A4) undergo a condensation reaction to give the compound represented by the general formula (IX-A) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0194] The present invention further relates to a method for producing a compound represented by general formula (IX-B) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, which comprises the following steps:

[0195] [ka]

[0196] Deprotecting the compound of general formula (IX-B4) to obtain a compound of general formula (IX-B3) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The general formula (IX-B3) and the general formula (IX-A4) undergo a condensation reaction to obtain a compound represented by the general formula (IX-B2) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The compounds of general formula (IX-B2) and general formula (IX-B1) undergo a coupling reaction to give the compound represented by general formula (IX-B) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0197] The present invention further relates to a method for producing a compound represented by general formula (IX-B) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, which comprises the following steps:

[0198] [ka]

[0199] Deprotecting the compound of general formula (IX-B6) to obtain a compound of general formula (IX-B5) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; The general formula (IX-B5) and the general formula (IX-A4) undergo a condensation reaction to give a compound represented by the general formula (IX-B) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0200] The present invention further provides a preferred technical solution, which further relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of general formula (I) and its stereoisomer or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0201] The present invention further relates to the use of any one of the compounds of general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, or said pharmaceutical composition in the manufacture of a KRAS inhibitor drug, preferably a KRAS G12C mutation drug.

[0202] The present invention further provides a preferred technical solution, which further relates to a method for treating diseases mediated by KRAS inhibitors using the compound of general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, or said pharmaceutical composition, comprising administering a therapeutically effective amount of the compound of general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, or said pharmaceutical composition to a patient.

[0203] In some embodiments, the compounds and compositions of the invention are used in the manufacture of a medicament for treating a disease or condition such as Noonan syndrome, leopard skin syndrome, leukemia, neuroblastoma, melanoma, breast cancer, esophageal cancer, head and neck tumors, stomach cancer, lung cancer, and colon cancer.

[0204] The compounds and compositions of the present invention are used in therapeutic methods in manufacture to treat diseases or conditions such as Noonan syndrome, leopard skin syndrome, leukemia, neuroblastoma, melanoma, breast cancer, esophageal cancer, head and neck tumors, lung cancer, and colon cancer.

[0205] In some embodiments, the present invention provides a method of treating a cancer condition, comprising administering to a patient suffering from the cancer condition a compound or composition of the present invention. In some embodiments, the cancer treated by the compounds or compositions of the present invention is Noonan syndrome, leopard skin syndrome, leukemia, neuroblastoma, melanoma, breast cancer, esophageal cancer, head and neck tumors, gastric cancer, lung cancer, and colon cancer, preferably non-small cell lung cancer, colon cancer, esophageal cancer, and head and neck tumors. Detailed Description of the Invention Unless otherwise stated, terms used in the specification and claims have the following meanings:

[0206] The term "alkyl" refers to a saturated aliphatic hydrocarbon group containing 1 to 20 carbon atoms. The alkyl groups may be linear or branched, preferably alkyl groups containing 1 to 8 carbon atoms, more preferably alkyl groups containing 1 to 6 carbon atoms, and most preferably alkyl groups containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof.More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. Alkyl can be substituted or unsubstituted, and if substituted, the substituents can be substituted at any available point of attachment. The substituents can be independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, or the like. Mercapto Preferably, the alkyl group is one or more groups selected from the group consisting of hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy, and carboxylate. In the present invention, the alkyl group is preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkyl substituted with alkoxy, and alkyl substituted with hydroxy.

[0207] The term "alkylene" refers to an alkyl in which one hydrogen atom has been further substituted. For example, "methylene" refers to -CH2-, "ethylene" refers to -(CH2)2-, "propylene" refers to -(CH2)3-, and "butylene" refers to -(CH2)4-. The term "alkenyl" refers to an alkyl as defined above composed of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, etc. Alkenyl can be substituted or unsubstituted, and when substituted, the substituents can be independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio.

[0208] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic carbon atom. refers to a hydrogen substituent. Cycloalkyl rings contain 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene, cyclooctyl, and the like. Polycyclic cycloalkyls include spirocyclic, fused-ring, and bridged-ring cycloalkyls, with cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl being preferred.

[0209] The term "spirocycloalkyl" refers to a polycyclic group in which one carbon atom (called a spiro atom) is shared between 5- to 20-membered monocyclic rings; it may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. It is preferably 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of spiro atoms shared between the rings, spirocycloalkyls are classified as monospirocycloalkyls, bisspirocycloalkyls, or polyspirocycloalkyls; preferred are monospirocycloalkyls and bisspirocycloalkyls. More preferred are 3-membered / 6-membered, 3-membered / 5-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocycloalkyls. Non-limiting examples of spirocycloalkyls include:

[0210] [ka]

[0211] Additionally included are monospirocycloalkyls and spirocycloalkyls in which the heterocycloalkyls share a spiro atom. Non-limiting examples include:

[0212] [ka]

[0213] The term "fused cycloalkyl" refers to an all-carbon polycyclic group of 5 to 20 members in which each ring in the system shares an adjacent pair of carbon atoms with another ring in the system, and one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. It is preferably 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of constituent rings, fused cycloalkyls are classified as bicyclic, tricyclic, tetracyclic, or polycyclic. They are preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyls. Non-limiting examples of fused cycloalkyls include the following:

[0214] [ka]

[0215] The term "bridged cycloalkyl" refers to a 5- to 20-membered all-carbon polycyclic group having any two rings that share two carbon atoms that are not directly connected, where one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. It is preferably 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of constituent rings, bridged cycloalkyls are classified as bicyclic, tricyclic, tetracyclic, or polycyclic. They are preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyls include the following:

[0216] [ka]

[0217] Said cycloalkyl ring can be fused to an aryl, heteroaryl, or heterocycloalkyl ring, where the ring connected to the parent structure is a cycloalkyl, non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc. Cycloalkyls can be substituted or unsubstituted, and if substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylate.

[0218] The term "heterocyclic group" refers to a saturated or partially unsaturated, monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more of the ring atoms is nitrogen, oxygen, or S(O). m(m is an integer of 0 to 2), but does not include the ring moiety -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. The heterocyclic group preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably contains 3 to 8 ring atoms, most preferably contains 3 to 8 ring atoms, and even more preferably is a 3- to 8-membered heterocyclic group containing 1 to 3 nitrogen atoms, optionally substituted by 1 to 2 oxygen atoms, sulfur atoms, or oxo groups, and includes a nitrogen-containing monocyclic heterocyclic group, a nitrogen-containing spiro heterocyclic group, or a nitrogen-containing fused heterocyclic group.

[0219] Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and the like. The heterocyclic groups include pyrrolidinyl, morpholinyl, homopiperazinyl, azepinyl, 1,4-diazepanyl, pyranyl, etc., and are preferably pyrrolidinyl, morpholinyl, piperidinyl, azepinyl, 1,4-diazepanyl, and piperazinyl. The polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups. Here, the spirocyclic, fused-ring, and bridged-ring heterocyclic groups are optionally connected to other groups via a single bond, or further connected to other cycloalkyl, heterocyclic, aryl, and heteroaryl groups via any two or more atoms on the ring.

[0220] The term "spiroheterocyclic group" refers to a polycyclic heterocyclic group that shares one atom (called a spiro atom) between 5- to 20-membered monocyclic rings, where one or more ring atoms is nitrogen, oxygen, or S(O) m(m is an integer of 0 to 2), and the remaining ring atoms are carbon. Spiroheterocyclic groups may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. They are preferably 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of spiro atoms shared between rings, spiroheterocyclic groups are classified as monospiroheterocyclic groups, dispiroheterocyclic groups, or polyspiroheterocyclic groups, with monospiroheterocyclic groups and dispiroheterocyclic groups being preferred. More preferred are 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospiroheterocyclic groups. Non-limiting examples of spiroheterocyclic groups include the following:

[0221] [ka]

[0222] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, and one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, where one or more ring atoms is nitrogen, oxygen, or S(O) m (m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered. Depending on the number of constituent rings, it is classified as a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, and is preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include the following:

[0223] [ka]

[0224] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group having any two rings that share two atoms that are not directly connected, where one or more rings may contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system, and where one or more ring atoms is nitrogen, oxygen, or S(O) m (m is an integer of 0 to 2), and the remaining ring atoms are carbon. Preferably, it has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it is classified as a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group, and is preferably a bicyclic, tricyclic or tetracyclic group, more preferably a bicyclic or tricyclic group. Non-limiting examples of bridged heterocyclic groups include the following:

[0225] [ka]

[0226] The heterocyclic group can be fused to an aryl, heteroaryl, or cycloalkyl ring, where the ring connected to the parent structure is a heterocyclic group, non-limiting examples of which include:

[0227] [ka]

[0228] Heterocyclic groups may be substituted or unsubstituted, and if substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylate.

[0229] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated π-electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. Phenyl is more preferred. The aryl ring can be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, including 5- to 10-membered benzo heteroaryl, 3- to 8-membered benzo cycloalkyl, and 3- to 8-membered benzo heteroalkyl, preferably 5- to 6-membered benzo heteroaryl, 3- to 6-membered benzo cycloalkyl, and 3- to 6-membered benzo heteroalkyl, where the heterocyclic group is a heterocyclic group containing 1 to 3 nitrogen, oxygen, or sulfur atoms, or also includes ternary nitrogen-containing fused rings containing a benzene ring.

[0230] where the ring connected to the parent structure is an aryl ring, non-limiting examples include:

[0231] [ka]

[0232] Aryl may be substituted or unsubstituted, and if substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate.

[0233] The term "heteroaryl" refers to a heteroaryl group containing 1 to 4 heteroatoms and 5 to 14 ring atoms. Heteroaryl refers to an aromatic system, where the heteroatom is selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5-12 membered, more preferably 5-6 membered, and is, for example, imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably triazolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, pyrimidinyl, or thiazolyl, more preferably pyrazolyl, pyrrolyl, or oxazolyl. The heteroaryl ring can be fused to an aryl, heterocyclic group, or cycloalkyl ring, where the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:

[0234] [ka]

[0235] Heteroaryl may be optionally substituted or unsubstituted, and if substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate.

[0236] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), where alkyl is as defined above. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy. An alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, or the like. Mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate.

[0237] The term "alkylthio" refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), where alkyl is as defined above. Non-limiting examples of alkoxy include methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, and cyclohexylthio. Alkylthio may be optionally substituted or unsubstituted, and when substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate.

[0238] "Alkylthio-alkyl" refers to an alkylthio connected to an alkyl, where alkyl and alkylthio are defined above. "Alkylaminocarbonyl" refers to (alkyl)-NC(O)-, where alkyl is defined above.

[0239] "Haloalkyl" refers to an alkyl substituted with one or more halogens, where the alkyl group is as defined above. "Haloalkoxy" refers to an alkoxy substituted with one or more halogens, where alkoxy is defined above.

[0240] "Haloalkoxy" refers to alkylthio substituted with one or more halogens, where alkylthio is defined above. "Hydroxyalkyl" refers to alkyl substituted with hydroxy, where alkyl is defined above.

[0241] "Alkenyl" refers to an alkenyl group, also called an olefin group, wherein the alkenyl is an alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy, or carboxylate.

[0242] "Alkynyl" refers to (CH≡C-), where alkynyl is alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, Mercapto , hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy, or carboxylate and related groups.

[0243] The term "alkenylcarbonyl" refers to -C(O)-(alkenyl), where alkenyl is as defined above. Non-limiting examples of alkenylcarbonyl include vinylcarbonyl, propenylcarbonyl, and butenylcarbonyl. Alkenylcarbonyl can be optionally substituted or unsubstituted, and when substituted, the substituents are independently alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, or the like. Mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate.

[0244] "Hydroxy" refers to the group --OH. "Halogen" refers to fluorine, chlorine, bromine, or iodine. "Amino" refers to -NH2.

[0245] "Cyano" refers to -CN. "Nitro" refers to -NO2. "Carbonyl" refers to -C(O)-.

[0246] "Carboxyl" refers to --C(O)OH. "THF" refers to tetrahydrofuran. "EtOAc" refers to ethyl acetate.

[0247] "MeOH" refers to methanol. "DMF" refers to N,N-dimethylformamide. "DIPEA" refers to diisopropylethylamine.

[0248] "TFA" refers to trifluoroacetic acid. "MeCN" refers to acetonitrile. "DMA" refers to N,N-dimethylacetamide.

[0249] "Et2O" refers to diethyl ether. "DCE" refers to 1,2-dichloroethane. "DIPEA" refers to N,N-diisopropylethylamine.

[0250] "NBS" refers to N-bromosuccinimide. "NIS" refers to N-iodosuccinimide. "Cbz-Cl" refers to benzyl chloroformate.

[0251] "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium. "Dppf" refers to 1,1'-bisdiphenylphosphinoferrocene. "HATU" refers to 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[0252] "KHMDS" refers to potassium hexamethyldisilazide. "LiHMDS" refers to lithium bistrimethylsilylamide. "MeLi" stands for methyllithium.

[0253] "n-BuLi" refers to n-butyllithium. "NaBH(OAc)3" refers to sodium triacetoxyborohydride. Different terms such as "X is selected from A, B, or C," "X is selected from A, B, and C," "X is A, B, or C," and "X is A, B, and C" all mean the same thing, i.e., X is one or more of A, B, and C.

[0254] Any hydrogen atom described in the present invention can be substituted with its isotope, deuterium, and any hydrogen atom in the compounds of the examples of the present invention can also be substituted with a deuterium atom.

[0255] "Optional" or "optionally" means that the event or circumstance described below may occur, but does not necessarily have to occur, and the description includes cases where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with alkyl" means that alkyl may be present, but is not necessarily present. The description includes cases where the heterocyclic group is substituted with alkyl and cases where the heterocyclic group is not substituted with alkyl.

[0256] "Substituted" refers to one or more, preferably 5, more preferably 1 to 3 hydrogen atoms in a group being independently replaced by a corresponding number of substituents. Needless to say, the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, amino or hydroxyl having free hydrogen may be unstable when bonded to a carbon atom having an unsaturated (e.g., olefinic) bond.

[0257] A "pharmaceutical composition" refers to a mixture containing one or more of the compounds described herein, or physiologically / pharmaceutically acceptable salts or prodrugs thereof, and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, which is advantageous for the absorption of the active ingredient and therefore the exertion of biological activity.

[0258] "Pharmaceutically acceptable salt" refers to salts of compounds of the present invention, which are safe and effective when used in a mammalian body and possess the appropriate biological activity. DETAILED DESCRIPTION OF THE INVENTION

[0259] The present invention will be described below in conjunction with examples, but these examples do not limit the scope of protection of the present invention. Example The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (?) are expressed in parts per million (pp The NMR was measured using a Bruker AVANCE-400 nuclear magnetic resonance spectrometer in deuterated dimethyl sulfoxide (DMSO-d), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3), with tetramethylsilane (TMS) as the internal standard.

[0260] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1200 Infinity Series mass spectrometer. HPLC analysis was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150 × 4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C). 18 A 150 x 4.6 mm column is used.

[0261] Thin-layer chromatography silica gel plates are Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plates. The TLC specifications are 0.15mm to 0.20mm, while the thin-layer chromatography specifications for separating and purifying products are 0.4mm to 0.5mm. Column chromatography typically uses Yantai Yellow Sea silica gel 200-300 mesh silica gel as the carrier.

[0262] The starting materials in the examples of the present invention are known, commercially available, or can be synthesized using or according to methods known in the art. Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring under a dry nitrogen or argon atmosphere, solvents are dry solvents, and reaction temperatures are in degrees Celsius.

[0263] Example 1 Preparation of (S)-2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(4-methylpiperazine-1-carbonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[0264] [ka]

[0265] [ka]

[0266] Step 1: Preparation of 7-(tert-butyl) 2-methyl 4-hydroxy-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate

[0267] [ka]

[0268] 1-(tert-butyl) 4-ethyl 3-carbonylpiperidine-1,4-dicarboxylate (10 g, 37 mmol) and methyl 2-amino-2-iminoacetate hydrochloride (5.1 g, 37 mmol) were dissolved in ethanol (100 mL), sodium ethoxide (2.7 g, 40 mmol) was added, the mixture was heated to 75°C and stirred for 15 hours, concentrated under reduced pressure to remove excess solvent, water was added, and the mixture was neutralized with 1 M dilute hydrochloric acid. The solid precipitated was filtered, washed with water, and dried to obtain the target product, 7-(tert-butyl) 2-methyl 4-hydroxy-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (3.8 g, yield: 33%).

[0269] MS m / z (ESI): 310.1 [M+H] + . Step 2: Preparation of 7-(tert-butyl) 2-methyl 4-(((trifluoromethyl)sulfonyl)oxo)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate

[0270] [ka]

[0271] 7-(tert-butyl) 2-methyl 4-hydroxy-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (3.7 g, 12.0 mmol) was dissolved in dichloromethane (100 mL), cooled to 0 °C, DIPEA (2.7 g, 24.1 mmol) and TfO (5.1 g, 18.1 mmol) were added, and the mixture was stirred at room temperature overnight. The mixture was concentrated and purified by column chromatography (EtOAc / Petro ether = 5:1) to give the target product 7-(tert-butyl) 2-methyl 4-hydroxy-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (3.7 g, 12.0 mmol). 4-(((trifluoromethyl)sulfonyl)oxo)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (4.5 g, yield: 85%) was obtained.

[0272] Step 3: Preparation of 7-(tert-butyl) 2-methyl(S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate

[0273] [ka]

[0274] 7-(tert-Butyl) 2-methyl 4-(((trifluoromethyl)sulfonyl)oxo)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (3.5 g, 7.9 mmol) was dissolved in DMF (50 mL), and benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate (2.5 g, 9.7 mmol) and DIPEA (2.7 g, 24.1 mmol) were added. The mixture was heated to 100 °C under nitrogen protection and stirred for 3 h. After cooling, the mixture was extracted with water and ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (Et0Ac / Petro ether = 3:1) to give the target product 7-(tert-butyl) 2-methyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (3.7 g, yield: 85%).

[0275] MS m / z (ESI): 551.1 [M+H] + . Step 4: Preparation of (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate

[0276] [ka]

[0277] 7-(tert-butyl) 2-methyl (S)-4-(4-(benzyloxy)carbonyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (1.5 g, 2.7 mmol) was dissolved in dichloromethane (30 mL), TFA (2 mL, 27.2 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was adjusted to neutral with saturated aqueous NaHCO3 and extracted three times with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the target product, methyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (1.3 g, crude).

[0278] MS m / z (ESI): 451.1 [M+H] + . Step 5: Preparation of (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate

[0279] [ka]

[0280] Methyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (1.3 g, 2.7 mmol) was dissolved in toluene (50 mL). 1-Bromo-8-methylnaphthalene (1.2 g, 5.4 mmol), Pd(dba) (275 mg, 0.3 mmol), RuPhos (280 mg, 0.6 mmol), and CsCO (326 mg, 1.0 mmol) were added. The mixture was purged with nitrogen three times and stirred at 100 °C for 15 h. The mixture was concentrated to remove the toluene and extracted with water and ethyl acetate (3 × 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (Et0Ac / Petro ether = 3:1) to give the target product, methyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (550 mg, yield: 35%).

[0281] MS m / z (ESI): 591.1 [M+H] + . Step 6: Preparation of (S)-methyl 4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate

[0282] [ka]

[0283] Ammonia was poured into MeOH (20 mL) at -70°C for 30 minutes, and methyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (500 mg, 0.85 mmol) and Pd / C (250 mg, water content 10%) were added. The mixture was purged with hydrogen and stirred at room temperature for 1 hour under 15 psi of hydrogen. After completion of the reaction, the catalyst was filtered off and washed with MeOH, and the organic phase was concentrated to give the target product, (S)-4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (320 mg, yield: 83%).

[0284] MS m / z (ESI): 457.1 [M+H] + . Step 7: Preparation of (S)-methyl 4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate

[0285] [ka]

[0286] (S)-4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (300 mg, 0.66 mmol) was dissolved in dichloromethane (10 mL), DIPEA (220 mg, 2.0 mmol) was added, and acrylic acid chloride (66 mg, 0.73 mmol) was added dropwise at room temperature. After the addition, the mixture was stirred for an additional 1 h. The mixture was quenched with water and extracted three times with dichloromethane (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (EtOAc / Petro ether = 5:1) to give the target product, (S)-4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate methyl ester (275 mg, yield: 82%).

[0287] MS m / z (ESI): 511.1 [M+H] + . Step 8: (S)-4-(4-acryloyl-3-(cyanomethyl)piperazine-1-yl) Preparation of (1-methyl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylic acid

[0288] [ka]

[0289] (S)-4-(4-Acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylate (270 mg, 0.53 mmol) was dissolved in THF / HO (10 mL / 5 mL), LiOH·HO (220 mg, 5.3 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The mixture was adjusted to neutrality with 1M hydrochloric acid and extracted three times with ethyl acetate (3*20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude target product (S)-4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylic acid (280 mg, crude).

[0290] MS m / z (ESI): 497.1 [M+H] + . Step 9: Preparation of (S)-2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(4-methylpiperazine-1-carbonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[0291] [ka]

[0292] (S)-4-(4-Acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-carboxylic acid (30 mg, 0.05 mmol) was dissolved in DMF (10 mL), DIPEA (0.5 mL) and HATU (20 mg, 0.06 mmol) were added, and the mixture was stirred at room temperature for 0.5 h. N-methylpiperazine (10 mg, 0.1 mmol) was added, and the mixture was stirred for another 3 hours. Water was added, and the mixture was extracted with dichloromethane (3*20 mL), washed with water (20 mL), washed with saturated brine (20 mL), and the organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (CHCl / MeOH=10:1) to give the target product (S)-2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(4-methylpiperazine-1-carbonyl)-5-methylpiperazine-1- ... ,6,7,8-Tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (10 mg, yield: 35%) was obtained. MS m / z (ESI): 579.1 [M+H] + . For the preparation of Examples 2 to 20, refer to Example 1.

[0293] Example 21 Preparation of 1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0294] [ka]

[0295] [ka]

[0296] Step 1: Preparation of 2,5,6-trichloronicotinamide

[0297] [ka]

[0298] 2,5,6-Trichloronicotinic acid (8 g, 35.5 mmol) was dissolved in 80 mL of anhydrous tetrahydrofuran, and N'N-carbonyldiimidazole (6.3 g, 39 mmol) was added to the reaction solution in batches. The mixture was heated to 50°C and stirred for 1 hour. Toluene was added and the mixture was concentrated to 50 mL under reduced pressure. The mixture was cooled to 0°C and ammonia water (9.5 mL, 22 mmol) was added. The reaction mixture was then added dropwise and stirred at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated and extracted three times with ethyl acetate / petroleum ether (1 / 3). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give a white solid. The solid was slurried in ethyl acetate / petroleum ether (1 / 5) and purified to give the target product, 2,5,6-trichloronicotinamide (5.6 g, yield: 70%).

[0299] Step 2: Preparation of N-carbamoyl-2,5,6-trichloronicotinamide

[0300] [ka]

[0301] 2,5,6-Trichloronicotinamide (5 g, 22.3 mmol) was dissolved in 40 mL of anhydrous tetrahydrofuran. Oxalyl chloride (2.0 mL, 23.8 mmol) was added dropwise at -78 °C, and the mixture was heated to 60 °C and stirred for 3.5 h. The mixture was cooled to -78 °C, triethylamine (9.7 mL, 68.9 mmol) and aqueous ammonia (22 mL, 51 mmol) were added, and the mixture was stirred at room temperature for 1 h to complete the reaction. The mixture was concentrated and extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, concentrated, slurried in ethyl acetate / petroleum ether (1 / 5), and purified to give the target product, N-carbamoyl-2,5,6-trichloronicotinamide (3.5 g, 58% yield).

[0302] Step 3: Preparation of 6,7-dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0303] [ka]

[0304] N-Carbamoyl-2,5,6-trichloronicotinamide (3.2 g, 12.0 mmol) was dissolved in THF (100 mL) and KHMDS (24.0 mL, 1 M THF solution, 24.0 mmol) was added dropwise under nitrogen protection in an ice-water bath. After the addition was complete, the mixture was gradually warmed to room temperature and stirred for 1 h. The mixture was quenched with saturated aqueous NH4Cl and extracted with ethyl acetate (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl2 / MeOH = 10:1) to give the target product, 6,7-dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.1 g, yield: 76%).

[0305] MS m / z (ESI): 232.1 [M+H] + ,234.1 [M+H+2] + . Step 4: Preparation of 6-chloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0306] [ka]

[0307] 6,7-Dichloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2 g, 8.6 mmol) was dissolved in dioxane (100 mL), 2-fluoro-6-methoxyphenylboronic acid (2.2 g, 12.9 mmol), tris(dibenzylideneacetone)dipalladium (459 mg, 0.5 mmol), Xantphos (580 mg, 1 mmol), and CsCO (8.5 g, 25.9 mmol) were added, and the atmosphere was purged with nitrogen. The reaction mixture was heated to 110 °C and reacted overnight. After cooling to room temperature, it was diluted with 200 mL of ethyl acetate, filtered through Celite, and the filtrate was rotovapped and purified by column chromatography (CHCl / MeOH=10:1) to give the target product 6-chloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (1.9 g, yield: 68%).

[0308] MS m / z (ESI): 322.1 [M+H] + ,324.1 [M+H+2] + . Step 5: Preparation of 2,4,6-trichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine

[0309] [ka]

[0310] 6-Chloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (1.8 g, 5.6 mmol) was dissolved in POCl (50 mL), protected with nitrogen, and stirred for 10 h at 80 °C. The mixture was quenched by adding ice water dropwise, and the solid product was filtered, washed with water, and dried to give the crude target product, 2,4,6-trichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine (1.5 g, 75% yield).

[0311] Step 6: Preparation of tert-butyl 4-(2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate

[0312] [ka]

[0313] 2,4,6-Trichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine (1.5 g, 4.2 mmol) was dissolved in dichloromethane (30 mL), N-tert-butyloxyformyl-piperazine (940 mg, 5.0 mmol), and triethanolamine (1.3 g, 12.9 mmol) were added, and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was poured into ice water and extracted three times with dichloromethane (30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give the crude product, which was purified by column chromatography (EtOAc / petro ether = 3:1) to give the target product, tert-butyl 4-(2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.4 g, yield: 65%).

[0314] MS m / z (ESI): 508.1 [M+H] + ,510.1 [M+H+2] + . Step 7: Preparation of 2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)-4-(piperazin-1-yl)pyrido[2,3-d]pyrimidine

[0315] [ka]

[0316] tert-Butyl 4-(2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.4 g, 2.8 mmol) was dissolved in dichloromethane (20 mL), TFA (2 mL) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was adjusted to neutral with saturated aqueous NaHCO3 and extracted three times with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the target product, 2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)-4-(piperazin-1-yl)pyrido[2,3-d]pyrimidine (1.4 g, crude).

[0317] MS m / z (ESI): 408.1 [M+H] + ,410.1 [M+H+2] + . Step 8: Preparation of 1-(4-(2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0318] [ka]

[0319] 2,6-Dichloro-7-(2-fluoro-6-methoxyphenyl)-4-(piperazine (4-(2,6-dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidine-4-yl)piperazin-1-yl)prop-2-en-1-one (1 g, 77% yield).

[0320] MS m / z (ESI): 462.1 [M+H] + ,464.1 [M+H+2] + . Step 9: Preparation of 1-(4-(6-chloro-7-(2-fluoro-6-methoxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0321] [ka]

[0322] 1-(4-(2,6-Dichloro-7-(2-fluoro-6-methoxyphenyl)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (200 mg, 0.43 mmol) was dissolved in THF (20 mL), (S)-(1-methylpyrrolidin-2-yl)methanol (100 mg, 0.86 mmol) and sodium tert-butoxide (124 mg, 1.29 mmol) were added, the mixture was protected with nitrogen, and stirred at room temperature for 2 hours. The mixture was quenched with water and extracted three times with ethyl acetate (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product 1-(4-(6-chloro-7-(2-fluoro-6-methoxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (40 mg, yield: 18%).

[0323] MS m / z (ESI): 541.1 [M+H] + ,543.1 [M+H+2] + . Step 10: Preparation of 1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0324] [ka]

[0325] 1-(4-(6-chloro-7-(2-fluoro-6-methoxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (40 mg, 0.07 mmol) was dissolved in dichloromethane (10 mL), cooled to -40 °C, BBr (35 mg, 0.14 mmol) was added dropwise, and the mixture was gradually warmed to room temperature and stirred for 2 hours. The mixture was quenched by the addition of saturated aqueous NaHCO and extracted three times with ethyl acetate (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by preparative HPLC to give the target product 1-(4-(6-chloro-7-(2-fluoro-6-hydroxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (13 mg, yield: 33%). MS m / z (ESI): 527.1 [M+H] + ,529.1 [M+H+2] + . For the preparation of Examples 22 to 30, refer to Example 21.

[0326] Example 31 Preparation of (S)-1-(4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazin-1-yl)prop-2-en-1-one

[0327] [ka]

[0328] [ka]

[0329] Step 1: Preparation of tert-butyl 5-methoxy-3-carbonyl-3,6-dihydropyridine-1(2H)-carboxylate

[0330] [ka]

[0331] tert-Butyl 3,5-dicarbonylpiperidine-1-carboxylate (10 g, 46.9 mmol) and triethyl orthoformate (6 mL) were dissolved in methanol / toluene (50 mL / 150 mL), p-toluenesulfonic acid (400 mg, 2.3 mmol) was added, the mixture was heated to 110° C. and stirred for 5 hours, cooled to room temperature, washed with 10% NaOH in saturated aqueous NaCl solution, the organic phase was dried over anhydrous sodium sulfate, concentrated to give the crude product, which was purified by column chromatography (EtOAc / Petro ether = 10:1) to give the target product tert-butyl 5-methoxy-3-carbonyl-3,6-dihydropyridine-1(2H)-carboxylate (7.8 g, yield: 73%).

[0332] Step 2: Preparation of tert-butyl 7-methoxy-5-azaspiro[2.5]oct-7-ene-5-carboxylate

[0333] [ka]

[0334] tert-Butyl 5-methoxy-3-carbonyl-3,6-dihydropyridine-1(2H)-carboxylate (7.6 g, 33.5 mmol) was dissolved in 100 mL of ether, tetraisopropyl titanyl oxide (10 mL) was added, and ethylmagnesium bromide (33.5 mL, 3 M ether solution, 100.5 mmol) was added dropwise at room temperature. After the addition was complete, the mixture was stirred for another 3 hours. After the reaction was complete, the mixture was quenched by adding water dropwise, filtered through Celite, washed with ethyl acetate, and extracted three times with ethyl acetate. The organic layers were combined and washed with anhydrous sodium sulfate. Drying and concentration gave the target product tert-butyl 7-methoxy-5-azaspiro[2.5]oct-7-ene-5-carboxylate (8.8 g, crude).

[0335] Step 3: Preparation of tert-butyl 7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate

[0336] [ka]

[0337] tert-Butyl 7-methoxy-5-azaspiro[2.5]oct-7-ene-5-carboxylate (8.8 g, 33.5 mmol) was dissolved in THF (50 mL), protected with nitrogen, and p-toluenesulfonic acid monohydrate (2 g, 10.5 mmol) was added and stirred at room temperature for 15 h. The organic layer was washed with saturated aqueous NaHCO3, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (EtOAc / petro ether = 10:1) to give the target product, tert-butyl 7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate (4.5 g, 60% yield).

[0338] Step 4: Preparation of tert-butyl (Z)-8-((dimethylamino)methylene)-7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate

[0339] [ka]

[0340] tert-Butyl 7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate (4.3 g, 19.1 mmol) was dissolved in DMF-DMA (10 mL), protected with nitrogen, heated to 100 °C, and stirred for 5 h. Concentration gave the crude target product tert-butyl (Z)-8-((dimethylamino)methylene)-7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate (4.5 g), which was used directly in the next reaction.

[0341] MS m / z (ESI): 281.1 [M+H] + . Step 5: Preparation of tert-butyl 2'-hydroxy-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]-7'(8'H)-carboxylate

[0342] [ka]

[0343] (Z)-tert-Butyl 8-((dimethylamino)methylene)-7-carbonyl-5-azaspiro[2.5]octane-5-carboxylate (4.5 g, 19.1 mmol) was dissolved in EtOH (20 mL), and urea (1.7 g, 28.7 mmol) was added. The mixture was heated to °C and stirred for 15 hours. After cooling to room temperature, water was added and the mixture was extracted three times with ethyl acetate (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product, tert-butyl 2'-hydroxy-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]-7'(8'H)-carboxylate (4.6 g, yield: 69%).

[0344] MS m / z (ESI): 278.1 [M+H] + . Step 6: Preparation of tert-butyl (S)-2'-((1-methylpyrrolidin-2-yl)methoxy)-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]-7'(8'H)-carboxylate

[0345] [ka]

[0346] tert-Butyl 2'-hydroxy-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]-7'(8'H)-carboxylate (1 g, 3.6 mmol) was dissolved in DMF (100 mL), (S)-(1-methylpyrrolidin-2-yl)methyl methanesulfonate (1 g, 5.2 mmol), and K2CO3 (1.5 g, 10.8 mmol) were added, and the mixture was stirred at room temperature for 15 h. Water was added, and the mixture was extracted three times with ethyl acetate (30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH=10:1) to give the target product tert-butyl (S)-2′-((1-methylpyrrolidin-2-yl)methoxy)-6′H-spiro[cyclopropane-1,5′-pyrido[3,4-d]pyrimidine]-7′(8′H)-carboxylate (1.1 g, yield: 82%).

[0347] MS m / z (ESI): 375.1 [M+H] + . Step 7: Preparation of (S)-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]

[0348] [ka]

[0349] (S)-tert-Butyl 2'-((1-methylpyrrolidin-2-yl)methoxy)-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]-7'(8'H)-carboxylate (1 g, 2.7 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (2 mL) was added, stirred at room temperature for 3 hours, and concentrated to give the crude product. 1-Bromo-8-methylnaphthalene (1.2 g, 5.4 mmol), Pd2(dba)3 (275 mg, 0.3 mmol), RuPhos (280 mg, 0.6 mmol), and Cs2CO3 (326 mg, 1.0 mmol) were dissolved in toluene (20 mL). The reaction mixture was stirred at 100°C for 15 hours after adding 1,000 ml of toluene and purging with nitrogen three times. The mixture was concentrated to remove toluene, and extracted with water and ethyl acetate (3 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product (S)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] / / / (S)-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (450 mg, yield: 41%).

[0350] MS m / z (ESI): 415.1 [M+H] + . Step 8: Preparation of (S)-4'-chloro-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]

[0351] [ka]

[0352] (S)-7'-(8-Methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (400 mg, 0.97 mmol) was dissolved in DMF (10 mL), protected with nitrogen, and NCS (150 mg, 1.13 mmol) was added and stirred at 80°C for 15 hours. Water was added and the mixture was extracted three times with ethyl acetate (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product (S)-4'-chloro-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (180 mg, yield: 41%).

[0353] MS m / z (ESI): 449.1 [M+H] + . Step 9: Preparation of (S)-tert-butyl 4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazine-1-carboxylate

[0354] [ka]

[0355] (S)-4'-Chloro-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (180 mg, 0.40 mmol) was dissolved in DMF (10 mL), N-tert-butoxyacylpiperazine (224 mg, 1.20 mmol) and DIPEA (155 mg, 1.20 mmol) were added, and the mixture was protected with nitrogen, heated to 80 °C, and stirred for 3 h. The mixture was cooled and extracted with water and ethyl acetate (3 x 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product (S)-tert-butyl 4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazine-1-carboxylate (120 mg, yield: 50%).

[0356] MS m / z (ESI): 599.1 [M+H] + . Step 10: Preparation of (S)-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-4'-(piperazin-1-yl)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine]

[0357] [ka]

[0358] (S)-tert-Butyl 4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazine-1-carboxylate (110 mg, 0.18 mmol) was dissolved in dichloromethane (10 mL), TFA (0.5 mL) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was adjusted to neutrality with saturated aqueous NaHCO3 and extracted three times with dichloromethane (3 x 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the target product (S)-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-4'-(piperazin-1-yl)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (130 mg, crude).

[0359] MS m / z (ESI): 499.1 [M+H] + . Step 11: Preparation of (S)-1-(4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazin-1-yl)prop-2-en-1-one

[0360] [ka]

[0361] (S)-7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-4'-(piperazin-1-yl)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidine] (130 mg, 0.18 mmol) was dissolved in dichloromethane (10 mL), DIPEA (71 mg, 0.55 mmol) was added, and acrylic acid chloride (20 mg, 0.22 mmol) was added dropwise at room temperature. After the addition, the mixture was stirred for an additional 1 h. The mixture was quenched with water and extracted three times with dichloromethane (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by preparative HPLC to give the target product (S)-1-(4-(7'-(8-methylnaphthalen-1-yl)-2'-((1-methylpyrrolidin-2-yl)methoxy)-7',8'-dihydro-6'H-spiro[cyclopropane-1,5'-pyrido[3,4-d]pyrimidin]-4'-yl)piperazin-1-yl)prop-2-en-1-one (32 mg, yield: 32%). MS m / z (ESI): 553.1 [M+H] + . For the preparation of Examples 32 to 35, refer to Example 31.

[0362] Example 36 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-hydroxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one

[0363] [ka]

[0364] [ka]

[0365] Step 1: Preparation of 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diphenol

[0366] [ka]

[0367] Ethyl 1-benzyl-3-carbonylpiperidine-4-carboxylate (10 g, 38.3 mmol) was dissolved in EtOH (100 mL), urea (3.4 g, 57.5 mmol) was added, and the mixture was heated to 100 °C and stirred for 15 h. After cooling to room temperature, water was added, and the mixture was extracted three times with ethyl acetate (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product, 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diphenol (8.7 g, yield: 89%).

[0368] MS m / z (ESI): 258.1 [M+H] + . Step 2: Preparation of 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-phenol

[0369] [ka]

[0370] 7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diphenol (8 g, 31.1 mmol) was dissolved in 100 mL of dioxane. The mixture was heated to 0°C, and a solution of Lawesson's reagent (6.3 g, 15.5 mmol) in dioxane (20 mL) was added dropwise. After the addition, the mixture was allowed to react for another 1 hour; the mixture was cooled to room temperature and concentrated to remove the solvent. The solid was washed with a small amount of acetic acid, then with water, and dried. The crude product was added to SOCl2 (50 mL) in an ice-water bath, gradually warmed to room temperature, stirred for 10 hours, and concentrated to remove excess SOCl2 to obtain the crude target product, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-phenol (7.5 g, crude product), which was used directly in the next reaction.

[0371] MS m / z (ESI): 276.1 [M+H] + ,278.1 [M+H+2] + . Step 3: Preparation of tert-butyl (2R,5S)-4-(7-benzyl-2-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0372] [ka]

[0373] 7-Benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2-phenol (7.5 g, crude product) was dissolved in DMF (50 mL), tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (8.7 g, 40.8 mmol), and DIPEA (10.5 g, 81.6 mmol) were added, and the mixture was heated to 80°C under nitrogen protection and stirred for 3 h. After cooling, the mixture was extracted with water and ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product tert-butyl (2R,5S)-4-(7-benzyl-2-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (5.3 g, 38% yield for two steps).

[0374] MS m / z (ESI): 454.1 [M+H] + . Step 4: Preparation of tert-butyl (2R,5S)-4-(7-benzyl-1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0375] [ka]

[0376] (2R,5S)-4-(7-benzyl-2-hydroxy-5,6,7,8-tetrahydrofuran tert-Butyl propylido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (1 g, 2.2 mmol) was dissolved in dichloromethane (50 mL), and (4-fluoro-2-isopropylpyridin-3-yl)boric acid (806 mg, 4.4 mmol), copper acetate (72 mg, 0.4 mmol), pyridine (348 mg, 4.4 mmol), and molecular sieves were added. The mixture was stirred overnight at room temperature in an open-mouthed state. The mixture was washed with saturated aqueous Na2CO3 and then with water. After washing, the organic layer was dried over anhydrous sodium sulfate and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH=10:1) to give the target product (2R,5S)-tert-butyl 4-(7-benzyl-1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (650 mg, yield: 50%).

[0377] MS m / z (ESI): 591.1 [M+H] + . Step 5: Preparation of tert-butyl (2R,5S)-4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0378] [ka]

[0379] (2R,5S)-tert-butyl 4-(7-benzyl-1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (600 mg, 1.0 mmol) was dissolved in EtOH (20 mL), Pd(OH)2 / C (60 mg) was added, the mixture was purged with hydrogen three times, and the mixture was stirred at room temperature under a hydrogen balloon for 15 hours. Filtration, washing with ethanol, and concentration gave the target product (2R,5S)-tert-butyl 4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (420 mg, yield: 83%).

[0380] MS m / z (ESI): 501.1 [M+H] + . Step 6: Preparation of tert-butyl (2R,5S)-4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0381] [ka]

[0382] (2R,5S)-tert-Butyl 4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (400 mg, 0.8 mmol) was dissolved in toluene (20 mL). 2-Bromo-1-fluoro-3-methoxybenzene (326 mg, 1.6 mmol), Pd(dba) (92 mg, 0.1 mmol), RuPhos (93 mg, 0.2 mmol), and CsCO (105 mg, 3.2 mmol) were added. The mixture was purged with nitrogen three times and stirred at 100 °C for 15 h. The mixture was concentrated to remove the toluene and extracted with water and ethyl acetate (3 × 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH=10:1) to give the target product (2R,5S)-4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate tert-butyl ester (270 mg, yield: 54%).

[0383] MS m / z (ESI): 625.1 [M+H] + . Step 7: Preparation of 4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one

[0384] [ka]

[0385] (2R,5S)-tert-butyl 4-(1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-2-carbonyl-1,2,5,6,7,8-hexahydropyrido[3,4-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (250 mg, 0.4 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (0.5 mL) was added, stirred at room temperature for 3 hours, and concentrated to give the crude target product 4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-5,6,7,8-tetrahydropyrido[ 3,4-d]pyrimidin-2(1H)-one (320 mg, crude product) was obtained.

[0386] MS m / z (ESI): 525.1 [M+H] + . Step 8: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one

[0387] [ka]

[0388] 4-((2S,5R)-2,5-Dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one (320 mg, 0.4 mmol) was dissolved in dichloromethane (10 mL), DIPEA (155 mg, 1.2 mmol) was added, and acrylic acid chloride (45 mg, 0.5 mmol) was added dropwise at room temperature. After the addition, the mixture was stirred for an additional 1 hour. The mixture was quenched with water and extracted three times with dichloromethane (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one (170 mg, yield: 74%).

[0389] MS m / z (ESI): 579.1 [M+H] + . Step 9: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-hydroxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one

[0390] [ka]

[0391] 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro- 6-Methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one (150 mg, 0.26 mmol) was dissolved in dichloromethane (10 mL), cooled to -40 °C, BBr (650 mg, 2.60 mmol) was added dropwise, and the mixture was allowed to warm to room temperature and stirred for 1 h. The mixture was quenched with saturated aqueous NaHCO and extracted with dichloromethane (3 x 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by preparative HPLC to give the target product 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(4-fluoro-2-isopropylpyridin-3-yl)-7-(2-fluoro-6-hydroxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2(1H)-one (52 mg, yield: 36%). MS m / z (ESI): 565.1 [M+H] + . For the preparation of Examples 37 to 50, refer to Example 36.

[0392] Example 51 Preparation of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0393] [ka]

[0394] Step 1: Preparation of tert-butyl 4-(4-chlorobutyrylamino)piperidine-1-carboxylate

[0395] [ka]

[0396] tert-Butyl 4-aminopiperidine-1-carboxylate (5 g, 24.9 mmol) and 4-chlorobutyryl chloride (4.2 g, 29.8 mmol) were dissolved in CHCl (50 mL). DIPEA (6.5 g, 49.8 mmol) was added under ice-bath conditions and stirred at room temperature for 4 hours. Water was added and the mixture was extracted three times with CHCl (50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (petro ether / EtOAc = 4:1) to give the target product tert-butyl 4-(4-chlorobutyrylamino)piperidine-1-carboxylate (7.2 g, yield: 94%).

[0397] MS m / z (ESI): 305.2 [M+H] + . Step 2: 4-(2-oxopyrrolidin-1-yl)piperidine-1-carboxylic acid tert- Preparation of t-butyl

[0398] [ka]

[0399] tert-Butyl 4-(4-chlorobutyrylamino)piperidine-1-carboxylate (1.0 g, 3.3 mmol) was dissolved in THF (10 mL), added with NaH (0.26 g, 6.6 mmol) in an ice bath, heated to reflux, stirred for 16 h, and extracted three times with water and ethyl acetate (50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (petro ether / EtOAc = 2:1) to give the target product tert-butyl 4-(2-oxopyrrolidin-1-yl)piperidine-1-carboxylate (0.85 g, 94% yield).

[0400] MS m / z (ESI): 269.1 [M+H] + . Step 3: Preparation of tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate

[0401] [ka]

[0402] tert-Butyl 4-(2-oxopyrrolidin-1-yl)piperidine-1-carboxylate (0.5 g, 1.86 mmol) was dissolved in anhydrous THF (10 mL), protected with nitrogen, and cooled to -78 °C. LiHMDS (3.8 mL, 3.72 mmol) was added and stirred for 1 h. Diethyl carbonate (0.44 g, 3.72 mmol) was added and stirred at -78 °C for 1 h, then gradually warmed to room temperature. Stirring continued for an additional 2 h. The mixture was quenched with water and extracted with water and ethyl acetate (3 × 10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude product tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate (0.6 g, crude).

[0403] Step 4: Preparation of 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxopyrrolidine-3-carboxylic acid

[0404] [ka]

[0405] Tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate (0.6 g, crude product) was dissolved in MeOH / HO (1:1, 20 mL), lithium hydroxide (89 mg, 2.1 mmol) was added, and the mixture was stirred at room temperature overnight. 20% aqueous acetic acid was added to adjust the pH to 5.0-6.0. Extraction with chloromethane (3*15 mL) was added, and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude target product 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxopyrrolidine-3-carboxylic acid (0.52 g, yield: 79%).

[0406] MS m / z (ESI): 311.1 [MH] + . Step 5: Preparation of tert-butyl 4-(3-methylene-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate

[0407] [ka]

[0408] 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-oxopyrrolidine-3-carboxylic acid (0.5 g, crude product) and paraformaldehyde (72 mg, 2.4 mmol) were dissolved in ethyl acetate (10 mL). Diethylamine (0.14 g, 1.9 mmol) was added to the reaction mixture under ice bath conditions. The reaction mixture was then heated to reflux and stirred for 3 hours. After cooling, water and ethyl acetate (3*10 mL) were added and extracted. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (Petro ether / EtOAc = 2:1) to obtain the target product tert-butyl 4-(3-methylene-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate. (0.36 g, yield: 80%).

[0409] MS m / z (ESI): 281.1 [M+H] + . Step 6: Preparation of 3-methylene-1-(piperidin-4-yl)pyrrolidin-2-one hydrochloride

[0410] [ka]

[0411] tert-Butyl tert-butyl 4-(3-methylene-2-oxopyrrolidin-1-yl)piperidine-1-carboxylate (100 mg, 0.35 mmol) was dissolved in 2M HCl / EtOH (5 mL), stirred at room temperature for 2 hours, and concentrated to remove the solvent to give crude product 3-methylene-1-(piperidin-4-yl)pyrrolidin-2-one hydrochloride (80 mg, crude).

[0412] MS m / z (ESI): 181.1 [M+H] + . Step 7: Preparation of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0413] [ka]

[0414] N,N-diisopropylethylamine (0.14 g, 1.11 mmol) was added to a solution of 7-chloro-6-fluoro-4-hydroxy-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[4,3-d]pyrimidin-2(1H)-one (130 mg, 0.37 mmol) in acetonitrile (10 mL) at room temperature, and phosphorus oxychloride (167 mg, 1.11 mmol) was added and stirred at 80 ° C. for 1 hour. The mixture was cooled to room temperature. N,N-diisopropylethylamine (0.14 g, 1.11 mmol) was added to the reaction mixture, and the mixture was stirred for 5 minutes. 3-methylene-1-(piperidin-4-yl)pyrrolidin-2-one hydrochloride (80 mg, crude product) was added and stirred for 1 hour. The reaction was quenched with aqueous ammonium chloride solution (10 mL), extracted with ethyl acetate (30 mL × 3), and the organic phase was washed with aqueous sodium chloride solution (10 mL), rotary evaporated, and purified by preparative chromatography [eluent: dichloromethane:methanol = 20:1] to give a pale yellow solid product, 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyridin-2(1H)-one (52 mg, yield: 27%).

[0415] MS m / z (ESI): 511.2 [M+H] + . Step 7: Preparation of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0416] [ka]

[0417] 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (52 mg, 0.10 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (34 mg, 0.2 mmol), [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium dichloromethane complex (9 mg, 0.01 mmol), and cesium carbonate (97 mg, 0.3 mmol) were heated in a microwave oven at 100 °C in dioxane (4 mL) and water (1 mL) and stirred for 1 h. The reaction mixture was spun down and purified by preparative HPLC to give the yellow solid product 6-fluoro-7-(4-chloro-6-fluoro-7-(4-methylpyridin-3-yl)pyridin-1-yl)pyridin-1-ylpyridin-1-yl)pyridin-2(1H)-one (52 mg, 0.10 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (34 mg, 0.2 mmol), [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium dichloromethane complex (9 mg, 0.01 mmol), and cesium carbonate (97 mg, 0.3 mmol). The reaction mixture was heated in a microwave oven at 100 °C in dioxane (4 mL) and water (1 mL) and stirred for 1 h. The reaction mixture was spun down and purified by preparative HPLC to give the yellow solid product 6-fluoro-7-(4-chloro-6-fluoro-7-(4-methylpyridin-3-yl)pyridin-1-yl)pyridin-1-ylpyridin-1-yl)pyridin-2(1 -(2-Fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(4-(3-methyl-2-oxopyrrolidin-1-yl)piperidin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (15 mg, yield: 25%) was obtained.

[0418] MS m / z (ESI): 589.3 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 9.39 (s, 1H), 8.65 (s, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.30 (s, 2H), 6.82 - 6.57 (m, 2H), 6.04 (s, 1H), 5.39 (s, 1H), 4.75 (s, 2H), 4.50 (s, 1H), 3.45 (s, 4H), 2.83 (s, 2H), 2.06 (d, J = 29.5 Hz, 7H), 1.29 (s, 3H), 1.12 (s, 3H). For the preparation of Example 52 and Examples 58 to 74, refer to Example 51.

[0419] Example 60 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0420] [ka]

[0421] [ka]

[0422] Step 1: Preparation of 4-chloro-2-(prop-1-en-2-yl)pyridin-3-amine Made

[0423] [ka]

[0424] 2,4-Dichloropyridin-3-amine (4.5 g, 27.78 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (5.13 g, 30.56 mmol), potassium carbonate (11.5 g, 83.34 mmol), and Pd(PPh3)4 were added to dioxane (120 mL). The reaction mixture was mixed homogeneously and then heated to 100 °C in an oil bath and stirred overnight. The mixture was concentrated under reduced pressure, and the resulting crude product was purified by high-performance silica gel column chromatography to give the target compound, 4-chloro-2-(prop-1-en-2-yl)pyridin-3-amine (4.5 g, 96% yield), as a colorless oil.

[0425] MS m / z (ESI): 169.1 [M+H] + . Step 2: Preparation of 4-(methylthio)-2-(prop-1-en-2-yl)pyridin-3-amine

[0426] [ka]

[0427] 4-Chloro-2-(prop-1-en-2-yl)pyridin-3-amine (2 g, 11.9 mmol) and sodium methanethiol (10 mL, 20% aqueous solution) were added to dioxane (3 mL), and the reaction mixture was mixed homogeneously. The mixture was then reacted at 100°C for 2 days, cooled to room temperature, and concentrated under reduced pressure. The resulting crude product was separated and purified by high-performance silica gel column chromatography to obtain the compound 4-(methylthio)-2-(prop-1-en-2-yl)pyridin-3-amine (1.7 g, yield 79%) as a pale yellow liquid.

[0428] MS m / z (ESI): 181.2 [M+H] + . Step 3: Preparation of 2-isopropyl-4-(methylthio)pyridin-3-amine

[0429] [ka]

[0430] Methanol (50 mL) was added to 4-(methylthio)-2-(prop-1-en-2-yl)pyridin-3-amine (2 g, 11.11 mmol) and Pd / C (4 g), and the reaction mixture was homogeneously mixed. The mixture was then reacted overnight at room temperature and concentrated under reduced pressure. The resulting crude product was dissolved in methanol (5 mL), N,N-diisopropylethylamine (0.5 mL), and The mixture was added to a solution of acrylonitrile (1 mL) and reacted at room temperature for 2 hours. After concentration under reduced pressure, the resulting crude product was purified by high-performance silica gel column chromatography to obtain the compound 2-isopropyl-4-(methylthio)pyridin-3-amine (500 mg, yield 25%) as a colorless liquid.

[0431] MS m / z (ESI): 183.2 [M+H] + . Step 4: Preparation of 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide

[0432] [ka]

[0433] 2,6-dichloro-5-fluoronicotinamide (500 mg, 2.44 mmol), oxalyl chloride (1.32 mL, 2.54 mmol) and THF (10 mL) were added, and the reaction mixture was mixed homogeneously. The mixture was then reacted at 60 ° C. for 3 hours, and the reaction temperature was lowered to room temperature. Triethylamine (680 mg, 6.6 mmol), 2-isopropyl-4-(methylthio)pyridin-3-amine (400 mg, 2.2 mmol) were added, and the mixture was reacted at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by high-performance silica gel column chromatography to obtain the white solid compound 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (800 mg, yield 87%).

[0434] MS m / z (ESI): 417.1 [M+H] + . Step 5: Preparation of 7-chloro-6-fluoro-4-hydroxy-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0435] [ka]

[0436] 2,6-Dichloro-5-fluoro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (800 mg, 1.92 mmol) was added to THF (20 mL), and the reaction mixture was mixed uniformly. Then, under the condition of 0 ° C., KHMDS (4.8 mL, 4.8 mmol) was slowly added, and the mixture was allowed to react at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by high-performance silica gel column chromatography to obtain the white solid compound 7-chloro-6-fluoro-4-hydroxy-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (600 mg, yield 82%).

[0437] MS m / z (ESI): 381.1 [M+H] + . Step 6: Preparation of tert-butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

[0438] [ka]

[0439] 7-Chloro-6-fluoro-4-hydroxy-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (300 mg, 0.79 mmol), phosphorus oxychloride (600 mg, 3.95 mmol), DIPEA (1 g, 7.9 mmol) were added to THF (40 mL), the reaction mixture was mixed uniformly, and then reacted at 80°C for 1 hour. The reaction temperature was then lowered to room temperature, and tert-butyl (S)-3-methylpiperazine-1-carboxylate (240 mg, 1.19 mmol) was slowly added to the reaction mixture, and the reaction mixture was reacted at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the resulting crude product was separated and purified by high-performance silica gel column chromatography to obtain the compound tert-butyl ester as a white solid. (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (400 mg, 90% yield) was obtained.

[0440] MS m / z (ESI): 563.1 [M+H] + . Step 7: Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0441] [ka]

[0442] tert-Butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (400 mg, 0.71 mmol), TFA (2 mL) in CHCl (30 mL) After adding the mixture and mixing the reaction mixture homogeneously, the mixture was reacted at room temperature for 1 hour and then concentrated under reduced pressure. To the resulting crude product, CHCl (20 mL) and DIPEA (0.3 mL) were added, the reaction temperature was lowered to 0 °C, and acrylic acid chloride (0.1 mL) was slowly added to the reaction mixture. The mixture was reacted at room temperature for 1 hour and then concentrated under reduced pressure. The resulting crude product was separated and purified by high-performance silica gel column chromatography to give the desired compound (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (200 mg, 55% yield) as a yellow solid.

[0443] MS m / z (ESI): 517.1 [M+H] + . Step 8: Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0444] [ka]

[0445] (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (50 mg, 0.1 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (30 mg, 0.2 mmol), Pd(dppf)Cl2 (16 mg, 0.02 mmol), cesium carbonate (100 mg, 0.3 mmol) was added to dioxane (1.5 mL), and the reaction mixture was mixed homogeneously. After 1 hour of reaction under microwave heating at 100 ° C., the mixture was concentrated under reduced pressure. To the resulting crude product, CHCl (20 mL) and DIPEA (0.3 mL) were added, and the reaction temperature was lowered to 0 ° C. Acryloyl chloride (0.1 mL) was slowly added to the reaction mixture, and the mixture was reacted at room temperature for 1 hour and concentrated under reduced pressure. The resulting crude product was separated and purified by pre-HPLC to obtain the compound 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (14 mg, yield: 24%) as a white solid. MS m / z (ESI): 593.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.40 (d, J=5.6 Hz, 1H), 8.22-8.27 (m, 1 H),7.21-7.27 (m, 2H), 6.79-6.88(m, 1H), 6.58-6.66(m, 2H), 6.28-6.34 (m, 1H), 5.84(d, J=12.0 Hz, 1H), 5.06 (s, 1H), 4.43-4.59 (m, 2H), 4.07-4.23 (s, 1H), 3.57-3.85 (m, 2H), 3.20-3.48(m, 1H), 2.79-2.85(m, 1H), 2.41(s, 3H), 1.47(d, J=4.8Hz, 3H), 1.20 (d, J=6.4 Hz, 3H), 1.06 (d, J=6.8 Hz, 3H).

[0446] Example 60-1 and Example 60-2 (M / P-4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0447] [ka]

[0448] [ka]

[0449] [ka]

[0450] Example 60 is a compound obtained by SFC separation of two axially chiral isomers, Example 60-1 and Example 60-2. Example 60-2 was obtained. SFC: Chiral preparation conditions:

[0451] [Table 13]

[0452] Chiral analysis conditions:

[0453] [Table 14]

[0454] Example 60-1: t R =1.92 min MS m / z (ESI): 593.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.40 (d, J=5.6 Hz, 1H), 8.22-8.27 (m, 1 H), 7.21-7.27 (m, 2H), 6.79-6.88(m, 1H), 6.58-6.66(m, 2H), 6.28-6.34 (m, 1H), 5.84(d, J=12.0 Hz, 1H), 5.06 (s, 1H), 4.43-4.59 (m, 2H), 4.07-4.23 (s, 1H), 3.57-3.85 (m, 2H), 3.20-3.48(m, 1H), 2.79-2.85(m, 1H), 2.41(s, 3H), 1.47(d, J=4.8 Hz, 3H), 1.20 (d, J=6.4 Hz, 3H), 1.06 (d, J=6.8 Hz, 3H). Example 60-2: t R =2.43 min MS m / z (ESI):593.1 [M+H] + . 1 HNMR(400MHz, MeOD-d4) δ 8.40(d, J=5.6Hz, 1H), 8.25(t, J=10.8Hz, 1H), 7.21-7.27(m, 2H), 6.79-6.90(m, 1H), 6.58-6.66(m, 2H), 6.28-6.34(m, 1H), 5.83(dd, J=10.8Hz, 2.0Hz, 1H), 5.05-5.10(m, 1H), 4.41-4.57(m, 2H), 4.07-4.21(m, 1H), 3.61-3.87(m, 2H), 3.24-3.36(m, 1H), 2.77-2.83(m, 1 H), 2.41(s, 3H), 1.46-1.49 (m, 3H), 1.19(d, J=6.8Hz, 3H), 1.06(d, J=6.8Hz, 3H). For the preparation of Examples 71, 81-84, 114-117, 130-134, and Examples 139-141, refer to Example 60.

[0455] Example 75 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0456] [ka]

[0457] Step 1: Preparation of (2-fluoro-6-(methylthio)phenyl)boronic acid

[0458] [ka]

[0459] A solution of (3-fluorophenyl)(methyl)sulfane (500 mg, 3.52 mmol) in tetrahydrofuran (15 mL) at -78 °C was added to lithium diisopropylamide (5. After the addition, the dry ice bath was removed, the mixture was allowed to warm to room temperature, and the mixture was stirred for an additional 1 hour. The reaction was quenched with hydrochloric acid (2N, 20 mmol) and stirred for an additional 30 minutes. The reaction mixture was extracted with ethyl acetate (40 mL x 3), and the organic phase was washed with brine (30 mL), concentrated, and then purified by column chromatography [eluent: petroleum ether to ethyl acetate / petroleum ether 0% to 30%] to give (2-fluoro-6-(methylthio)phenyl)boronic acid (73 mg, 11% yield) as a white solid.

[0460] 1 H NMR (400 MHz, CDCl3) δ 7.43 - 7.33 ( m, 1H), 7.24 (d, J = 8 Hz, 1H), 7.01 - 6 .93 (m, 1H), 6.08 (br, 2H), 2.51 (s, 3H). Step 2: Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0461] [ka]

[0462] (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (50 mg, 0.103 mmol), (2-fluoro-6-(methylthio)phenyl)boronic acid (55 mg, 0.296 mmol), [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium dichloromethane complex (17 mg, 0.0206 mmol), and cesium carbonate (100 mg, 0.309 mmol) were stirred in dioxane (2.5 mL) and water (3 drops) at 100 °C under microwave heating for 1 hour. The reaction mixture was concentrated and purified by preparative chromatography [eluent: dichloromethane / methanol = 12 / 1] to give a yellow solid, 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (25 mg, yield: 41%).

[0463] MS m / z (ESI): 591.2 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.42 - 8.24 (m, 2H), 7.49 - 7.39 (m, 1H), 7.27 - 7.16 (m, 2H), 6.97 (t, J = 12 Hz, 1H), 6.85 (m, 1H), 6.31 (d, J = 12 Hz, 1H), 5.83 (d, J = 12 Hz, 1H), 5.22 - 5.00 (m, 1H), 4.65 - 4.37 (m, 2H), 4.28 - 4.02 (m, 1H) , 3.99 - 3.54 (m, 2H), 3.49 - 3.35 (m, 1H), 2.94 - 2.70 (m, 1H), 2.33 (s, 3H), 2. 04 (s, 3H), 1.60 - 1.41 (m, 3H), 1.18 (d , J = 8 Hz, 3H), 1.00 (s, 3H).

[0464] Example 75-1 and Example 75-2 (M / P-4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0465] [ka]

[0466] [ka]

[0467] [ka]

[0468] Example 75 was separated by SFC to give two axially chiral isomers, Example 75-1 and Example 75-2. SFC: Chiral preparation conditions:

[0469] [Table 15]

[0470] キラル analysis conditions:

[0471] Table 16

[0472] Example:75-1: t R =1.97 min MS m / z (ESI): 591.2 [M+H] + .

[0473] 1 H NMR (400 MHz, MeOD-d4) δ 8.42 - 8.24 (m, 2H), 7.49 - 7.39 (m, 1H), 7.27 - 7.16 (m, 2H), 6.97 (t, J = 12 Hz, 1H), 6.85 (m, 1H), 6.31 (d, J = 12 Hz, 1H), 5.83 (d, J = 12 Hz, 1H), 5.22 - 5.00 (m, 1H), 4.65 - 4.37 (m, 2H), 4.28 - 4.02 (m, 1H), 3.99 - 3.54 (m, 2H), 3.49 - 3.35 (m, 1H), 2.94 - 2.70 (m, 1H), 2.33 (s, 3H), 2. 04 (s, 3H), 1.60 - 1.41 (m, 3H), 1.18 (d , J = 8 Hz, 3H), 1.00 (s, 3H).

[0474] Example 75-2: t R =3.75 min MS m / z (ESI): 591.2 [M+H] + .

[0475] 1 H NMR (400 MHz, MeOD-d4) δ 8.40 - 8.23 (m, 2H), 7.48 - 7.38 (m, 1H), 7.25 - 7.16 (m, 2H), 6.96 (t, J = 12 Hz, 1H), 6.85 (m, 1H), 6.31 (d, J = 12 Hz, 1H), 5.82 (d, J = 12 Hz, 1H), 5.20 - 5.00 (m, 1H), 4.64 - 4.36 (m, 2H), 4.28 - 4.02 (m, 1H), 3.99 - 3.54 (m, 2H), 3.48 - 3.34 (m, 1H), 2.93 - 2.70 (m, 1H), 2.33 (s, 3H), 2. 04 (s, 3H), 1.58 - 1.40 (m, 3H), 1.18 (d , J = 8 Hz, 3H), 1.00 (s, 3H).

[0476] Example 77 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylsulfonyl-6-fluoro)phenyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0477] [ka] MS m / z (ESI): 623.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.37 (d, J = 4 Hz, 2H), 7.92 (d, J = 4 Hz, 1H), 7.86 - 7.73 (m, 1H), 7.62 (t, J = 8 Hz, 1H) , 7.27 - 7.15 (m, 1H), 6.95 - 6.74 (m, 1H), 6.39 - 6.23 (m, 1H), 5.89 - 5.79 (m, 1H), 5.32 - 5.00 (m, 1H), 4.66 - 4.31 (m, 2H), 4.28 - 4.03 (m, 1H), 3.97 - 3.51 (m, 2H), 3.48 - 3.34 (m, 2H), 2.70 (s, 3H), 2.13 (s, 3H), 1.60 - 1.37 (m, 3H), 1.17 - 1.09 (m, 3H), 0.92 (d, J = 8 Hz, 3H).

[0478] Example 85 Preparation of 4-(4-acryloyl-2-vinylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0479] [ka]

[0480] [ka]

[0481] Step 1: Preparation of tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazine-1-carboxylate

[0482] [ka]

[0483] N,N-diisopropylethylamine (1.63 g, 12.9 mmol) was added to a solution of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (1.5 g, 4.3 mmol) in acetonitrile (50 mL) at room temperature, followed by phosphorus oxychloride (1.94 g, 12.9 mmol) and stirring at 80 °C for 1 hour. The mixture was cooled to room temperature. N,N-diisopropylethylamine (1.63 g, 12.9 mmol) was added to the reaction mixture, followed by stirring for 5 minutes. tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate (2.8 g, 12.9 mmol) was added and stirred for 1 hour. The reaction was quenched with aqueous ammonium chloride solution (10 mL), extracted with ethyl acetate (50 mL × 3), and the organic phase was washed with aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (CHCl:MeOH = 10:1) to give the target product tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazine-1-carboxylate (1.9 g, yield: 81%).

[0484] MS m / z (ESI): 547.1 [M+H] + , 549.1 [M+H+2] + . Step 2: tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2, Preparation of [3-d]pyrimidin-4-yl)-3-formylpiperazine-1-carboxylate

[0485] [ka]

[0486] tert-Butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazine-1-carboxylate (1.8 g, 3.3 mmol) was dissolved in dichloromethane (100 mL), and the Dess-Martin oxidant DMP (1.7 g, 4.0 mmol) was added in portions at room temperature. The mixture was stirred for 3 hours, filtered through Celite, and the filtrate was washed with saturated aqueous NaHCO3 (30 mL), then with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (Petro ether / EtOAc = 5:1-1:1) to give the target product tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl)-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazine-1-carboxylate (1.8 g, 3.3 mmol). 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-formylpiperazine-1-carboxylate (1.2 g, yield: 67%) was obtained.

[0487] MS m / z (ESI): 545.1 [M+H] + , 547.1 [M+H+2] + . Step 3: Preparation of tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-vinylpiperazine-1-carboxylate

[0488] [ka]

[0489] Methyltriphenylphosphonium bromide (295 mg, 0.83 mmol) was dissolved in anhydrous THF (20 mL), protected with nitrogen, and cooled to -78 °C. n-BuLi (3 mL, 0.75 mmol, 2.5 M in hexane) was added and stirred for 10 minutes. The mixture was then warmed to room temperature and stirred for 1 hour. The mixture was cooled to -78 °C and tert-butyl 4-(7-chloro- A solution of 6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-formylpiperazine-1-carboxylate (300 mg, 0.55 mmol) in THF (5 mL) was added dropwise and stirred for 1 hour. The mixture was gradually warmed to room temperature and stirred for an additional 2 hours. The mixture was quenched with saturated aqueous ammonium chloride solution and extracted with water and ethyl acetate (3 x 10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (Petro ether / EtOAc = 5:1-1:1) to give tert-butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-vinylpiperazine-1-carboxylate (160 mg, yield: 54%).

[0490] MS m / z (ESI): 543.1 [M+H] + , 545.1 [M+H+2] + . Step 4: Preparation of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-vinylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0491] [ka]

[0492] tert-Butyl 4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-vinylpiperazine-1-carboxylate (150 mg, 0.28 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (1 mL) was added, stirred at room temperature for 1 hour, and concentrated to give the crude target product 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-vinylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (220 mg, crude).

[0493] MS m / z (ESI): 443.1 [M+H] + , 445.1 [M+H+2] + . Step 5: Preparation of 4-(4-acryloyl-2-vinylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0494] [ka]

[0495] 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-vinylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (220 mg, 0.28 mmol) was dissolved in dichloromethane (10 mL), DIPEA (108 mg, 0.84 mmol) was added, and acrylic acid chloride (30 mg, 0.34 mmol) was added dropwise at room temperature. After the addition, the mixture was stirred for another 1 h. The mixture was quenched with water and extracted three times with dichloromethane (10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 10:1) to give the target product 4-(4-acryloyl-2-vinylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (75 mg, total yield for two steps: 54%).

[0496] MS m / z (ESI): 497.1 [M+H] + , 499.1 [M+H+2] + . Step 6: Preparation of 4-(4-acryloyl-2-vinylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0497] [ka]

[0498] 4-(4-Acryloyl-2-vinylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (50 mg, 0.10 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (34 mg, 0.2 mmol), [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium dichloromethane complex (9 mg, 0.01 mmol), and cesium carbonate (97 mg, 0.3 mmol) were stirred in dioxane (4 mL) and water (1 mL) at 100 °C under microwave heating for 1 hour. The reaction was concentrated and purified by preparative HPLC to give the product 4-(4-acryloyl-2-vinylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl)- To the obtained product, 8 mg (14% yield) of (4-methyl-4-pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was obtained.

[0499] MS m / z (ESI): 573.1 [M+H] + . See Example 75 for the preparation of Examples 76-80, Examples 85-113 and Examples 118-129.

[0500] Example 114 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0501] [ka]

[0502] Step 1: Preparation of 4,7-dichloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0503] [ka]

[0504] To a solution of 7-chloro-6-fluoro-4-hydroxy-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (200 mg, 0.526 mmol) in acetonitrile (10 mL) was added N,N-diisopropylethylamine (407 mg, 3.16 mmol) and phosphorus oxychloride (242 mg, 1.58 mmol) at room temperature, followed by stirring at 80 ° C. for 1 hour. The mixture was cooled to room temperature and used as is in the next reaction.

[0505] Step 2: Preparation of tert-butyl (2R,5S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0506] [ka]

[0507] To the reaction mixture from the above step were added N,N-diisopropylethylamine (678 mg, 5.26 mmol) and tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (224 mg, 1.005 mmol), and the mixture was stirred at room temperature for 1 hour. Water (60 mL) was added, and the mixture was extracted with ethyl acetate (40 mL × 3). The organic phase was washed with aqueous ammonium chloride solution (40 mL) and then with aqueous sodium chloride solution (30 mL). After concentration, the mixture was purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 2.2%] to give a yellow solid, tert-butyl (2R,5S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (200 mg, 66% yield for two steps).

[0508] MS m / z (ESI): 577.2 [M+H] + ,579.2 [M+H+2] + Step 3: Preparation of 7-chloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate

[0509] [ka]

[0510] To a solution of tert-butyl (2R,5S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (200 mg, 0.347 mmol) in dichloromethane (6 mL), trifluoroacetic acid (1.2 mL) was added, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated at low temperature to give a red oil, 7-chloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (200 mg), which was used immediately in the next step.

[0511] MS m / z (ESI): 477.2 [M+H] + , 479.2 [M+H+2] + . Step 4: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0512] [ka]

[0513] 7-chloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (200 mg, 0.347 mmol) in dichloromethane (15 mL) solution, N,N-diisopropylethylamine (447 mg, 3.47 mmol) was added, and acrylic acid chloride (63 mg, 0.694 mmol) was added dropwise at 0 ° C., and the mixture was stirred for 1 hour. The reaction was quenched with aqueous ammonium chloride solution (30 mL) and extracted with dichloromethane (30 mL × 3). The dichloromethane layer was washed with saturated aqueous NaCl solution (20 mL), dried over anhydrous sodium sulfate, concentrated, and then purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 2.5%] to give a yellow solid, 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (130 mg, 71% yield for two steps).

[0514] MS m / z (ESI): 530.2 [M+H] + , 532.2 [M+H+2] + . Step 5: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0515] [ka]

[0516] 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (130 mg, 0.2 46 mmol), (2-fluoro-6-hydroxyphenyl)boronic acid (77 mg, 0.491 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (40 mg, 0.0491 mmol), and cesium carbonate (240 mg, 0.738 mmol) were added to dioxane (8 mL) and water (1 mL), the atmosphere was purged with nitrogen, and the mixture was stirred at 100°C under microwave heating for 1 hour. The reaction mixture was concentrated and purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 2.5%] to give a yellow solid, 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (90 mg, 60% yield). MS m / z (ESI): 606.2 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.40 (d, J = 8 Hz, 1H), 8.29-8.18 (m, 1H), 7.30- 7. 18 (m, 2H), 6.93-6.73 (m, 1H), 6.70-6.56 (m, 2H), 6.36-6.20 (m, 1H), 5.89-5.75 (m, 1H), 5.15-4.98 (m, 1H), 4.63-4.22 (m, 2H), 4.11-3.82 (m, 2H), 3.68-3.40 (m, 1H), 2.88-2.65 (m, 1H), 2.40 (d, J = 4 Hz, 3H ), 1.53 - 1.43 (m, 3H), 1.36 (t, J = 8H z, 1H), 1.28 (t, J = 8 Hz, 2H), 1.23 - 1 .16 (m, 3H), 1.10 - 1.01 (m, 3H).

[0517] Example 114-1 and Example 114-2 (M / P-4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0518] [ka]

[0519] [ka]

[0520] [ka]

[0521] Example 114 was separated by SFC to give two axially chiral isomers, Example 114-1 and Example 114-2. SFC: Chiral preparation conditions:

[0522] [Table 17]

[0523] Chiral analysis conditions: [Table 18]

[0524] Example 114-1: t R =1.99 min MS m / z (ESI): 606.2 [M+H] + .

[0525] 1 H NMR (400 MHz, MeOD-d4) δ 8.40 (d, J = 8 Hz, 1H), 8.29-8.18 (m, 1H), 7.30 - 7. 18 (m, 2H), 6.93-6.73 (m, 1H), 6.70-6.56 (m, 2H), 6.36-6.20 (m, 1H), 5.89-5.75 (m, 1H), 5.15-4.98 (m, 1H), 4.63-4.22 (m, 2H), 4.11-3.82 (m, 2H), 3.68-3.40 (m, 1H), 2.88-2.65 (m, 1H), 2.40 (d, J = 4 Hz, 3H ), 1.53 - 1.43 (m, 3H), 1.36 (t, J = 8 H z, 1H), 1.28 (t, J = 8 Hz, 2H), 1.23 - 1 .16 (m, 3H), 1.10 - 1.01 (m, 3H).

[0526] Example 114-2: t R =2.87 min MS m / z (ESI): 606.2 [M+H] + .

[0527] 1 H NMR (400 MHz, MeOD-d4) δ 8.40 (d, J = 8 Hz, 1H), 8.27-8.18 (m, 1H), 7.30 - 7 .19 (m, 2H), 6.94 - 6.74 (m, 1H), 6.70 - 6.56 (m, 2H), 6.36 - 6.20 (d, J = 16 Hz, 1H), 5.90 - 5.75 (m, 1H), 5.14 - 4.98 (m, 1H), 4.63 - 4.22 (m, 2H), 4.12 - 3.82 (m, 2H), 3.68 - 3.41 (m, 1H), 2.87 - 2.65 (m, 1H), 2.40 (d, J = 4 Hz, 3H), 1.53 - 1.42 (m, 3H), 1.36 (t, J = 8 Hz, 1H), 1.28 (t, J = 8 Hz, 2H), 1.23 - 1.16 (d, J = 4 Hz, 3H), 1.10 - 1.01 (d, J = 4 Hz, 3 H).

[0528] Example 115 Preparation of 4-((3S,5R)-4-acryloyl-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0529] [ka] For the preparation of 4-((3S,5R)-4-acryloyl-3,5-dimethylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one, see Example 114.

[0530] MS m / z (ESI): 607.1 [M+H] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.39-8.34 (m, 2H), 7.25 - 7.20 (m, 2H), 6.86-6. 80 (m, 1H), 6.67-6.58 (m, 2H), 6.32- 6.27 (dd, J = 16.6, 4.0 Hz, 1H), 5.83-5.79 (dd, J = 12.0, 4.0 Hz, 1H), 4.65-4.48 (m, 4H), 3.84-3.72 (m, 2H), 2.82-2.75 (m, 1H), 2.38 (s, 3H), 1.50-1.44 (dd, J = 16.0, 8.0Hz, 6H), 1.20-1.18 (d, J = 8.0 Hz, 3H), 1.07-1.05 (d, J = 8.0 Hz, 3H).

[0531] Example 133 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylsulfonyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0532] [ka] Step 1: Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylsulfonyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0533] [ka]

[0534] 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (80 mg, 0.14 mmol) and potassium hydrogen persulfate complex (520 mg, 0.84 mmol) were dissolved in a solvent (acetonitrile:water = 2:1). (9 mL) and reacted overnight at room temperature. The resulting crude product was separated and purified by preparative HPLC to obtain the target compound 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylsulfonyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (13 mg, 15% yield) as a white solid.

[0535] MS m / z (ESI): 625.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.88 (d, J=4.8Hz, 1H), 8.23-8.29 (m, 1 H),7.87 (d, J=5.2 Hz, 1H), 7.23(dd, J1=14.8Hz, J2=8.0Hz, 1H), 6.78-6.85 (m, 1H), 6.57-6.65 (m, 2H), 6.31(dd, J1=16.4Hz, J2=3.2Hz, 1H), 5.83(dd, J1=10.8Hz, J2=1.6Hz, 1H), 5.08 (s, 1H),4.43-4.55 (m, 2H), 4.06-4.23 (s, 1H), 3.61-3.86 (m,2H), 3.11-3.40 (m, 1H), 2.94-2.99(m, 4H), 1.46-1.50(m, 3H), 1.20-1.22(m, 3H), 1.07-1.09 (m, 3H).

[0536] Example 134 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0537] [ka] Step 1: Preparation of N-(4-chloro-3-fluorophenyl)-2,2,2-trifluoroacetamide

[0538] [ka]

[0539] 4-Chloro-3-fluoroaniline (1.45 g, 0.01 mol) was dissolved in THF (150 mL), Na2CO3 (3.18 g, 0.03 mol) was added, and the mixture was protected with nitrogen and cooled to 0 °C. Trifluoroacetic anhydride (4.2 mL, 0.03 mol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 10 hours. The reaction mixture was added to water (150 mL). The mixture was extracted three times with ethyl acetate (100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (PE / EA = 5:1) to give the target product N-(4-chloro-3-fluorophenyl)-2,2,2-trifluoroacetamide (2.3 g, 95% yield) as a white solid.

[0540] 1 H NMR (400 MHz, MeOD-d4) δ 7.70 (dd, J = 11.1, 2.0 Hz, 1H), 7.49 - 7.40 (m, 2H ); 19 F NMR (376 MHz, MeOD-d4) δ -77.17 (s); MS m / z (ESI): 242.1 [M+H] + .

[0541] Step 2: Preparation of (6-amino-3-chloro-2-fluorophenyl)boronic acid

[0542] [ka]

[0543] N-(4-chloro-3-fluorophenyl)-2,2,2-trifluoroacetamide (2.3 g, 9.5 mmol) was dissolved in THF (40 mL), protected with nitrogen, cooled to -78 °C, and n-BuLi (7.9 mL, 19.0 mmol, 2.4 M) was added dropwise. After completion of the addition, the mixture was stirred at -50°C for 50 minutes. The reaction mixture was cooled to -78°C and triisopropyl borate (2.3 g, 9.5 mmol) (4.8 mL, 20.9 mmol) was added dropwise. After the addition was complete, the mixture was stirred at the same temperature for 20 minutes. The dry ice bath was removed and the mixture was stirred at room temperature for 2 hours. The reaction mixture was then cooled to 0°C, and dilute hydrochloric acid (19 mL, 1 M) was added dropwise. The mixture was then heated to 40°C and stirred for 1 hour. The mixture was extracted three times with ethyl acetate (100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product, which was purified by column chromatography (PE / EA = 4:1) to give the target product (6-amino-3-chloro-2-fluorophenyl)boronic acid (1.1 g, 56% yield) as a gray solid.

[0544] MS m / z (ESI): 190.0 [M+H] + . Step 3: Preparation of (2-amino-6-fluorophenyl)boronic acid

[0545] [ka]

[0546] (6-Amino-3-chloro-2-fluorophenyl)boronic acid (100 mg, 0.53 mmol) was dissolved in MeOH (20 mL), Pd / C (20 mg) was added, and the mixture was purged with hydrogen three times and stirred at 15 psi for 2 h. The reaction was complete as determined by TLC (PE / EA 1:1). The filtrate was filtered and concentrated to give the target product (2-amino-6-fluorophenyl)boronic acid (80 mg, 97% yield) as a yellow solid, which was used directly in the next reaction without further purification.

[0547] MS m / z (ESI): 156.0 [M+H] + . Step 4: Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0548] [ka]

[0549] (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (26 mg, 0.05 mmol), (6-amino-3-chloro-2-fluorophenyl)boronic acid (23.2 mg, 0.15 mmol), and cesium carbonate (48.87 mg, 0.15 mmol) were dissolved in dioxane / HO (1.5 mL / 0.3 mL). The atmosphere was purged with nitrogen for 1 minute, and the reaction was carried out under microwave conditions at 100°C for 1 hour. After completion of the reaction, the reaction solution was concentrated and purified by column chromatography. -(CHCl / MeOH=20:1) to give the crude product, which was then purified by preparative HPLC to give the target product 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (7.0 mg, 24% yield) as a yellow solid.

[0550] 1 H NMR (400 MHz, MeOD-d4) δ 8.46 (d, J = 5.4 Hz, 1H), 8.25 (dd, J = 21.2, 12.0 Hz, 1H), 7.27 (d, J = 5.5 Hz, 1H), 7.11 (dd, J = 14.7, 8.2 Hz, 1H), 6.84 (d, J = 14.2 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.41 - 6.27 (m, 2H), 5.83 (dd, J = 10.6 , 1.6 Hz, 1H), 4.48 (dd, J = 52.4, 11.6 Hz, 2H), 4.30 - 3.83 (m, 2H), 3.74 (d, J = 9.7 Hz, 2H), 3.22 (s, 1H), 2.98 - 2.8 0 (m, 1H), 2.43 (d, J = 0.7 Hz, 3H), 1.56 - 1.40 (m, 3H), 1.22 (d, J = 6.6 Hz, 3 H), 1.01 (d, J = 6.6 Hz, 3H). 19 F NMR (376 MHz, MeOD-d4) δ -114.58 - -114.95 (m), -114.95 - -115.34 (m), -125 .12 - -126.48 (m). MS m / z (ESI): 592.2 [M+H] + .

[0551] Example 136 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0552] [ka]

[0553] Step 1: Preparation of 6-fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0554] [ka]

[0555] 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (200 mg, 0.575 mmol), 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (192 mg, 0.862 mmol), [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium dichloromethane complex (47 mg, 0.0575 mmol), and cesium carbonate (561 mg, 1.725 mmol) were added to dioxane (8 mL) and water (1 mL) and stirred at 100°C in a microwave oven for 1 hour. The reaction mixture was concentrated and purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 3%] to give a yellow solid, 6-fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (200 mg, yield: 85%).

[0556] MS m / z (ESI): 410.1 [M+H] + Step 2: Preparation of 6-fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0557] [ka]

[0558] 6-Fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (170 mg, 0.416 mmol) and 20% sodium methanethiol The aqueous solution (218 mg, 0.623 mmol) was added to dimethyl sulfoxide (5 mL) and stirred at 85° C. for 4 hours. Water (40 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL × 3). The organic phase was washed with aqueous sodium chloride solution (30 mL) and concentrated. The resulting mixture was purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 2.5%] to give a yellow solid, 6-fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (128 mg, yield 70%).

[0559] MS m / z (ESI): 438.1 [M+H] + Step 3: Preparation of 4-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0560] [ka]

[0561] At room temperature, 6-fluoro-7-(2-fluoropyridin-3-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (200 mg, 0.458 mmol) was added to a solution of N,N-diisopropylethylamine (354 mg, 2.75 mmol) in acetonitrile (20 mL), and then phosphorus oxychloride (210 mg, 1.37 mmol) was added and stirred at 80 ° C. for 1 hour. The mixture was cooled to room temperature and used as is in the next reaction.

[0562] Step 4: Preparation of tert-butyl (S)-4-(6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

[0563] [ka]

[0564] To the reaction mixture from the above step were added N,N-diisopropylethylamine (588 mg, 4.58 mmol) and tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (183 mg, 4.5 mmol), and after the addition, the mixture was stirred at room temperature for 0.5 hours. The reaction was quenched with aqueous ammonium chloride (60 mL) and extracted with ethyl acetate (40 mL × 3). The organic phase was washed with aqueous sodium chloride (30 mL), concentrated, and then purified by column chromatography [eluent: dichloromethane to methanol / dichloromethane 0% to 2.8%] to give a yellow solid, tert-butyl (S)-4-(6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (220 mg, 78% yield for two steps).

[0565] MS m / z (ESI): 620.3 [M+H] + Step 5: Preparation of (S)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-methylpiperazin-1-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate

[0566] [ka]

[0567] tert-Butyl (S)-4-(6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (75 mg, 0.121 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL), and the mixture was stirred at room temperature for 0.5 hours. The reaction mixture was concentrated at low temperature to give a yellow oil, (S)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-methylpiperazin-1-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (80 mg), which was used immediately in the next step.

[0568] MS m / z (ESI): 520.2 [M+H] + Step 6: Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0569] [ka]

[0570] (S)-6-Fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-4-(2-methylpiperazin-1-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (80 mg, 0.121 mmol) in dichloromethane (10 mL) was added N,N-diisopropylethylamine (156 mg, 1.21 mmol), and acrylic acid chloride (33 mg, 0.363 mmol) was added at 0 ° C., and the mixture was stirred for 1 hour. The reaction was quenched with aqueous ammonium chloride solution (30 mL) and extracted with dichloromethane (30 mL × 3). The dichloromethane layer was washed with saturated brine solution (20 mL), dried over anhydrous sodium sulfate, and purified by preparative chromatography [eluent: dichloromethane / methanol = 12 / 1] to give a yellow solid, (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-7-(2-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-3-yl). The compound was purified by HPLC to give 26 mg of benzo-2(1H)-one (37% yield over two steps).

[0571] 1 H NMR (400 MHz, MeOD-d4) δ 8.50 - 8.45 (m, 1H), 8.40 (d, J = 4 Hz, 1H), 8.36 - 8.24 (m, 1H), 7.67 (d, J = 8 Hz, 1H), 7.26 (d, J = 8 Hz, 1H), 7.18 - 7.09 (m, 1 H), 6.94 - 6.76 (m, 1H), 6.38 - 6.26 (m, 1H), 5.89 - 5.79 (m, 1H), 5.23 - 4.93 (m, 2H), 4.63 - 4.36 (m, 2H), 4.28 - 4.02 (m, 1H), 3.99 - 3.52 (m, 2H), 2.90 - 2.72 (m, 1H), 2.37 (s, 3H), 2.07 (s, 3H), 1.58 - 1.40 (m, 3H), 1.18 (d, J = 8 Hz, 3H), 1.01 (d, J = 8 Hz, 3H). MS m / z (ESI): 574.2 [M+H] + .

[0572] Example 143 Preparation of 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-4-((S)-4-(2-fluoroacryloyl)-2-methylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0573] [ka]

[0574] Step 1: Preparation of tert-butyl (3S)-4-(6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

[0575] [ka]

[0576] tert-Butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (25 A mixture of (2-fluoro-6-(methylthio)phenyl)boronic acid (132 mg, 0.708 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (96 mg, 0.118 mmol), and cesium carbonate (460 mg, 1.42 mmol) in dioxane (8 mL) and water (1 mL) was stirred at 100°C in a microwave for 1 hour. The reaction mixture was spun down and purified by column chromatography [eluent: dichloromethane / methanol 0% to 3.5%] to give a yellow solid, tert-butyl (3S)-4-(6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (230 mg, 77% yield). MS m / z (ESI): 637.3 [M+H] + .

[0577] Step 2: Preparation of 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-((S)-2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate

[0578] [ka]

[0579] To a solution of tert-butyl (3S)-4-(6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (50 mg, 0.0786 mmol) in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was spun down at low temperature to give a red oil, 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-((S)-2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (51 mg, 100% yield), which was used immediately in the next step.

[0580] Step 3: Preparation of 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-4-((S)-4-(2-fluoroacryloyl)-2-methylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0581] [ka]

[0582] At 0 ° C., 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-((S)-2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one trifluoroacetate (51 mg, 0.0786 mmol) and N-methylmorpholine (55 mg, 0.55 mmol) in dichloromethane (10 mL) were added 2-fluoroacrylic acid (21 mg, 0.233 mmol) and 1-n-propylphosphoric acid anhydride (100 mg, 0.314 mmol), and the mixture was stirred at 0 ° C. for 1 hour. Water (20 mL) was added to the reaction mixture, which was then extracted with dichloromethane (20 mL * 2). The organic phase was concentrated and then purified by preparative chromatography [eluent: dichloromethane / methanol = 12 / 1] to obtain a yellow solid, 6-fluoro-7-(2-fluoro-6-(methylthio)phenyl)-4-((S)-4-(2-fluoroacryloyl)-2-methylpiperazin-1-yl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (35 mg, yield 61%).

[0583] 1 H NMR (400 MHz, MeOD-d4) δ 8.38 (d, J = 4 Hz, 1H), 8.35 - 8.25 (m, 1H), 7.49 - 7.39 (m, 1H), 7.26 - 7.17 (m, 2H), 6.98 (t, J = 8 Hz, 1H), 5.41 - 5.31 (m, 1H), 5.31 - 5.24 (m, 1H), 5.21 - 4.94 (m, 2H), 4.59 - 3.68 (m, 4H), 3.54 - 3.38 (m, 1H), 2.81 (s, 1H), 2.33 (s, 3H), 2.05 (s, 3H), 1.59 - 1.42 (m, 3H), 1.18 (d, J = 8 Hz, 3H), 0.99(brd, 3H). MS m / z (ESI): 609.2 [M+H] + .

[0584] For the preparation of Examples 144-149, see Example 143. Example 150 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0585] [ka]

[0586] (S)-4-(4-Acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (26.7 mg, 0.05 mmol), (6-amino-3-chloro-2-fluorophenyl)boronic acid (28.4 mg, 0.15 mmol), and potassium acetate (15.0 mg, 0.15 mmol) were dissolved in dioxane / HO (1.5 mL / 0.3 mL). The atmosphere was purged with nitrogen for 1 minute and the reaction was carried out under microwave conditions at 100 °C for 1 hour. After completion of the reaction, the reaction solution was concentrated and purified by column chromatography (CHCl / MeOH=20:1) to obtain the crude product, which was then purified by preparative HPLC to obtain the target product 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (3.7 mg, 14% yield) as a yellow solid.

[0587] MS m / z (ESI): 642.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.56 - 8.39 (m, 2H), 7.24 (t, J = 5.3 Hz, 1H), 7.15 (dd, J = 15.4, 6.9 Hz, 1H), 6.84 (d, J = 9.9 Hz, 1H), 6.53 - 6.46 (m, 1H), 6.32 (d, J = 15.9 Hz, 1H), 5.84 (d, J = 12.2 Hz, 1H), 4.68 - 4.36 (m, 3H), 4.10 (dd, J = 45.7, 31.6 Hz, 2H), 3.76 (s, 1H), 2.94 (s, 2H), 2.42 (d, J = 6.2 Hz, 3H), 1.57 - 1.43 (m, 3H), 1.22 (d, J = 6.7 Hz, 3H), 1.06 (dd, J = 42.4, 6.7 Hz, 3H). 19 F NMR (376 MHz, MeOD) δ -117.04 - -117. 24 (m), -117.24 - -117.51 ​​(m).

[0588] Example 150-1 and Example 150-2 (M / P-4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0589] [ka] [ka]

[0590] [ka]

[0591] Example 150 was separated by SFC to give two axially chiral isomers, Example 150-1 and Example 150-2. SFC: Chiral preparation conditions:

[0592] [Table 19]

[0593] Chiral analysis conditions:

[0594] [Table 20]

[0595] Example 150-1: t R =1.87 min MS m / z (ESI): 642.1 [M+H] + .

[0596] 1 H NMR (400 MHz, MeOD-d4) δ 8.56 - 8.39 (m, 2H), 7.24 (t, J = 5.3 Hz, 1H), 7.15 (dd, J = 15.4, 6.9 Hz, 1H), 6.84 (d, J = 9.9 Hz, 1H), 6.53 - 6.46 (m, 1H), 6.32 (d, J = 15.9 Hz, 1H), 5.84 (d, J = 12.2 Hz, 1H), 4.68 - 4.36 (m, 3H), 4.10 (dd, J = 45.7, 31.6 Hz, 2H), 3.76 (s, 1H), 2.94 (s, 2H), 2.42 (d, J = 6.2 Hz, 3H), 1.57 - 1.43 (m, 3H), 1.22 (d, J = 6.7 Hz, 3H), 1.06 (dd, J = 42.4, 6.7 Hz, 3H). 19F NMR (376 MHz, MeOD-d4) δ -117.04 - -117.24 (m), -117.24 - -117.51 ​​(m).

[0597] Example 150-2: t R =2.80 min MS m / z (ESI): 642.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.56 - 8.39 (m, 2H), 7.27 - 7.10 (m, 2H), 6.84 (dd, J = 28.3, 17.7 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 6.32 (d, J = 16.9 Hz, 1H), 5.83 (d, J = 11.7 Hz, 1H), 4.63 - 4.41 (m, 2H), 4.23 - 4.02 (m, 1H), 3.79 - 3.57 (m, 2H), 3.36 (s, 2H), 2.99 - 2.86 (m, 1H) , 2.41 (d, J = 7.6 Hz, 3H),1.51 (d, J = 25.9 Hz, 3H), 1.21 (d, J = 6.6 Hz, 3H), 1.05 (dd, J = 44.8, 6.7 Hz, 3H).

[0598] Example 151 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0599] [ka] (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (26 mg, 0.05 mmol), (6-amino-3-chloro-2-fluorophenyl)boronic acid (28.4 mg, 0.15 mmol), and cesium carbonate (48.8 mg, 0.15 mmol) were dissolved in dioxane / HO (1.5 mL / 0.3 mL). The atmosphere was purged with nitrogen for 1 minute, and the reaction was carried out in a microwave oven at 100 °C for 1 hour. After completion of the reaction, the reaction solution was spun dry and purified by column chromatography (CHCl / MeOH = 20:1) to obtain the crude product, which was then purified. Purification by preparative HPLC gave the target product 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (4.4 mg, 14% yield) as a yellow solid.

[0600] 1 H NMR (400 MHz, MeOD-d4) δ 8.47 (d, J = 5.4 Hz, 1H), 8.38 - 8.24 (m, 1H), 7.27 (d, J = 5.4 Hz, 1H), 7.17 (t, J = 8.6 Hz, 1H), 6.85 (d, J = 14.9 Hz, 1H), 6.49 (d, J = 8.9 Hz, 1H), 6.32 (d, J = 16.3 Hz, 1H), 5.84 (d, J = 10.5 Hz, 1H), 4.57 (d, J = 23.5 Hz, 2H), 4.42 (s, 1H), 4.24 - 3.89 (m, 2H), 3.73 (dd, J = 14.4, 7.9 Hz, 1H), 2.92 (s, 1H), 2.43 (s, 3H), 1.54 - 1.40 (m, 3H), 1.22 (d, J = 6.7 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H). 19 F NMR (376 MHz, MeOD-d4) δ -116.46 - -116.73 (m), -116.87 (dd, J = 39.0, 8.4 Hz), -126.18 (dd, J = 24.9, 15.2 Hz). MS m / z (ESI): 626.1 [M+H] + .

[0601] Example 152 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0602] [ka]

[0603] Step 1: Preparation of 6-bromo-2-isopropyl-4-(methylthio)pyridin-3-amine

[0604] [ka]

[0605] 2-Isopropyl-4-(methylthio)pyridin-3-amine (1g, 5.5mmol ) was dissolved in acetonitrile (15 mL), and N-bromosuccinimide (970 mg, 5.5 mmol) was added at 0 °C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was cooled to 0 °C, and saturated Na2SO3 was added dropwise to quench the reaction. Water and dichloromethane (3 × 10 mL) were added and extracted. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (Petro ether / EtOAc = 10:1 to 3:1) to give the target product, 6-bromo-2-isopropyl-4-(methylthio)pyridin-3-amine (480 mg, 34% yield).

[0606] MS m / z (ESI): 261.1 [M+H] + . Step 2: Preparation of 2-isopropyl-6-methyl-4-(methylthio)pyridin-3-amine

[0607] [ka]

[0608] Under N2 protection, 6-bromo-2-isopropyl-4-(methylthio)pyridin-3-amine (480 mg, 1.85 mmol) was dissolved in a mixture of 1,4-dioxane and water (3 mL:0.1 mL). Methylboronic acid (560 mg, 9.25 mmol), Pd(dppf)Cl2. DCM (100 mg, 0.2 mmol), and K2CO3 (510 mg, 3.7 mmol) were added and the mixture was heated in a microwave oven at 100 °C for 1 h. The reaction mixture was extracted with water and dichloromethane (3 × 10 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (petro ether / EtOAc = 3:1 to 1:1) to give the target product, 2-isopropyl-6-methyl-4-(methylthio)pyridin-3-amine (200 mg, 55% yield).

[0609] MS m / z (ESI): 197.1 [M+H] + . Step 3: Preparation of 2,6-dichloro-5-fluoro-N-((2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide

[0610] [ka]

[0611] Under N2 protection, 2,6-dichloro-5-fluoronicotinamide (220 mg, 1.05 mmol) was dissolved in THF (20 mL), and oxalyl chloride (0.6 mL, 1.2 mmol) (2 M / L dichloromethane solution) was added dropwise at -78 °C. The mixture was stirred at -78 °C for 10 minutes and then at 60 °C for 3 hours. The reaction mixture was cooled to 0 °C, and triethylamine (1 mL, 3.2 mmol) and a THF solution of 2-isopropyl-6-methyl-4-(methylthio)pyridin-3-amine (200 mg, 1.05 mmol) were added dropwise. The mixture was stirred at room temperature for 2 hours. The mixture was quenched with brine, extracted with water and ethyl acetate (3 × 50 mL), and the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was then purified by column chromatography. Purification by chromatography (DCM / MeOH = 100:1 to 70:1) gave the target product 2,6-dichloro-5-fluoro-N-((2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (320 mg, yield: 67%). MS m / z (ESI): 457.1 [M+H] + . Step 4: Preparation of 7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0612] [ka]

[0613] 2,6-Dichloro-5-fluoro-N-((2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (320 mg, 0.75 mmol) was dissolved in anhydrous THF (20 mL), protected with nitrogen, cooled to 0 °C, and KHMDS (1.5 mL, 1.5 mmol) was added dropwise and stirred for 0.5 h. The mixture was quenched with saturated aqueous ammonium chloride solution and extracted with water and ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (DCM / MeOH = 200:1 to 80:1) to give the target product 7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (270 mg, yield: 91%). MS m / z (ESI): 395.1 [M+H] + .

[0614] Step 5: Preparation of 4,7-dichloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0615] [ka]

[0616] 7-Chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (270 mg, 0.57 mmol) was dissolved in acetonitrile (10 mL), DIEA (1.2 mL, 2.3 mmol) and POCl3 (0.12 mL, 1.1 mmol) were added, and the mixture was stirred at 80 °C for 0.5 hours. It was used as it was in the next reaction. MS m / z (ESI): 413.1 [M+H] + .

[0617] Step 6: Preparation of tert-butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate

[0618] [ka]

[0619] 4,7-Dichloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (230 mg, 0.57 mmol) was dissolved in acetonitrile (10 mL), DIEA (1.2 mL, 2.3 mmol) was added, and tert-butyl (S)-3-methylpiperazine-1-carboxylate (230 mg, 1.1 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with water and ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH=30:1) to give the target product tert-butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (290 mg, 88% yield).

[0620] MS m / z (ESI): 577.1 [M+H] + . Step 7: Preparation of (S)-7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-4-(2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0621] [ka]

[0622] tert-Butyl (S)-4-(7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-3-methylpiperazine-1-carboxylate (290 mg, 0.5 mmol) was dissolved in dichloromethane (6 mL), TFA (1 mL) was added, and the mixture was stirred at room temperature for 1 hour. Concentration afforded the crude target product ( S)-7-Chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-4-(2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (240 mg, 100% yield) was obtained. MS m / z (ESI): 477.1 [M+H] + .

[0623] Step 8: Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0624] [ka]

[0625] (S)-7-Chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)-4-(2-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (240 mg, 0.5 mmol) was dissolved in dichloromethane (10 mL), DIEA (3 mL, 5 mmol) was added, and acrylic acid chloride (45 mg, 0.5 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with water and ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 20:1) to give the target product 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (300 mg, yield: 100%). MS m / z (ESI): 531.1 [M+H] + .

[0626] Step 9: Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0627] [ka]

[0628] Under N protection, 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-chloro-6-fluoro-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (300 mg, 0.57 mmol) and (2-fluoro-6-hydroxyphenyl)boronic acid (177 mg, 1.1 mmol) were dissolved in a mixture of 1,4-dioxane and water (6 mL:0.3 mL). Pd(dppf)Cl.DCM (50 mg, 0.06 mmol) and CsCO (280 mg, 0.86 mmol) were added and the reaction was heated at 100 °C in a microwave oven for 1 h. The reaction was quenched with water and extracted with water and ethyl acetate (3 × 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH=200:1 to 80:1) to give the target product 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-6-methyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (90 mg, 26% yield).

[0629] 1 H NMR (400 MHz, Methanol-d4) δ 8.38 (d, J = 5.0 Hz, 1H), 8.30-8.22 (m, 1H), 7.56- 7.41 (m, 3H), 7.25-7.19 (m, 2H), 6.91 - 6.80 (m, 1H), 6.34-6.29 (dd, J = 17. 0, 5.6 Hz, 1H), 5.84-5.82 (dd, J = 10.6, 1.8 Hz, 1H), 5.11-5.04 (m, 2H), 4.53-4.46 (m, 2H), 4.23- 4.07 (m, 1H), 3.90-3.7 3 (m, 2H), 2.81-2.79 (m, 1H), 2.28 (s, 3H), 2.05 (s, 3H), 1.50-1.46 (m, 3H), 1.19-1.17 (d, J = 6.8 Hz, 3H), 1.01-0.99 (d, J = 6.8Hz, 3H). MS m / z (ESI): 573.1 [M+H] + .

[0630] Example 153 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2,3-difluoro-6-hydroxyphenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0631] [ka] See Example 114 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2,3-difluoro-6-hydroxyphenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.

[0632] MS m / z (ESI): 611.1 [M+H] + . 1 H NMR (400 MHz, MeOD-d4) δ 8.41 (d, J = 5.6 Hz, 1H), 8.32 - 8.25 (m, 1H), 7.25 (d, J = 5.6 Hz, 1H), 7.20 - 7.13 (m, 1H), 6.92 - 6.82 (m, 1H), 6.62 - 6.58 (m, 1H), 6.34 - 6.28 (m, 1H), 5.83 (d, J = 10.4 Hz, 1H), 5.14 - 5.04 (m, 1H), 4.64 - 4.42 (m, 2H), 4.25 - 4.07 (m, 1H), 3.89 - 3.61 (m, 3H), 2.88 - 2.77 (m, 1H), 2.42 (s, 3H), 1.52 - 1.46 (m, 3H), 1.20 (d, J = 6.4 Hz, 3H), 1.05 (d, J = 6.4 Hz, 3H).

[0633] Example 154 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-(2,6-difluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0634] [ka] See Example 114 for the preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-(2,6-difluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.

[0635] MS m / z (ESI): 595.1 [M+H] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.40 - 8.32 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 5.4 Hz, 1H), 7.05 (t, J = 8.4 Hz, 2H), 6.86 - 6.79 (m, 1H), 6.37 - 6.26 (m, 1H), 5.84 (d, J = 10.6 Hz, 1H), 5.08 (m, 2H), 4.56-4.46 (m, 2H), 4.21-4.08 (m, 1H), 3.85-3.62 (m, 2H), 2.86-2.82 (m, 1H), 2.40 (s, 3H), 1.47 (d, J = 6.6 Hz, 3H), 1.21 - 1.19 (d, J = 6.8 Hz, 3H ), 1.04 (d, J = 6.8 Hz, 3H).

[0636] Example 155 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylsulfonyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0637] [ka] See Example 133 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylsulfonyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.

[0638] MS m / z (ESI): 641.1 [M+H] + . 1H NMR (400 MHz, MeOD-d4) δ 8.86 (d, J=5.2Hz, 1H), 8.44-8.46 (m, 1 H),7.85 (d, J=4.8 Hz, 1H), 7.20(dd, J1=15.2Hz, J2=8.4Hz, 1H), 6.82-6.85 (m, 1H), 6.55-6.64 (m, 2H), 6.31(d, J=17.2Hz, 1H), 5.82(d, J=12.0 Hz, 1H), 5.07 (s, 1H),4.43-4.58 (m, 2H), 4.06-4.23 (s, 1H), 3.38-3.86 (m,3H), 2.94-2.98(m, 4H), 1.46-1.51(m, 3H), 1.18-1.22(m, 3H), 1.07-1.09 (m, 3H).

[0639] Example 165 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0640] [ka] Step 1: Preparation of 2,5,6-trichloro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide

[0641] [ka]

[0642] Under N2 protection, 2,5,6-trichloronicotinamide (6.2 g, 27.7 mmol) was dissolved in THF (60 mL), and oxalyl chloride (15.2 mL, 31.5 mmol) (2 M / L dichloromethane solution) was added dropwise at -78°C. The mixture was stirred at -78°C for 10 minutes and at 60°C for 3 hours. The reaction solution was cooled to 0°C, and triethylamine (18 mL, 111 mmol) was added dropwise. A THF solution of 2-isopropyl-4-(methylthio)pyridin-3-amine (5 g, 27.7 mmol) was added dropwise, and the mixture was stirred at room temperature for 2 hours. Quenched with brine, extracted with water and ethyl acetate (3*100 mL), the organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified by column chromatography (DCM / MeOH=100:1 to 70:1) to give the target product 2,5,6-trichloro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (8.6 g, 72% yield). MS m / z (ESI): 433.1 [M+H] + , 435.1 [M+H+2] + . Step 2: Preparation of 6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

[0643] [ka]

[0644] 2,5,6-Trichloro-N-((2-isopropyl-4-(methylthio)pyridin-3-yl)carbamoyl)nicotinamide (10.4 g, 24.1 mmol) was dissolved in anhydrous THF (80 mL), protected with nitrogen, cooled to 0 °C, and KHMDS (48 mL, 48.2 mmol) was added dropwise and stirred for 0.5 h. The mixture was quenched with saturated aqueous ammonium chloride solution and extracted with water and ethyl acetate (3 × 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was slurried with ethyl acetate and purified to give the target product, 6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (8 g, 84% yield). MS m / z (ESI): 397.1 [M+H] + , 399.1 [M+H+2] + .

[0645] Step 3: Preparation of 4,6,7-trichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0646] [ka]

[0647] 6,7-Dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (5.2 g, 13.1 mmol) was dissolved in ACN (50 mL), DIEA (23 mL, 66 mmol) and POCl3 (3 mL, 19.7 mmol) were added, and the mixture was stirred at 80 °C for 0.5 h. It was used as it was in the next reaction. MS m / z (ESI): 415.1 [M+H] + , 417.1 [M+H+2] + . Step 4: Preparation of tert-butyl (2R,5S)-4-(6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate

[0648] [ka]

[0649] 4,6,7-Trichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one was dissolved in acetonitrile (50 mL), DIEA (23 mL, 66 mmol) was added, and tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate (6.2 g, 26.2 mmol) was added. The mixture was stirred at room temperature for 1 h. The mixture was quenched with water and extracted with water and ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 30:1) to give the target product tert-butyl (2R,5S)-4-(6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (6.1 g, 77% yield). MS m / z (ESI): 593.1 [M+H] + , 595.1 [M+H+2] + . Step 5: 6,7-dichloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyridin [ Preparation of 2,3-d]pyrimidin-2(1H)-one

[0650] [ka]

[0651] tert-Butyl (2R,5S)-4-(6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-2-carbonyl-1,2-dihydropyrido[2,3-d]pyrimidin-4-yl)-2,5-dimethylpiperazine-1-carboxylate (6.1 g, 10.3 mmol) was dissolved in dichloromethane (20 mL), TFA (20 mL) was added, and the mixture was stirred at room temperature for 1 hour. Concentration gave the crude target product 6,7-dichloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (6.1 g, 100% yield).

[0652] MS m / z (ESI): 493.1 [M+H] + , 495.1 [M+H+2] + . Step 6: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0653] [ka]

[0654] 6,7-Dichloro-4-((2S,5R)-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (6 g, 12.2 mmol) was dissolved in dichloromethane (30 mL), DIEA (30 mL, 131 mmol) was added, and acrylic acid chloride (1.08 mL, 13.13 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The mixture was quenched with water and extracted with water and ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (C Purification with HCl / MeOH (20:1) gave the target product 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (1.6 g, 22% yield). MS m / z (ESI): 547.1 [M+H] + , 549.1 [M+H+2] + . Step 7: Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0655] [ka]

[0656] Under N2 protection, 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6,7-dichloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (700 mg, 1.3 mmol) and (6-amino-3-chloro-2-fluorophenyl)boronic acid (380 mg, 2.6 mmol) were dissolved in a mixture of 1,4-dioxane and water (6 mL:0.3 mL). Pd(dppf)Cl2.DCM (100 mg, 0.1 mmol) and KOAc (400 mg, 4 mmol) were added and the reaction was heated at 100 °C in a microwave oven for 1 h. The reaction was quenched with water and extracted with water and ethyl acetate (3 × 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by column chromatography (CHCl / MeOH = 200:1 to 80:1) to give the target product 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one (400 mg, 48% yield).

[0657] MS m / z (ESI): 656.1 [M+H] + , 658.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.47 - 8.34 (m, 2H), 7.24-7.20 (m, 1H), 7.10-7.14 (m, 1H), 6.79-6.68 (m, 1H), 6.42 - 6. 40 (d, J = 8.0 Hz, 1H), 6.24 - 6.17 (m, 1H), 5.75-5.71 (m, 1H), 5.01 -4.94 (m, 2 H), 4.46-4.40 (m, 1H), 4.26-4.17 (m, 1H), 4.03-3.99 (m, 1H), 3.84-3.79 (m, 1H), 2.86-2.77 (m, 1H), 2.36 (s, 3H), 1.26-1.19 (m, 9H), 1.14-1.11 (m, 3H).

[0658] Example 165-1 and Example 165-2 (M / P-4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(6-amino-3-chloro-2-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0659] [ka] [ka]

[0660] [ka]

[0661] Example 165 was separated by SFC to give two axially chiral isomers, Example 165-1 and Example 165-2. SFC: Chiral preparation conditions: [Table 21]

[0662] Chiral analysis conditions: [Table 22]

[0663] Example 165-1: t R =1.74 min MS m / z (ESI): 656.1 [M+H] + , 658.1 [M+H+2] + . 1 1H NMR (400 MHz, MeOD-d4) δ 8.47 - 8.34 (m, 2H), 7.24 - 7.20 (m, 1H), 7.10 - 7.14 (m, 1H), 6.79 - 6.68 (m, 1H), 6.42 - 6.40 ( d, J = 8.0 Hz, 1H), 6.24 - 6.17 (m, 1H), 5.75 - 5.71 (m, 1H), 5.01 - 4.94 (m, 2H), 4.46 - 4.40 (m, 1H), 4.26 - 4.17 (m, 1H), 4.03 - 3.99 (m, 1H), 3.84 - 3.79 (m, 1H), 2.86 - 2.77 (m, 1H), 2.36 (s, 3H), 1.26 - 1.19 (m, 9H), 1.14 - 1.11 (m, 3H).

[0664] Example 165 - 2: t R = 2.49 min MS m / z (ESI): 656.1 [M+H] + , 658.1 [M+H+2] + . 1 1H NMR (400 MHz, DMSO-d6) δ 8.55 - 8.38 (m, 2H), 7.25 - 7.20 (m, 1H), 7.18 - 7.11 (m, 1H), 6.88 - 6.76 (m, 1H), 6.51 - 6.47 (d , J = 8.0 Hz, 1H), 6.33 - 6.27 (m, 1H), 5.84 - 5.80 (m, 1H), 5.12 - 5.10 (m, 2H), 4 .46-4.23 (m, 2H), 4.15-3.89 (m, 2H), 3.64-3.50 (m, 1H), 2.89-2.82 (m, 1H), 2.43 (s, 3H), 1.51-0.99 (m, 12H).

[0665] Example 166 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0666] [ka]

[0667] See Example 165 for the preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 623.1 [M+H] + , 625.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.47 - 8.34 (m, 2H), 7.21-7.20 (m, 2H), 6.89-6.77 (m, 1H), 6.64 - 6.55 (m, 2H), 6.32 - 6.26 (m, 1H), 5.84-5.80 (m, 1H), 5.08 -5. 03 (m, 2H), 4.56-4.49 (m, 1H), 4.34-4.26 (m, 1H), 4.13-4.04 (m, 1H), 3.92-3.88 (m, 1H), 2.79-2.72 (m, 1H), 2.40 (s, 3H), 1.55 - 1.43 (m, 3H), 1.35-1.27 (m, 3H), 1.20-1.17 (m, 3H), 1.08-1.05 (t, J = 8. 0 Hz, 3H).

[0668] Example 166-1 and Example 166-2 (M / P-4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one)

[0669] [ka]

[0670] [ka]

[0671] [ka]

[0672] Example 166 was separated by SFC to give two axially chiral isomers, Example 166-1 and Example 166-2. SFC: Chiral preparation conditions:

[0673] [Table 23]

[0674] Chiral analysis conditions:

[0675] [Table 24]

[0676] Example 166-1: tR = 2.46 min MS m / z (ESI): 623.1 [M+H] + , 625.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.47 - 8.34 (m, 2H), 7.21 - 7.20 (m, 2H), 6.89 - 6.77 (m, 1H), 6.64 - 6.55 (m, 2H), 6.32 - 6.26 (m, 1H), 5.84 - 5.80 (m, 1H), 5.08 - 5. 03 (m, 2H), 4.56 - 4.49 (m, 1H), 4.34 - 4.26 (m, 1H), 4.13 - 4.04 (m, 1H), 3.92 - 3.88 (m, 1H), 2.79 - 2.72 (m, 1H), 2.40 (s, 3H), 1.55 - 1.43 (m, 3H), 1.35 - 1.27 (m, 3H), 1.20 - 1.17 (m, 3H), 1.08 - 1.05 (t, J = 8.0 Hz, 3H). Example 166 - 2: t R = 3.08 min MS m / z (ESI): 623.1 [M+H] + , 625.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.48 - 8.34 (m, 2H), 7.23 - 7.21 (m, 2H), 6.90 - 6.78 (m, 1H), 6.66 - 6.58 (m, 2H), 6.33 - 6.28 (m, 1H), 5.85 - 5.82 (m, 1H), 5.10 - 5. 06 (m, 2H), 4.58 - 4.50 (m, 1H), 4.34 - 4.27 (m, 1H), 4.13-4.06 (m, 1H), 3.93-3.88 (m, 1H), 2.79-2.71 (m, 1H), 2.41 (s, 3H), 1.56 - 1.46 (m, 3H), 1.37-1.29 (m, 3H), 1.21-1.18 (m, 3H), 1.07-1.05 (t, J = 8.0 Hz, 3H).

[0677] Example 169 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-(2,6-difluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0678] [ka] See Example 114 for the preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-7-(2,6-difluorophenyl)-6-fluoro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.

[0679] MS m / z (ESI): 595.1 [M+H] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.40 - 8.32 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 5.4 Hz, 1H), 7.05 (t, J = 8.4 Hz, 2H), 6.86 - 6.79 (m, 1H), 6.37 - 6.26 (m, 1H), 5.84 (d, J = 10.6 Hz, 1H), 5.08 (m, 2H), 4.56-4.46 (m, 2H), 4.21-4.08 (m, 1H), 3.85-3.62 (m, 2H), 2.86-2.82 (m, 1H), 2.40 (s, 3H), 1.47 (d, J = 6.6 Hz, 3H), 1.21 - 1.19 (d, J = 6.8 Hz, 3H ), 1.04 (d, J = 6.8 Hz, 3H).

[0680] Example 191 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0681] [ka] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one.

[0682] MS m / z (ESI): 676.1 [M+H] + , 678.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.40 - 8.32 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 5.4 Hz, 1H), 7.05 (t, J = 8.4 Hz, 2H), 6.86 - 6.79 (m, 1H), 6.37 - 6.26 (m, 1H), 5.84 (d, J = 10.6 Hz, 1H), 5.08 (m, 2H), 4.56-4.46 (m, 2H), 4.21-4.08 (m, 1H), 3.85-3.62 (m, 2H), 2.86-2.82 (m, 1H), 2.40 (s, 3H), 1.47 (d, J = 6.6 Hz, 3H), 1.21 - 1.19 (d, J = 6.8 Hz, 3H ), 1.04 (d, J = 6.8 Hz, 3H).

[0683] Example 192 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylsulfinyl)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0684] [ka] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylsulfinyl<sulfinyl>)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 692.1 [M+H] + , 694.1 [M+H] + .

[0685] Example 193 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0686] [ka]

[0687] See Example 165 for the preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 690.1 [M+H] + , 692.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.46 - 8.34 (m, 2H), 7.25-7.21 (m, 1H), 7.11-7.14 (m, 1H), 6.44 - 6.42 (d, J = 8.0 Hz, 1H), 6.23 - 6.16 (m, 1H), 5.73-5.70 (m, 1H), 5.03 -4.97 (m, 2H), 4.47-4.42 (m, 1 H), 4.25-4.16 (m, 1H), 4.06-4.02 (m, 1H) , 3.86-3.83 (m, 1H), 2.84-2.79 (m, 1H), 2.34 (s, 3H), 1.27-1.19 (m, 9H), 1.16-1.14 (m, 3H).

[0688] Example 194 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-5-chloro-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0689] [ka]

[0690] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-5-chloro-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 660.1 [M+H] + , 662.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.58 - 8.38 (m, 2H), 7.53 - 7.36 (m, 1H), 7.23 - 7.15 (m, 1H), 6.97 - 6.79 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 5.77 (d, J = 8 Hz, 1H), 5.45 - 5.40 (m, 2H), 5.07 - 4.82 (m, 1H), 4.50 - 3.98 (m, 3H), 3.92 - 3.49 (m, 2H), 3.17 - 3.02 (m, 1H), 2.93 - 2.63 (m, 1H), 2.44 - 2.26 (m, 3H), 1.43 - 1.27 (m, 3H), 1.08 (d, J = 4 Hz, 3H), 1.04 - 0.86 (m, 3H).

[0691] Example 195 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-5,6-difluoro-3-methylphenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0692] [ka]

[0693] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-5,6-difluoro-3-methylphenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 640.1 [M+H] + , 642.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.57 - 8.35 (m, 3H), 7.25 - 7.04 (m, 2H), 6.96 - 6.79 (m, 1H), 6.29 - 6.14 (m, 1H), 5.77 (d, J = 12 Hz, 1H), 5.09 - 4.82 (m, 1H) , 4.76 - 4.58 (m, 2H), 4.48 - 3.98 (m, 3H), 3.94 - 3.59 (m, 2H), 2.93 - 2.69 (m, 1H), 2.44 - 2.29 (m, 3H), 2.10 - 1.95 (m, 3H), 1.42 - 1.26 (m, 3H), 1.08 (d, J = 4 Hz, 3H), 1.05 - 0.87 (m, 3H).

[0694] Example 196 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-5-chloro-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0695] [ka]

[0696] 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-5-chloro-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyridin See Example 165 for the preparation of mydin-2(1H)-one. MS m / z (ESI): 674.1 [M+H] + , 676.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.61 - 8.39 (m, 2H), 7.56 - 7.35 (m, 1H), 7.27 - 7.14 (m, 1H), 6.96 - 6.75 (m, 1H), 6.20 (d, J = 16 Hz, 1H), 5.82 - 5.71 (m, 1H) , 5.53 - 5.38 (m, 2H), 4.95 - 4.69 (m, 1H), 4.57 - 4.30 (m, 1H), 4.24 - 4.00 (m, 2H), 3.98 - 3.79 (m, 2H), 2.95 - 2.60 (m, 1H), 2.44 - 2.25 (m, 3H), 1.40 - 1.13 (m, 6H), 1.10 - 0.87 (m, 6H).

[0697] Example 198 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0698] [ka]

[0699] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(2-amino-3,6-difluorophenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 626.1 [M+H] + , 628.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.58 - 8.34 (m, 2H), 7.26 - 6.99 (m, 2H), 6.95 - 6.77 (m, 1H), 6.47 - 6.27 (m, 1H), 6.26 - 6.13 (m, 1H), 5.77 (d, J = 16 Hz, 1H) , 5.22 (s, 2H), 5.09 - 4.80 (m, 1H), 4.5 0 - 3.99 (m, 3H), 3.95 - 3.53 (m, 2H), 3.20 - 2.98 (m, 1H), 2.94 - 2.65 (m, 1H), 2.42 - 2.24 (m, 3H), 1.43 - 1.25 (m, 3H), 1.09 (d, J = 4 Hz, 3H), 1.04 - 0.82 (m, 3H).

[0700] Example 201 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-5,6-difluoro-3-methylphenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0701] [ka]

[0702] See Example 165 for the preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-5,6-difluoro-3-methylphenyl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 654.1 [M+H] + , 656.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.58 - 8.31 (m, 2H), 7.25 - 7.03 (m, 2H), 6.94 - 6.73 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 5.81 - 5.69 (m, 1H), 4.96 - 4.59 (m, 3H), 4.55 - 4.38 (m, 1H), 4.29 - 3.96 (m, 2H), 3.93 - 3.72 (m, 2H), 3.00 - 2.60 (m, 1H), 2.45 - 2.25 (m, 3H), 2.07 - 1.94 (m, 3H), 1.43 - 1.13 (m, 6H), 1.12 - 0.82 (m, 6H).

[0703] Example 206 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-methylphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0704] [ka]

[0705] See Example 165 for the preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-7-(2-fluoro-6-methylphenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 607.1 [M+H] + , 609.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.57 - 8.34 (m, 2H), 7.43 - 7.31 (m, 1H), 7.18 (d, J = 4 Hz, 1H), 7.15 - 7.01 (m, 2H), 6.95 - 6.78 (m, 1H), 6.28 - 6.14 (m, 1H), 5.77 (d, J = 12 Hz, 1H), 5.07 - 4.86 (m , 1H), 4.45 - 4.25 (m, 2H), 4.22 - 3.98 (m, 1H), 3.93 - 3.58 (m, 2H), 3.21 - 3.02 (m, 1H), 2.87 - 2.69 (m, 1H), 2.40 - 2.27 (m, 3H), 1.98 - 1.85 (m, 3H), 1.41 - 1.28 (m, 3H), 1.08 (d, J = 8 Hz, 3H), 1.02 - 0.79 (m, 3H).

[0706] Example 208 Preparation of 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-7-(2-chloro-6-fluorophenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0707] [ka]

[0708] 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-chloro- See Example 165 for the preparation of 7-(2-chloro-6-fluorophenyl)-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 627.1 [M+H] + , 629.1 [M+H+2] + . 1 H NMR (400 MHz, Methanol-d4) δ 8.56- 8 .30 (m, 2H), 7.58-7.36 (m, 3H), 7.19 (s, 1H), 6.87 (s, 1H), 6.24-6.19 (d, J = 20.0 Hz, 1H), 5.79-5.76 (d, J = 12.0 Hz, 1H), 4.97 (s, 1H), 4.32-4.04 (m, 3H), 3.80-3.49 (m, 3H), 2.72 (s, 1H), 2.35 (s, 3H), 1.34-0.91 (m, 9H).

[0709] Example 210 Preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-7-(o-benzyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0710] [ka]

[0711] See Example 165 for the preparation of (S)-4-(4-acryloyl-2-methylpiperazin-1-yl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-7-(o-benzyl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 589.1 [M+H] + , 591.1 [M+H+2] + .

[0712] Example 213 Preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-7-(o-benzyl)pyrido[2,3-d]pyrimidin-2(1H)-one

[0713] [ka]

[0714] See Example 165 for the preparation of 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(2-isopropyl-4-(methylthio)pyridin-3-yl)-7-(o-benzyl)pyrido[2,3-d]pyrimidin-2(1H)-one. MS m / z (ESI): 603.1 [M+H] + , 605.1 [M+H+2] + .

[0715] Biological Test Evaluation The present invention will be further described below in conjunction with test examples, but these examples are not intended to limit the scope of the present invention.

[0716] Test Example 1: Measurement of inhibitory effect on NCI-H358 / Mia PaCa-2 cell proliferation activity 1.1 Experimental Objectives: The inhibitory effect of the example compounds on the proliferation activity of KRASG12C mutant cell lines NCI-H358 and MiaPaCa-2 is measured.

[0717] 1.2. Laboratory equipment and reagents: 1.2.1 Equipment: Microplate reader (BioTek Synergy H1) Pipettes (Eppendorf & Rainin) 1.2.2 Reagents: NCI-H358 was purchased from Nanjing Kebai Biotechnology Co., Ltd.; Mia PaCa-2 was purchased from ATCC; Cell Titer-Glo cells were purchased from Promega company, product number G7573; RPMI 1640 was purchased from Gibco, product number 22400089; DMEM was purchased from Gibco, product number 11995065; FBS was purchased from Gibco, product number 10091148; PBS was purchased from Gibco, product number 10010023; Pancreatin was purchased from Gibco, product number 25200056; The cell culture plate was purchased from Corning Corporation and has the product number 3610.

[0718] 1.3. Experimental Method: When NCI-H358 or Mia PaCa-2 cells were cultured to an appropriate confluence, they were harvested and adjusted to an appropriate cell concentration using complete medium. The cell suspension was then plated onto a 96-well plate at 90 μl per well. L of each compound was sprayed onto the cells and allowed to adhere overnight in a 37°C, 5% CO2 incubator. Compound solutions of different concentrations were prepared using DMSO and medium as solvent controls. 10 μL of each compound solution was added to a 96-well plate and incubated for 72 hours in a 37°C, 5% CO2 incubator. CellTiter-Glo solution was added and mixed well by shaking. The plate was then incubated in the dark for 10 minutes and read using a BioTek Synergy H1 microplate reader.

[0719] 1.4. Experimental data processing method: The luminescence signal values ​​were used to calculate the percent inhibition, and the concentration versus percent inhibition was fitted to a nonlinear regression curve using Graphpad Prism software to determine the IC 50 The value was calculated.

[0720] 1.5. Experimental Results: The experimental results are shown in Table 25. The IC values ​​of the growth inhibitory activity of the example compounds against NCI-H358 and Mia PaCa-2 cells were 50 The values ​​are shown.

[0721] [Table 25]

[0722] Note: "NT" means not detected. 1.6. Experimental Conclusions: The data show that the compounds of the present invention have good growth inhibitory effects on NCI-H358 and MiaPaCa-2 cells.

[0723] Test Example 2. Determination of the ability of the compounds of the present invention to improve the stability (melting temperature) of KRASg12C protein upon binding 2.1. Experimental Objectives: The ability of the compound to improve the stability of the KRASg12C protein is measured (the degree of increase in the melting temperature of the protein can characterize the binding ability of the compound to the KRASg12C protein).

[0724] 2.2. Experimental Reagents and Equipment: 2.2.1 Experimental equipment: The quantitative PCR instrument (Quantstudio6 Flex) was purchased from Life Company; Pipettes were purchased from Eppendorf or Rainin companies.

[0725] 2.2.2 Experimental reagents: Protein Thermal Shift<trademark> Dye Kit was purchased from Thermofisher company, product number is 4461146; KRASg12C protein was purchased from Beijing Yiqiao Shenzhou Technology Co., Ltd., product number 12259-H07E2; HEPES, 1M Buffer Solution was purchased from Thermofisher company, product number 15630080; DTT was purchased from Sigma company, product number 43816-50mL; NaCl was purchased from Sinopharm Group Chemical Reagents Co., Ltd., product number 10019318.

[0726] 2.3 Experimental Method: In this experiment, the degree of change in the melting temperature (Tm) of the KRASg12C protein before and after binding of the compound is measured by the thermal shift method to characterize the ability of the compound to improve the stability of the KRASg12C protein.

[0727] The specific experimental procedures are as follows. A solution containing 20 μM HEPES (pH 7.5), 1 mM DTT, 5X SYPRO Orange, and 150 mM NaCl was prepared as the experimental buffer, and human KRASg12C protein was added to a final concentration of 5.37 μM. The reaction mixture was divided into eight rows of PCR tubes, each containing 19.5 μL of test compound or DMSO. 0.5 μL of test compound or DMSO was added to each tube, resulting in a total reaction volume of 20 μL. The final compound concentration was 10 μM. 2.5% DMSO was used as a solvent control. After incubation in the dark at room temperature for 1 hour, the PCR tubes were placed in a PCR machine, and the QuantStudio Software v1.3 software was opened. The melt The curve function was selected to detect the melting temperature of KRASg12C protein in different treatment groups (heating from 25°C to 95°C at 0.03°C / s).

[0728] 2.4. Experimental data processing method: Import the experimental data file from the PCR machine into the thermal shift software to obtain the melting temperature (Tm) of each treatment group, and subtract the Tm of the DMSO solvent control group to obtain the melting temperature shift value (ΔTm).

[0729] 2.5. Experimental Results: According to the above method, experiments with compounds of the present invention that improve the stability of KRASg12C protein by binding show the ability to increase the melting temperature of the protein, as shown in Table 26.

[0730] [Table 26]

[0731] 2.6 Experimental conclusions: The above data demonstrate that the compounds of the examples of the present invention have good binding ability to KRASg12C protein.

[0732] Test Example 3. Inhibitory activity of the compounds of the present invention against p-ERK in Miapaca-2 cells 3.1. Experimental Objectives: The inhibitory activity of the compounds of the examples on the level of phosphorylated ERK in KRASg12C mutant cells Mia PaCa-2 is measured.

[0733] 3.2. Experimental equipment: 3.2.1 Equipment: microplate reader (BioTek Synergy H1); Pipettes (Eppendorf & Rainin).

[0734] 3.2.2 Reagents: Phosphorylated ERK1 / 2 (T202-Y204) LANCE Ultra Cellular Detection Kit was purchased from PerkinElmer company, with product number TRF4000M; Cell culture plates were purchased from Corning company, with product number 3610; White opaque OptiPlate™-384 plates were purchased from PerkinElmer, product number 6007290.

[0735] 3.3. Experimental Method: After MiaPaCa-2 cells were cultured to an appropriate confluence, they were harvested and grown in complete medium at a cell density of 1 × 10 6 The cell suspension was adjusted to 1 mL / well, and 50 μL of the suspension was seeded into a 96-well plate. The plate was placed in a 37°C, 5% CO2 incubator and allowed to adhere overnight. Compound solutions with different concentrations were prepared using DMSO and medium. After setting up a solvent control, 25 μL of compound solution was added per well to a 96-well plate and incubated at 37°C in a 5% CO2 incubator for 2 hours. After discarding the supernatant from the cell culture plate, 50 μL of lysate was added to each well and lysed by shaking at room temperature for 30 minutes. The plate was then centrifuged at 1000 rpm for 1 minute. 15 μL of the supernatant was transferred to a 384-well plate, and 5 μL of detection mixture (Eu-labeled anti-ERK1 / 2 (T202-Y204) Antibody at a final detection concentration of 0.5 nM and ULight-labeled anti-ERK1 / 2 Antibody at a final detection concentration of 5 nM) was added to each well. The plate was centrifuged at 1000 rpm for 1 minute, mixed well, and incubated at room temperature overnight. The plate was read using a BioTekSynergy H1 and signal values ​​were detected at emission wavelengths of 620 nm and 665 nm using a time-resolved fluorescence program.

[0736] 3.4. Experimental data processing method: The ratio of the signal values ​​at emission wavelengths of 665 nm and 620 nm was calculated, and the ratio was used to calculate the inhibition rate. The concentration and inhibition rate were fitted to a nonlinear regression curve using Graphpad Prism software to determine the IC. 50 The value was calculated.

[0737] 3.5. Experimental Results:

[0738]

Table 27

[0739] 3.6. Conclusions of the Experiment: The above data indicate that the compound of the embodiment of the present invention has a good inhibitory effect on pERK in Mia PaCa-2 cells.

[0740] Test Example 4. Measurement of Pharmacokinetics in Mice 4.1. Research Objectives: Using Balb / c mice as test animals, study the pharmacokinetic behavior of the compound in mice (plasma) after oral administration.

[0741] 4.2. Test Program: 4.2.1 Test Agent: The compound of the embodiment of the present invention, self-made; 4.2.2 Test Animals: Balb / c mice, male, purchased from Shanghai Jiesijie Experimental Animal Co., Ltd., with the animal production license number (SCXK(Shanghai)2013-0006 N0.311620400001794).

[0742] 4.2.3 Preparation of the Agent: Weigh 5 g of hydroxyethyl cellulose (HEC, CMC-Na, viscosity: 800-1200 Cps), dissolve it in 1000 mL of purified water, add 10 g of Tween 80, and mix well to form a clear solution.

[0743] Weigh the compounds of the examples respectively, add them to a 4 mL glass bottle, add 2.4 mL of this solution, and perform ultrasonic treatment for 10 minutes to obtain a colorless and transparent solution with a concentration of 1 mg / mL. 4.2.4 Administration: Balb / c mice, male; after fasting overnight, they were each given PO, the dosage was 10 mg / kg, and the administration volume was 10 mL / kg.

[0744] ​ 4.2.5 Sample Collection: Blood samples were collected before administration and at 0.083, 0.25, 0.5, 1, 2, 4, 6, and 8 hours after administration. The samples were placed in EDTA-2K tubes and centrifuged at 6000 rpm for 6 minutes at 4°C to separate plasma, which was then stored at -80°C. Food was administered 4 hours after administration.

[0745] 4.3 Experimental results: The final measurement results obtained by applying the LCMS / MS method are shown in Table 28.

[0746] [Table 28]

[0747] 4.4 Experimental conclusions: The above data demonstrate that the compounds of the examples of the present invention have favorable pharmacokinetic parameters in mice.

[0748] Test Example 5. Tumor suppression experiment in MiaPaca 2 transplanted tumor model 5.1 Experimental Objectives: BALB / c nude mice are used as test animals, and human pancreatic cancer cell MiaPaca 2 xenograft tumor (CDX) model is used for in vivo pharmacodynamic experiments to evaluate the antitumor effects of test compounds.

[0749] 5.2 Laboratory equipment and reagents: 5.2.1 Equipment: Ultra-clean workbench (BSC-1300II A2, Shanghai Boxun Industrial Co., Ltd. Medical Device Factory); CO2 incubator (Thermo-311, Thermo); Centrifuge (Centrifuge 5720R, Eppendorf); fully automated cell counter (Countess II, Life Technologies); Pipette (10-20 μL, Eppendorf); Microscope (Ts 2, Nikon); Vernier caliper (CD-6''AX, Mitutoyo Japan); Cell culture flasks (T25 / T75 / T225, Corning); Constant temperature water tank (HWS12, Shanghai Yiheng Science).

[0750] 5.2.2 Reagents: DMEM (11995-065, Gibco); fetal bovine serum (FBS) (10091-148, Gibco); 0.25% trypsin (25200-056, Gibco); Penicillin double antibody (P / S) (SV30010,GE); phosphate buffer solution (PBS) (10010-023, Gibco); Matrigel (356234, Corning); Gln (25030-081, Gibco).

[0751] 5.3 Experimental Procedure: MiaPaca 2 cells were removed from the cell bank, resuscitated, and then added to DMEM medium (containing 10% FBS, 1% Glu, and 1% P / S) and cultured in a CO2 incubator (incubator temperature 37°C, CO2 concentration 5%). When the cells had spread to 80-90% of the bottom of the culture flask, they were subcultured. After subculture, the cells were continued to be cultured in a CO2 incubator. This process was repeated until the cell number met the in vivo pharmacodynamic inoculum requirements. Cells in the logarithmic growth phase were collected and counted using an automated cell counter. Depending on the counting results, the cells were resuspended in PBS and Matrigel (volume ratio 1:1) to form a cell suspension (density 8 x 10 7 / mL) was prepared and placed in an ice box for later use.

[0752] The animals used were BALB / c nude mice, female, 6-8 weeks old, weighing approximately 18-22 grams. Mice were housed in single ventilated cages with five mice per cage in a specific pathogen-free environment. All cages, bedding, and water were disinfected before use, and all animals had free access to standard certified commercial laboratory chow. Before the experiment, nude mice were tagged with disposable universal ear tags for rats and mice. Before inoculation, the skin at the inoculation site was disinfected with 75% medical alcohol, and MiaPaca was implanted on the right dorsal side of each mouse. 2 tumor cells 0.1ml (8*10 6 The average tumor volume was 100-200 mm. 3 Group dosing was initiated when the serotonin concentration reached 1. The test compound was administered orally daily (6 mg / kg QD x 3 wk) at the dose / frequency (6 mg / kg QD x 3 wk), and the efficacy of each group at the end of the experiment is shown in Table 29.

[0753] 5.4 Data Processing: Tumor volume (mm 3 ) was measured twice weekly using a vernier caliper. The formula was V = 0.5 * D * d * d, where D and d are the long and short diameters of the tumor, respectively. The antitumor effect was determined by dividing the mean tumor growth in compound-treated animals by the mean tumor growth in untreated animals. The formula for tumor inhibition rate was TGI (%) = 1 - [(Vt - V0) treatment group / (Vt - V0) vehicle control group] * 100%. All animals were euthanized after the experiment.

[0754] 5.5 Experimental results:

[0755] [Table 29]

[0756] 5.6 Experimental conclusions: The above data show that after 21 days of continuous oral administration, the compound of the present invention can significantly inhibit the growth of transplanted tumors in MiaPaca 2 nude mice under the condition of oral daily administration of 6 mg / kg.

[0757] Test Example 6. In vivo pharmacodynamic study in a human lung cancer NCI-H358 cell xenograft tumor model 6.1 Experimental Objectives: The in vivo efficacy of the compounds will be evaluated in a human lung cancer NCI-H358 cell xenograft tumor model.

[0758] 6.2 Laboratory equipment and reagents: 6.2.1 Equipment: 1) Biological safety cabinet (BSC-1300II A2, Shanghai Boqun Industrial Co., Ltd. medical equipment factory); 2) Ultra-clean workbench (CJ-2F, Suzhou Fengshi Laboratory Animal Equipment Co., Ltd.); 3) CO2 incubator (Thermo-311, Thermo); 4) Centrifuge (Centrifuge 5720R, Eppendorf); 5) Fully automated cell counter (Countess II, Life Technology ies); 6) Vernier caliper (CD-6''AX, Mitutoyo Japan); 7) Cell culture flasks (T75 / T225, Corning); 8) Electronic balance (CPA2202S, Sartorius); 9) Electronic balance (BSA2202S-CW, Sartorius); 10) Electronic balance (BS124S, Sartorius).

[0759] 6.2.2 Reagents: 1) RPMI-1640 medium (22400-089, Gibco); 2) DMEM medium (11995-065, Gibco); 3) fetal bovine serum (FBS) (10099-141C, Gibco); 4) Phosphate buffer solution (PBS) (10010-023, Gibco); 5) Tween 80 (30189828, National Pharmaceutical Reagents); 6) Sodium carboxymethylcellulose (30036365, National Pharmaceutical Reagents Co., Ltd.) 6.3 Experimental procedures and data processing: 6.3.1 Animals: BALB / c nude mice, 6-8 weeks old, female, were purchased from Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd.

[0760] 6.3.2 Cell culture and cell suspension preparation 1) MiaPaca-2 cell line was obtained from the cell bank and cultured in DMEM medium (DMEM + 1 The cells were resuscitated with 0% FBS, and the resuscitated cells were placed in a cell culture flask (the cell type, culture date, name of the culturer, etc. were written on the flask wall), and cultured in a CO2 incubator (incubator temperature 37°C, CO2 concentration 5%) (the method for resuscitating NCI-H358 cells was the same as that for MiaPaca-2 cells in Test Example 5, except that the culture medium was changed to RPMI-1640 medium). 2) The cells were passaged every 3-5 days, and after passage, they were kept in a CO2 incubator. This process was repeated until the cell number met the requirements for in vivo efficacy. 3) The cultured MiaPaca-2 cells were harvested and counted using an automated cell counter. Depending on the counting results, resuspend the cells in PBS and Matrigel (ratio 1:1) to obtain a cell suspension (cell density 5 × 10 7 / mL) was prepared and placed in an ice box for later use (NCI-H358 cells did not require the addition of Matrigel, and a cell density of 1 × 10 8 (You can simply resuspend it directly in PBS at 1 / mL.)

[0761] 6.3.3 Sample preparation: 1) Solvent: solvent (0.5% CMC-Na + 1% Tween 80), storage condition: 4°C. 0.5 g of CMC-Na was weighed and dissolved in a certain amount of ddH2O, 1.0 mL of Tween 80 was added, and the mixture was stirred to mix uniformly, and finally the volume was adjusted to 100 mL.

[0762] 2) Preparation of test compound (10 mg / kg): 8.42 mg of the AMG510 compound was weighed, and 8.260 mL of solvent was added, followed by ultrasonication, vortexing, and stirring to obtain a homogeneous solution.

[0763] 7.81 mg of the compound of Example 165-1 was weighed, and 7.654 mL of solvent was added, followed by ultrasonication, vortexing, and stirring to obtain a homogeneous solution. 6.3.3 Cell inoculation 1) Before inoculation, nude mice were tagged with disposable universal ear tags for rats and mice. Marked; 2) At the time of inoculation, mix the cell suspension evenly and inject 0.1 to 1 ml of the mixture into the well using a 1 mL syringe. L of cell suspension was aspirated, air bubbles were removed, and the syringe was then placed on an ice pack for later use; 3) Fix the nude mouse with your left hand and inject the right shoulder of the nude mouse's back (injection site). ) was disinfected with 75% alcohol, and inoculation was started after 30 seconds; 4) Nude mice were inoculated sequentially (0.1 mL of cell suspension was inoculated per mouse). ; 6.3.4 Tumor Measurement, Grouping, and Drug Administration in Tumor-Bearing Mice: 1) Tumors were measured according to tumor growth on the 18th day after inoculation, and tumor size was calculated. Tumor volume calculation: Tumor volume (mm 3 ) = length (mm) x width (mm) x width (mm) / 2 2) Tumor-bearing mice were grouped using a random grouping method according to their weight and tumor size. We divided the groups into groups. 3) Depending on the grouping results, administration of the test drug was initiated (administration method: oral; Dose: 10 mg / kg; Dosage volume: 10 mL / kg; Dosage frequency: once / day; Dosage period: 21 days; Vehicle: 0.5% CMC / 1% Tween 80). 4) After starting the administration of the test drug, tumors were measured and weighed twice a week. 5) After the experiment was completed, the animals were euthanized. 6) Data was processed using software such as Excel.

[0764] 6.4 Data Processing: Calculation of compound tumor inhibition rate TGI (%): If tumors do not regress, TGI (%) = [(1 - (mean tumor volume at the end of treatment for a treatment group - mean tumor volume at the start of treatment for that treatment group)) / (mean tumor volume at the end of treatment for the solvent control group - mean tumor volume at the start of treatment for the solvent control group)] × 100%. If tumors regress, TGI (%) = [1 - (mean tumor volume at the end of treatment for a treatment group - mean tumor volume at the start of treatment for that treatment group) / mean tumor volume at the start of treatment for that treatment group] × 100%.

[0765] 6.5 Experimental results:

[0766] [Table 30]

[0767] 6.6 Experimental conclusions: The above data show that after 15 days of continuous oral administration, the compound of the present invention can significantly inhibit the growth of transplanted tumors of human lung cancer NCI-H358 cells in nude mice under the condition of oral administration of 10 mg / kg / day, which is significantly superior to the reference data.

[0768] Test Example 7. hERG potassium channel inhibitory activity test 7.1 Cell preparation 7.1.1 CHO-hERG cells were cultured at 175 cm 2 The cells were cultured in a culture flask, and when the cell density reached 60 to 80%, the culture medium was removed, the cells were washed once with 7 mL of PBS, and then digested by adding 3 mL of Detachin. 7.1.2 After digestion is complete, add 7 mL of culture medium to neutralize the cells, centrifuge, aspirate the supernatant, and resuspend the cells in 5 mL of culture medium until the cell density reaches 2–5 × 10. 6 / mL.

[0769] 7.2 Preparation of solutions

[0770] [Table 31]

[0771] 7.3 Electrophysiological Recording Process The single-cell high-impedance blocking and whole-cell patterning processes were all completed automatically by the Qpatch device. After acquiring the whole-cell recording pattern, the cell was clamped at -80 mV and a pre-voltage of -50 mV was applied for 50 ms before a 5-second depolarizing stimulus of +40 mV was applied. This pre-voltage was then applied to -50 mV for 5 s, followed by a 5-minute repolarization to -50 mV and then a return to -80 mV. This voltage stimulus was applied every 15 s and recorded for 2 min. After this, extracellular recording was performed for 5 min. After this, the dosing process began: starting with the lowest test concentration, each test concentration was administered for 2.5 min. After all concentrations were administered consecutively, the positive control compound 0.1 μM Cisapride was administered. At least three cells (n ≥ 3) were tested for each concentration.

[0772] 7.4 Compound Preparation 7.4.1 The 20 mM compound stock solution was diluted with extracellular fluid, and 5 μL of the 20 mM compound stock solution was added to 2495 μL of extracellular fluid, resulting in a 500-fold dilution to 40 μM, which was then serially diluted 3-fold with extracellular fluid containing 0.2% DMSO to obtain the final concentration required for testing.

[0773] 7.4.2 The highest concentration tested was 40 μM, followed by six concentrations of 40, 13.33, 4.44, 1.48, 0.49, and 0.16 μM, respectively. 7.4.3 Final test concentrations contained 0.2% or less DMSO, which did not affect the hERG potassium channel.

[0774] 7.5 Data Analysis The experimental data were analyzed by XLFit software. 7.6 Quality control Environment: Humidity 20~50%, Temperature 22~25℃ Reagents: The experimental reagents used were purchased from Sigma, with a purity of >98%. The experimental data included in the report must meet the following criteria: Whole-cell blocking impedance >100MΩ Tail current amplitude >400pA Pharmacological parameters: The inhibitory effect of Cisapride at multiple concentrations on the hERG channel was measured as a positive control. It's set.

[0775] 7.7 Experimental results:

[0776] [Table 32]

[0777] 7.8 Experimental conclusions: Drug inhibition of cardiac hERG potassium channel is the main cause of drug-induced long QT syndrome. Experimental results show that the compounds of the present invention do not have significant inhibitory effects on cardiac hERG potassium channel, and can avoid cardiotoxic side effects even at high doses.

[0778] Test Example 8. Plasma Stability Test Protocol 8.1 Purpose of the experiment The purpose of this experiment is to test the stability of example compounds in mouse, rat, dog, and human plasma.

[0779] 8.2 Experimental procedure 8.2.1 Solution preparation 1), plasma preparation Whole blood from animals or humans was collected, placed in a test tube containing an anticoagulant, and centrifuged at 3500 rpm for 10 minutes, and the upper layer of pale yellow plasma was collected.

[0780] 2), 10 μM test compound (m / M / V=C) Compounds were weighed, stock solutions were prepared in DMSO, and working solutions were prepared in 100 mM phosphate buffer.

[0781] 3), 10 μM positive control (1) Propantheline (Propantheline bromide, Mr=449.4 Da) 2.36 mg of propantheline bromide was weighed and diluted to a 10 mM stock solution with 1 mL of DMSO; 10 μL of the 10 mM stock solution was transferred to 1 mL of 100 mM phosphate buffer to give a final concentration of 100 μM.

[0782] (2) Mevinolin (lovastatin) M=404.5 Da 4.05 mg of lovastatin was weighed and diluted to a 10 mM stock solution with 1 mL of DMSO; 10 μL of the 10 mM stock solution was transferred to 1 mL of 100 mM phosphate buffer to give a final concentration of 100 μM.

[0783] 8.2.2 Experimental process: 1) In a 96-well plate, 285 μL of plasma, 15 μL of 10 μM compound (test compound) The mixture was added in this order and incubated at 37°C.

[0784] 2) 40 μL was withdrawn at 0, 15, 30, 60, 90, and 120 minutes (withdrawal points were finely adjustable), and 160 μL of acetonitrile stop solution containing an internal standard was added. After centrifugation (3500 rpm, 10 min), 50 μL of the supernatant was collected and diluted with 50 μL of DDH2O, followed by injection into LC-MS / MS.

[0785] 8.3 Chromatography conditions Equipment: Shimadzu LC-20 AD Chromatography column: Phenomenexgemiu® C18 (50*4.6 mm, 5 μm particle size); Mobile phase: A: acetonitrile, B: 0.1% formic acid solution. 0–8 min: 5% A → 95% A, 2.0–2.1 min: 90% A → 5% A; flow rate: 0.8 mL / min; run time: 5.0 min; injection volume: 5 μL.

[0786] 8.4 Mass spectrometry conditions: Equipment: API4000 liquid chromatography mass spectrometer, AB Company, USA; Ion source: electrospray ionization source (ESI); Dry gas (N2) temperature 500℃; Electrospray voltage: 5500V; Detection method: cation detection; Scanning method: Selective reaction monitoring (MRM) method; Scan time: 0.1s.

[0787] 8.4 Experimental Results:

[0788] [Table 33] TIFF0007584451000268.tif237165TIFF0007584451000269.tif651658.6Conclusion of the experiment: The above data demonstrate that the compounds of the present invention have high plasma stability and small species differences.

[0789] Test Example 9. CYP enzyme single-point inhibition test 9.1 Purpose of the experiment A single-point method is used to rapidly predict the inhibition of CYP450 enzyme subtypes by compounds using a human liver microsome incubation system.

[0790] 9.2 Experimental procedure 9.2.1 Preparation of solutions 2.5 mM NADPH: 4.165 mg of NADPH (reduced nicotinamide adenine dinucleotide phosphate) was weighed out, and 100 mM phosphate buffer was added to make up to 2 mL.

[0791] 0.25 mg / mL microsomes: 4 mL of 100 mM phosphate buffer was added to 50 μL of 20 mg / mL microsomes and mixed well. Preparation of test compound reaction solution The example compounds to be tested were weighed and diluted to 10 mM in DMSO and then diluted to 100 μM in 100 mM phosphate buffer.

[0792] 9.2.2 Experimental process: 1. 40 μL of liver microsomes, 10 μL of substrate, and 10 μL of test compound were added to a 96-well plate and pre-incubated for 3 minutes.

[0793] 2. 40 μL of NADPH was added. 3. After 20 minutes, 300 μL of acetonitrile stop solution containing the internal standard was added. 4. Centrifuged and injected.

[0794] 9.3 Experimental Results:

[0795] [Table 34]

[0796] Note: Strong inhibition: IC 50 <1 μM; moderate inhibition: 1 μM <IC 50 <10 μM; weak inhibition: IC 50 >10 μM 9.4 Experimental conclusions: The above data indicate that the compounds of the present invention do not have strong inhibition against each CYP enzyme subtype and have a low risk of DDI.

[0797] Test Example 10. Plasma protein binding rate experiment 10.1 Experimental Objectives: The purpose of this experimental method is to detect plasma protein binding of example compounds in plasma.

[0798] 10.2 Experimental equipment and materials: Liquid-phase mass spectrometer, centrifuge, vortexer, pipette, continuous sparger, 96-well plate, tissue homogenizer (used for tissue sample analysis), 50% methanol in water, acetonitrile solution with internal standard, blank matrix (plasma, urine, or tissue homogenate, etc.) 10.3 Experimental Procedure: 10.3.1 Preparation of Test Substance Stock Solutions A The example compound was prepared as 1 mM solution A using DMSO.

[0799] 10.3.2 Preparation of Plasma Solution B Solution A was added to the plasma solution to prepare 5 μM solution B. 10.3.3 Treatment Process 1) Add 200uL of solution B to the membrane.

[0800] 2) Add 350uL of PBS to the outside of the membrane. 3) Incubate in a 37°C water bath for 6 hours. 4) The sample is diluted and detected by mass spectrometry.

[0801] 10.4 Chromatographic conditions: Equipment: Shimadzu LC-20 AD; Chromatography column: Phenomenexgemiu® C18 (50*4.6 mm, 5 μm particle size); Mobile phase: A: acetonitrile, B: 0.1% formic acid solution. 0–0.5 min: 5% A → 90% A, 2.0–2.1 min: 90% A → 5% A; flow rate: 0.8 mL / min; run time: 5.0 min; injection volume: 5 μL.

[0802] 10.5 Mass spectrometry conditions: Equipment: API4000 liquid chromatography mass spectrometer, AB Company, USA; Ion source: electrospray ionization source (ESI); Dry gas (N2) temperature 500℃; Electrospray voltage: 5500V; Detection method: cation detection; Scanning method: Selective reaction monitoring (MRM) method; Scan time: 0.1s.

[0803] 10.6 Experimental Results:

[0804] [Table 35]

[0805] 10.7 Experimental conclusions: The above data show that the compounds of the present invention exhibit high plasma protein binding rates with small species differences.

[0806] Test Example 11. Pharmacokinetic measurements in tumor-bearing mice 11.1. Purpose of the Study: MiaPaca 2 tumor-bearing mice were used as test animals to study the pharmacokinetic behavior of compound Example 165 and AMG-510 compounds in mice (plasma, tumor tissue and intestine) after oral administration at a dose of 6 mg / kg.

[0807] 11.2. Test Protocol 11.2.1 Study Drug: Inventive Example 165-1, AMG-510 compound, self-made.

[0808] 11.2.2 Test animals: Twenty-four female MiaPaca 2 tumor-bearing mice, three mice per time point (0 h, 1 h, 2 h, 4 h, 6 h, 8 h, 16 h, 24 h). Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd., Animal Production License No. SCXK(Hu) 2018-0006.

[0809] 11.2.3 Drug Preparation: 5 g of hydroxymethylcellulose was weighed and dissolved in 1000 mL of purified water, and 10 g of Tween 80 was added and mixed well to make a clear solution.

[0810] Example compound 165-1 and AMG-510 were weighed and dissolved in the solution, which was then shaken well and sonicated for 15 minutes to obtain a uniform suspension with a concentration of 0.6 mg / mL. 11.2.4 Administration: After fasting, MiaPaca 2 tumor-bearing mice were administered po according to their body weight (no administration to animals at 0 h), with a dose of 6 mg / kg and an administration volume of 10 mL / kg.

[0811] 11.2.5 Sample Collection: Before and after administration, mice were sacrificed with CO2, and 0.5 mL of blood was collected from the heart, placed in an EDTA-2K test tube, and centrifuged at 6000 rpm at 4°C for 6 minutes to separate the plasma, which was then stored at -80°C. Tumor tissue was weighed, placed in a 2 mL centrifuge tube, and stored at -80°C. Duodenal, ileal, and colonic tissues were cut to the appropriate length with scissors, the contents removed, washed twice with PBS, dried on absorbent paper, weighed, placed in a 2 mL centrifuge tube, and stored at -80°C.

[0812] 11.3 Experimental Results: The final measurement results obtained by applying the LCMS / MS method are shown in Table 36.

[0813] [Table 36]

[0814] 11.4 Experimental conclusions: At a dose of 6 mg / kg, the ratio of tumor exposure to blood exposure of the compounds of the present invention was higher than that of AMG-510, and T 1 / 2 The MRT is also getting longer. Although specific embodiments of the present invention have been described above, it should be understood by those skilled in the art that these are merely examples and that various changes and modifications can be made to these embodiments without departing from the principle and essence of the present invention. Therefore, the scope of protection of the present invention is limited by the appended claims.

Claims

1. A compound represented by formula (XI), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof: embedded image 【Chemistry 1】 (In the formula, M 1 teeth 【Chemistry 2】 and Ring C is phenyl; 【Chemistry 3】 teeth 【Chemistry 4】 Selected from: R 10 and R 11 are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl or cyano substituted C 1-6 alkyl; R 14 is selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 alkyl substituted with cyano, C 3-12 cycloalkyl or a 3- to 12-membered heterocyclic group, wherein said amino, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 alkyl substituted with cyano, C 3-12 Cycloalkyl and 3- to 12-membered heterocyclic groups are optionally substituted by one or more of hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, oxo, thioxo, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 1-6 alkyl substituted with cyano, C 3-12 cycloalkyl and 3- to 12-membered heterocyclic groups; R 15 is C 1-6 alkyl; R f is hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkylsulfonyl, C 1-6 Haloalkoxy or C 1-6 hydroxyalkyl; R g is hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl, cyano-substituted C 1-6 Alkyl, -NR ee (CH 2 ) n2 R ff , -(CH 2 ) n2 S.R. ee or -(CH 2 ) n2 C(O)NR ee Rff is selected from; R ee and Rff are each independently hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Hydroxyalkyl or cyano substituted C 1-6 alkyl; r is an integer from 0 to 5; s is an integer from 0 to 5; n2 is 0; and q is 0, 1 or 2.

2. Ring D is the following group: 【Chemistry 5】 2. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, selected from:

3. Ring C is the following group: 【Chemistry 6】 Selected from: R 14 is selected from hydrogen, chlorine, fluorine, bromine, amino, methyl, methoxy, cyclopropyl, azetidinyl, morpholinyl, wherein said amino, methyl, methoxy, cyclopropyl, azetidinyl and morpholinyl are optionally substituted by one or more of the following substituents: hydrogen, fluorine, chlorine, bromine and cyclopropyl; 2. The compound of claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein R15 is methyl.

4. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the compound is further represented by general formula (XI-B): 【Chemistry 7】 (In the formula, R f is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, methylthio, ethylthio, propylthio, isopropylthio, halomethoxy, haloethoxy, halopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxyisopropyl; R 10 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxyisopropyl; R 15 is selected from methyl, ethyl, propyl, or isopropyl; R 21 and R 22 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxyisopropyl; R 23 and R 24 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxyisopropyl; R 25 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, iodine, amino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, propyl, isopropyl, deuterated methyl, deuterated ethyl, deuterated propyl, deuterated isopropyl, halomethyl, haloethyl, halopropyl, haloisopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxyisopropyl.

5. R 10 is selected from fluorine or chlorine; R 15 is methyl; R 21 and R 22 are each independently selected from hydroxy, amino, fluorine, chlorine or methyl; R 23 and R 24 are each independently selected from hydrogen, fluorine, chlorine or methyl; 5. The compound, its stereoisomer or a pharma- ceutically acceptable salt thereof according to claim 4, characterized in that R25 is selected from hydrogen, fluorine or methyl.

6. The compound according to claim 4, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the compound is further represented by formula (XI-C) or (XI-D). 【Chemistry 8】 (where: R f is selected from hydrogen or methyl; R 10 is selected from hydrogen, fluorine, chlorine, bromine, or methyl; R 21 and R 22 are each independently selected from amino or fluorine; R 23 and R 24 are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, or isopropyl; Or, R 21 and R 22 are each independently selected from hydroxy or fluorine; R 23 and R 24 are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, or isopropyl; R 25 is selected from hydrogen, fluorine, chlorine, bromine, or methyl.

7. The structure of the compound is as follows: 【Chemistry 9】 【change】 【change】 【change】 7. The compound according to any one of claims 1 to 6, its stereoisomer or a pharma- ceutically acceptable salt thereof,

8. The compound structure shown below: 【Chemistry 10】 The compound according to any one of claims 1 to 7, its stereoisomer or its pharma- ceutically acceptable salt, characterized in that, when selected from the group consisting of:

9. The axially asymmetric compound structures of the above compounds are as follows: 【Chemistry 11】 9. The compound according to claim 8, wherein:

10. A method for producing a compound represented by general formula (XI-B) according to claim 4 or a stereoisomer thereof and a pharma- ceutical acceptable salt thereof, comprising the steps of: 【Chemistry 12】 Deprotecting the compound represented by general formula (XI-B4) to obtain a compound represented by general formula (XI-B3) or a stereoisomer or a pharma- ceutically acceptable salt thereof; The general formula (XI-B3) and the general formula (XI-A4) undergo a condensation reaction to obtain a compound represented by the general formula (XI-B2) or a stereoisomer or a pharma- ceutically acceptable salt thereof; A coupling reaction between general formula (XI-B2) and general formula (XI-B1) is carried out to obtain a compound represented by general formula (XI-B) or a stereoisomer or a pharma- ceutically acceptable salt thereof; Pg is tert-butoxycarbonyl; R 26 is —B(OH) 2 ; The process for producing a compound represented by general formula (XI-B) or a stereoisomer or a pharma- ceutically acceptable salt thereof according to claim 4, wherein R27 is halogen.

11. A method for producing a compound represented by general formula (XI-B) according to claim 4 or a stereoisomer thereof and a pharma- ceutical acceptable salt thereof, comprising the steps of: 【Chemistry 13】 Deprotecting the compound represented by formula (XI-B6) to obtain a compound represented by formula (XI-B5) or a stereoisomer or a pharma- ceutically acceptable salt thereof; A condensation reaction between general formula (XI-B5) and general formula (XI-A4) is carried out to obtain a compound represented by general formula (XI-B) or a stereoisomer or a pharma- ceutically acceptable salt thereof; Pg is tert-butoxycarbonyl; The process for producing a compound represented by general formula (XI-B) or a stereoisomer or a pharma- ceutically acceptable salt thereof according to claim 4, wherein R27 is halogen.

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, its stereoisomer or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.

13. Use of a compound according to any one of claims 1 to 9, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 12 in the manufacture of a KRAS inhibitor medicament.

14. The use of claim 13, wherein the KRAS inhibitor is a KRAS G12C mutation inhibitor.

15. Use of a compound according to any one of claims 1 to 9, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 12 in the manufacture of a medicament for treating a disease or condition of Noonan syndrome, leopard skin syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer and colon cancer.

16. The use described in claim 15, wherein the disease or condition is selected from non-small cell lung cancer, colon cancer, esophageal cancer, and head and neck tumors.

Citation Information

Patent Citations

  • KRAS g12c inhibitors and methods of using the same

    WO2018119183A2

  • KRAS g12c inhibitors and methods of using the same

    WO2018217651A1

  • Inhibitors of KRAS g12c and methods of using the same

    WO2019051291A1

  • KRAS g12c inhibitors

    WO2019099524A1

  • KRAS g12c inhibitors and methods of using the same

    WO2019213516A1

Cited By

  • Salts and crystals of nitrogen-containing heterocyclic derivatives, and methods for preparing and using the same

    JP2023551006A